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Telomeres are specialized protein-DNA complexes that compose the natural termini of 
linear chromosomes. Telomeres function as chromosome caps and prevent chromosome 
ends from undergoing deleterious degradation and fusion events. In most eukaryotes, 
telomere length is maintained by telomerase, a specialized reverse transcriptase, which 
adds telomeric DNA to the 3’ ends of chromosomes to ensure complete genome 
replication. In this work, I studied the structures and functions of three different telomere 
associated protein complexes. 
POT1 binds the single-stranded telomere overhangs at human chromosome ends 
and suppresses unwanted DNA repair activities. TPP1 is a binding partner of POT1 that 
forms part of a six-protein shelterin complex at telomeres. The crystal structure of TPP1 
reveals a structural similarity to the -subunit of the telomere end-binding protein of a 
ciliated protozoan, suggesting that TPP1 is the missing -subunit of human POT1 
protein. In addition, structural and bioinformatic analyses suggest that TPP1 is 
evolutionarily conserved and the yeast telomerase component Est3 is an ortholog of 
TPP1. Telomeric DNA end-binding proteins have generally been found to inhibit, rather 
than stimulate, the action of telomerase. In contrast, we find that TPP1 and POT1 form a 
complex that increases the activity and processivity of human telomerase. We propose 
 xv 
that the POT1–TPP1 complex is a processivity factor for telomerase during telomere 
extension.  
Taz1, the fission yeast double-stranded telomeric DNA binding protein, has long 
been considered as the structural homologue of mammalian shelterin proteins TRF1 and 
TRF2. Both TRF1 and TRF2 contain a central TRFH domain, and the dimerization of 
this domain is crucial for telomere localization of the TRF proteins. However, because of 
low sequence identity between Taz1 and the TRF proteins, a definitive answer to their 
structural similarity is still unknown. Here, my crystal structure of the Taz1 TRFH 
domain shows that although Taz1TRFH is still an -helical structure, it is not a structural 
homolog of the TRFH domains of human TRF1 and TRF2. Notably, Taz1TRFH is a 
monomer, and the dimerization of Taz1 is mediated by another domain outside of TRFH. 
The structure of the Taz1 dimerization domain reveals that Taz1 employs a different 
architectural principle for homodimerization. In addition, we also determined the NMR 
structure of Taz1 complexed with another telomere protein Rap1. Strikingly, with no 
apparent sequence similarity, the Taz1-Rap1 interaction closely resembles that of human 
TRF2-RAP1.  
The BLM-TOPOIII -RMI1/RMI2 (BTR) complex is a DNA structure-specific 
“dissolvasome”. BTR is essential for genome integrity and potentially plays an important 
role in telomere maintenance in telomerase-negative cancer cells. However, little is 
known about the molecular architecture of the BTR complex and how this multi-subunit 
machinery dissolves homologues recombination intermediates such as D-loops and 
double Holliday Junctions. To address these questions, I carried out structural studies of 
RMI1 and RMI2, the two regulatory subunits of the BTR complex. My data demonstrate 
 xvi 
that both RMI1 and RMI2 are OB-fold containing proteins. RMI2 binds to the C-
terminus of RMI1 to form a stable RPA-like complex, and this interaction is essential for 
the stability of the BTR complex. The crystal structure of the N-terminus of RMI1 
reveals a non-canonical OB-fold with two extra structural elements that are essential for 





1.1 An early history of telomere biology  
DNA in eukaryotic cells is associated with various proteins to form compact structures 
called chromosomes, which carry the genetic information. During cell division, when the 
sister chromosomes are replicated and separated, the genetic information is copied and 
passed down from mother cells to daughter cells. Therefore, the stability and integrity of 
the chromosomes are crucial to living organisms. Since the observation of chromosomes 
and cytokinesis, geneticists and cytogeneticists, including Hermann Muller (1890 – 1967, 
Nobel laureate 1946) and Barbara McClintock (1902 – 1992, Nobel laureate 1983), had 
contributed a lot in understanding the nature of chromosomes. In the 1920s, by treating 
fruit flies with X-rays, Muller observed several kinds of chromosome breaks such as 
inversions, translocations and deficiencies, and he was able to recover them by using his 
new genetic techniques. However, Muller failed to recover the chromosome terminal 
deficiencies. His explanation was that the recovered chromosomes were usually the result 
of the rejoining of two broken ends. However, such rejoining could not occur between 
“originally free ends” or between broken ends and “originally free ends”. Muller realized 
that the chromosome ends might have a more important function than people ever 
imagined. In 1938, Muller, his colleague Darlington and independently, J.D.S. Haldane 
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named the “free end” the “telomere” (The remaking of chromosomes. The Collecting 
Net). But at that time, Muller did not have a clear idea about the nature of telomeres. He 
hypothesized that each telomere contains a gene that cells could not lose.  
At the same time when Muller studied the defects in fruit flies caused by X-rays, 
Barbara McClintock was pursuing genetics and developmental research using another 
powerful system, maize. McClintock developed new microscopes that allowed her to 
visualize individual maize chromosomes. McClintock observed special chromosome 
“knobs” (locally heterochromatic regions), some of which were located at the 
chromosome ends. She recognized that these “knobs” at the chromosome ends might be 
very important and named them as the “natural ends” of the chromosomes (McClintock 
B. 1931. Cytological observations of deficiencies involving known genes, translocations 
and an inversion in Zea mays.). In agreement with Muller, McClintock pointed out that 
the intact chromosome ends have a unique function that is different from broken 
chromosome ends caused by X-ray irradiation, as the broken ends never fused with the 
“natural ends”. More importantly, McClintock also noticed that the broken ends could be 
healed and “remain permanently healed” in some early embryo tissues [1]. Based on her 
discoveries, McClintock reasoned that there must exist some mechanism that could heal a 
single broken end “during the reproductive cycle of the chromosome” (Maize genetics. 
1942-1943. Carnegie Inst. Wash. Year Book). McClintock’s insight perfectly pioneered 
the modern understanding that telomerase is actively involved in healing broken ends 
during S-phase. These pioneering discoveries on the “natural chromosome ends” by 
Muller and McClintock laid out the foundations of modern telomere biology.  
2
1.2 The Hayflick limit 
Besides maintaining the integrity of the chromosomes, telomeres are also related to 
cellular senescence. In the early 1960s, Leonard Hayflick at the University of 
Pennsylvania first observed that a population of normal human fetal cells in cell culture 
could only divide between 40 and 60 times (known as the Hayflick limit) before the cells 
entered the senescence phase [2-4]. In 1974, Alexei Olovnikov proposed that the non-
coding telomeric nucleotide repeats might provide a buffer region for the chromosomal 
shortening during DNA replication [5]. He proposed that the number of the telomeric 
repeats (or the telomere length) determines how many rounds the cells could divide. It 
was not until more than twenty years later that Cooke and Smith found convincing 
evidence to support Olovnikov’s proposal. In 1986, Cooke and Smith measured the 
average telomere length difference between the sex chromosomes from sperm cells and 
those from adult cells. The sperm cells were found to have longer telomere length than 
the adult cells [6]. It was just at that time that telomerase was discovered in Tetrahymena 
(see Section 1.5) [7]. Cooke and Smith reasoned that the telomere length and telomerase 
regulation could be linked with cell aging. Later observations confirmed this hypothesis.  
 
1.3 The end replication problem  
In the 1950s and 1960s, it had been revealed that all eukaryotic chromosomes are made 
of linear DNA molecules. The replication of the double-stranded DNA is semi-
conservative and each strand of the double helix is used as the template for the new stand 
synthesis [8]. The newly synthesized DNA strand that is synthesized in the 5’ to 3’ 
direction is defined as the leading stand (Fig. 1.1). On the opposite side is the lagging 
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strand, which runs in the 3’ to 5’ direction. Both the leading and the lagging strands are 
synthesized by DNA polymerase. During the replication process, initiated by a short 
RNA primer synthesized by primase, the DNA polymerase can only go in the direction 
from 5’ end to 3’ end. Therefore the leading strand can be synthesized continuously while 
the lagging strand is synthesized in short fragments that are referred to as Okazaki 
fragments [9, 10]. However, at the end of each round of DNA replication, when the last 
RNA primer was removed, the terminal DNA cannot be synthesized by polymerase, 
leaving a gap that is up to 500 nucleotides (mean value of 250 nucleotides) un-replicated 
at the 5' end of the chromosome [11, 12] (Berg JM, Tymoczko JL, Stryer L, Clarke ND. 
2002. Biochemistry Chapter 27: DNA Replication, Recombination, and Repair). This is 
the famous “end replication problem” initially raised by James Watson in 1972 [13] (Fig. 
1.1). If the cells continue to lose terminal sequences, they will stop growing and undergo 
cellular senescence. Therefore, the “end replication problem” is one important reason 
why cultured cells are only able to divide a certain numbers of generations [3] (also 
known as the Hayflick limit).  
The “end replication problem” would have to be solved by telomeres. Before the 
molecular details about telomeres or their DNAs were revealed, some knowledge had 
been gathered about the replication properties at the telomeres. Virus and bacteria bearing 
temporarily or permanently circular genomes won’t be bothered by the “end replication 
problem”. T4 and T7 virus that have linear genomes can overcome the problem by 
genome ends fusions so that they are able to use the adjacent DNA strand as the primer 
[13, 14]. For some species such as the mammalian adenoviruses, the Terminal Protein 
(TP) acts directly as the primer for initiation of replication of the linear genome [15-19]. 
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However, a puzzle still remained about how eukaryotic double-stranded linear DNA is 
replicated at the telomeres. One proposed solution was that of Cavalier-Smith (1974), 
who suggested that the sequences at the ends of eukaryotic linear chromosomes could be 
palindromic. Following DNA replication, the very end that carries the 3’-OH group 
would be able to fold back and pair with itself to form a terminal loop (Fig. 1.2). The 
remaining gap would be closed by the DNA polymerase fill-in and ligation. Then, the 
opposite strand could be nicked by a specific endonuclease to make a new 3’-OH end for 
priming after the loop had unfolded to become the template for the last step to fill in the 
gap by DNA polymerase [20]. Although Cavalier-Smith’s model was proved wrong, it 
brought insights in understanding the telomere replication machinery.  
 
1.4 Telomeric DNA sequences  
The identification of telomeric DNA sequences is essential for understanding telomere 
replication and chromosome end structure. However, this was not an easy task due to the 
fact that chromosomes are too long for direct sequencing. The limited number of 
chromosomes in somatic cell also made it difficult to gather enough telomere material. 
The discovery of minichromosomes that contain amplified ribosomal RNA genes 
(rDNAs) in some simple eukaryotes, such as the ciliated protozoan Tetrahymena, made it 
possible to sequence the telomeric DNA [21, 22].  Compared with regular chromosomes, 
these linear DNA minichromosomes are relatively shorter and abundant, providing 
enough telomere materials for the analyzing purpose. In 1976, Engberg, Karrer and Gall 
first showed that the linear rDNA minichromosomes in cillated protozoan Tetrahymena 
thermophila are palindromic [23, 24]. Later, Blackburn and Gall determined the end 
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sequence by in vitro labeling combined with restriction endonuclease digestion, 
depurination and fingerprinting analyses. The digested fragments were very 
heterogeneous in length and contained tandem hexanucleotide sequence repeats 5’- 
(CCCCAA) n -3’ (n is between 20 and 70) [25]. In the 1980s, Szostak and Blackburn 
designed a linear plasmid that allowed them to clone out the budding yeast 
(Saccharomyces cerevisiae) telomeres and mapped the sequences [26]. Soon after, 
telomeric DNA sequences from many other eukaryotes were determined. Generally, the 
telomeric DNA is made of tandem repeated sequences, which are usually guanine-riched 
in the 5’ - 3’ strand (also called G-strand). Most of the telomeric DNA sequence is 
conserved among all the chromosomes in one species, and is usually different from 
species to species. The telomeric DNA sequence in different species is summarized in 
TABLE 1.1. In vertebrates, the telomeric repeat sequence is “TTAGGG”. Notably, the 
DNA end is not blunt; there is a 3’ overhang of the G-riched strand extending at the DNA 
termini [27-29].  
 
1.5 A specialized reverse transcriptase, telomerase that synthesizes telomeric DNA 
In the semi-conservative DNA replication process, the newly synthesized strands cannot 
be fully replicated from the templates due to the end replication problem (Section 1.2), 
which causes telomere shortening in each round of DNA replication. It was predicted that 
the average rate of the telomere erosion in human cells would be about 63 base pairs in 
each cell division [30, 31]. If there were no mechanism to compensate this telomere 
attrition, chromosome ends would eventually lose the protection by telomeres, and the 
“nude” chromosome ends would be recognized as DNA damage sites. In consequence, 
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the cells would trigger downstream DNA repair pathways. Inappropriate chromosomal 
end-to-end fusions through non-homologous end joining (NHEJ) or homologous 
recombination (HR) pathways would create dicentric chromosomes, which are unstable 
in mitosis (and meiosis) and lead to genome instability [32-35]. Therefore, all eukaryotic 
organisms have evolved mechanisms to add telomere sequences to the chromosome ends 
and thus counterbalance the terminal DNA attrition caused by the “end replication 
problem”. Several hypotheses, including the “hairpin” model and the recombination 
model, had been proposed to solve the end replication problem. However, in yeast cells, 
telomeric repeats could be added to a plasmid end that is capped with Tetrahymena 
telomeric repeats, suggesting that telomere addition doesn’t require DNA templates [36]. 
Therefore, it was summarized that there must be an unknown enzyme that is responsible 
for the de novo telomere repeats addition to the chromosome ends.  
In 1985, Carol Greider and Elizabeth Blackburn first successfully demonstrated 
the activity of this enzyme from the extracts of mating Tetrahymena. This enzyme, 
known as telomerase, could add the correct Tetrahymena telomeric repeats TTGGGG to 
the 3’ end of an oligonucleotide [7]. More importantly, telomerase has the ability to 
recognize the ending sequence of the oligonucleotide that it is elongating. For example, if 
the oligonucleotide ends with TTG, telomerase will first add GGG and then start the next 
round of TTGGGG addition. In other words, the sequence at the 3’ end determines what 
telomerase will first add to the primer [37]. This special feature implied that telomerase 
might use an internal nucleic acid template to mediate the nucleotide addition. This was 
later confirmed by the isolation of telomerase RNA, which was used by telomerase as the 
replication template [38]. The RNA template of Tetrahymena telomerase contains one 
7
and a half telomeric repeats (5’-AACCCCAA-3’) and helps telomerase discern the end 
sequence [38]. When the RNA template was mutated, telomerase was found to add 
mutated telomeric repeats to the end of the primer [39]. This confirmed that telomerase is 
a ribonucleoprotein (RNP) reverse transcriptase. The discovery of telomerase solved 
Watson’s end replication problem. Since then, telomerase was identified in many other 
organisms. In 1996, Lungblad and coworkers identified three yeast telomerase 
components (EST1, EST2 and EST3) through genetic screening in Saccharomyces 
serevisiae [40]. At the same time, telomerase was also purified from the hypotrichous 
ciliate Euplotes aediculatus by using an anti-sense oligonucleotide bait that was 
complimentary to the telomerase RNA template by Cech and coworkers [41].  
Human telomerase includes an RNA template (telomerase RNA component, 
TERC, also known as TR or TER) [38, 42-45], a highly conserved reverse transcriptase 
catalytic subunit (telomerase reverse transcriptase, TERT) and some other accessory 
factors (for instance, Est1 and dyskerin in humans) [32, 45-50]. The RNA hTR and the 
catalytic subunit hTERT form the core of human telomerase. Two different genes in the 
human genome code for TERC and hTERT separately. TERT contain a C-terminal 
reverse transcriptase (RT) domain that is similar to RTs from retroelements and 
retroviruses. There are seven motifs (1, 2, A, B, C, D and E) that can be recognized in the 
conserved RT domain in all the TERTs (Fig. 1.3a). Three-dimension structural modeling 
results suggested that similar to the RT domains from human immunodeficiency virus 
(HIV) and murine leukemia virus (MLV), the seven RT motifs from TERT form a “right 
hand”-like structure. RT motifs 1 - B are the fingers, motifs C – E form the palm, and the 
carboxy-terminal extension (CTE) domain forms the thumb (Fig. 1.3b) [51-55]. The 
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active site of the enzyme is found within motifs A – C. Three aspartic acids from A and C 
are most important for composing the active site, as shown in the crystal structure of 
Tribolium castaneum TERT (Asp251, Asp343 and Asp344) [56]. The hTR gene, encodes 
an untranslated RNA which is 451 nucleotides in length that remains as an RNA in 
functional telomerase. The template region of human TERC is 3’-CAAUCCCAAUC-5’, 
which is complementary to the human telomeric DNA sequence TTAGGG. Human 
TERC can be divided into four regions, the template region, the TERT binding site, the 
pseudoknot domain, and the binding region for associated proteins such as the Dyskerin 
complex (Gar1, Nop10, Nhp2, Dyskerin) (Fig. 1.3c) [57-61]. Notably, the RNA template 
regions from different species share several common features. First, the RNA template is 
single-stranded and about 1.5 – 2 times of the telomeric repeats in length. The length of 
the template allows TERT to accomplish annealing and nucleotides addition within the 
same elongation step. Second, when the telomerase holoenzyme is assembled, the 
template will be buried into the TERT active site. TR and TERT are the most essential 
telomerase components and telomerase activity can be reconstituted in vitro when mixing 
TR and TERT properly under certain conditions. In my studies, HA-tagged hTERT and 
hTR were in vitro T7-transcribed/translated in the rabbit reticulocyte lysate and then the 
reconstituted enzyme was affinity purified by anti-HA conjugated Sepharose. Robust 
telomerase activity could be detected in direct telomerase activity assays by using the in 
vitro reconstituted telomerase via this method [62, 63].  
After telomerase holoenzyme is properly assembled, TERT forms a special 
“mitten” structure to warp the chromosome end in order to favor the telomeric repeats 
addition [45]. When telomerase adds nucleotides to telomere ends, it takes the following 
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steps: annealing, elongation, translocation and further elongation in a processive manner 
[64, 65]. Firstly, with the help of the accessory factors, telomerase locates to the 
chromosome end and anneals to the 3’ G-overhang) via its internal RNA template (Fig. 
1.4a). Then the protein component TERT functions as the reverse transcriptase and adds 
nucleotides to the end of the G-overhang according to the RNA template (Fig. 1.4b). 
After the initial round of nucleotide extension, the RNA template/telomere DNA hybrid 
duplex is disassembled and the telomere end realigns to the 3’ end region of the template 
(the “Translocation” step to the end “TTAG” sequence in this case, as shown in Fig. 1.4c) 
before starting the next round of “GGTTAG” nucleotide addition (the “Elongation” step 
as shown in Fig. 1.4d). Telomerase repeats the translocation and elongation steps, and 
add “GGTTAG” repeats to telomeres continuously (Fig 1.4e-f). Telomerase adds 
telomeric repeats to telomere without falling off the DNA and it is called repeat addition 
processivity of telomerase, which is defined as “the number of the bases synthesized 
when the cumulative probability of dissociation is ” [64]. Specifically, Processivity = 
R1/2 = -ln2/(2.303k), where k is the slope and R1/2 is the number of repeats synthesized 
before half of the chains have dissociated, analogous to t1/2 in radioactive decay [63]. 
After the telomerase extension at the 3’ G-overhang, the proper processing of 5’ C-strand 
is also required. The 3’ G-overhang could end with any nucleotide within the 
“TTAGGG” sequence [66]. However, when telomerase is present, TAG-3’ is most likely 
to be observed. Unlike the 3’ end, in contrast, the human 5’-strand usually ends with 
ATC-5’ and some evidence suggests that the C-strand sequence is determined by the 
single-stranded telomeric DNA binding protein POT1 [67]. However, the mechanism of 
C-strand processing is still unknown.  
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1.6 Telomere binding proteins 
Telomere binding proteins recognize the short tandem telomere repeats and are essential 
for stable chromosome maintenance as reflected in the precipitous genome-destabilizing 
outcomes following gene deletion and over-expression of mutant alleles [32]. The 
nucleoprotein complexes formed upon association of telomere binding proteins with 
telomeric DNA distinguish natural chromosome ends from double-stranded breaks and 
thereby protect chromosome termini from inappropriate end-to-end fusion. Additionally 
telomere binding proteins recruit and regulate telomerase to ensure an appropriate length 
of structural DNA that is maintained as a buffer against loss of genetic information stored 
in genes close to the ends of linear chromosomes. Telomere binding proteins can be 
broadly divided into two classes on the basis of double-stranded versus single-stranded 
DNA-binding specificity. DNA-binding specificity correlates with folding motifs 
particular to each class, with the OB-fold dictating the single-stranded G-overhang 
recognition and the Myb motif proteins directed towards double-stranded telomere DNA. 
 
1.6.1 Telomeric proteins that recognize the single-stranded G-overhang 
The 3’ end single-stranded G-overhang that extends beyond the duplex region of the 
telomere is a conserved structure in most eukaryotic organisms from ciliated protozoa, to 
yeasts and mammals [68-70]. The first protein to be identified that specifically recognizes 
and caps the single-stranded G-overhang was the ciliate Oxytricha nova TEBP (telomere 
end binding protein) [71, 72]. TEBP is composed of two subunits,  and . This 
telomere-specific structural protein complex recognizes and binds tenaciously to the 
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single-stranded G-overhang in a sequence-specific fashion, also protecting the 
neighboring duplex telomeric DNA [73].  
In budding yeast Saccharomyces cerevisiae, the single-stranded G-overhang is 
bound specifically by Cdc13 [74, 75]. Cdc13 was initially identified as a cell cycle 
related gene. Loss of cdc13 led a rad9-dependent cell cycle arrest and induced 
chromosomes ends recombination, indicating a connection between Cdc13 and telomeres 
[76, 77]. Cdc13 was also identified through a screening for the telomere length defect 
genes (referred as to ever shorter telomeres) [40, 75]. Cdc13 has two separate functions: 
it is involved in both chromosome end protection and the recruitment of the telomerase 
and hence in telomere replication [40, 74].  
Due to the very limited amount of materials, initial biochemical studies of single-
stranded G-overhang binding proteins failed to deliver the desired factors in organisms 
other than ciliates. Eventually, POT1 (protecting of telomeres 1), a conserved protein 
found in fission yeast Schizosaccharomyces pombe, humans and many other organisms, 
was identified through a database search based on a weak sequence similarity to the 
amino-terminal region of the O. nova TEBP  subunit [78-83]. Deletion of the pot1 gene 
in fission yeast leads to rapid loss of telomeric DNA and chromosome circularization, 
suggesting POT1 has a crucial role in telomere capping [78]. POT1 binds to the G-strand 
of S. pombe telomeric DNA with high affinity in a highly cooperative manner [78, 84]. In 
human cells, POT1 localizes to telomeres, and loss of the G-rich overhang causes a 
reduction in hPOT1 binding [79, 85]. In human cells, POT1 has a crucial role in telomere 
length homeostasis, acting as the terminal transducer of telomere length control. 




) led to rapid telomere lengthening in telomerase-positive cells [85]. In other 
studies, however, expression of full-length POT1 caused substantial telomere elongation 
by telomerase [86, 87]. These disparate conclusions indicate that human POT1 plays an 
essential but complicated role in the regulation of telomere length. Human POT1 also 
contributes to the protection of chromosome ends, since partial knockdown of POT1 with 
RNAi results in a DNA-damage response at telomeres, reduction in the single-stranded 
telomeric DNA, changes in the 5’ end of the chromosome, and a telomere fusion 
phenotype [67, 87, 88].  
Mechanistic insights into how the single-stranded G-overhang binding proteins 
bind and protect telomeres started to emerge after the determination of the three-
dimensional structures of the telomere end-binding proteins: TEBP, Cdc13, and POT1 
[89, 90] [91-93]. All these proteins bind the single-stranded G-overhang using a 
conserved DNA-binding motif, the OB (oligonucleotide/oligosaccharide binding)-fold 
[94]. The OB-fold is a structural domain of 70 – 180 amino acids in length with diverse 
functions, and has been found in many proteins including human replication protein A 
(RPA), the B subunit of E. coli verotoxin-1 and E. coli single-stranded DNA-binding 
protein (SSB) [94]. OB-folds are difficult to recognize by amino acid sequence analysis 
alone because of the very low sequence identity, and consequently structural information 
is often needed for OB-fold identification. The OB-fold comprises two orthogonally 
packed anti-parallel  sheets with 1: 4: 5 strand topology in one sheet and 1: 2: 3 
topology in the other. The N-terminal strand 1 continues as the outer edge of both 
sheets. Strands 4 and 5 often fold over to extend the other sheet and thus complete a 
closed -barrel-like structure. The segment joining strands 3 and 4 often includes a 
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short helix (Fig. 1.5)[94]. Most telomere-binding OB-folds are further characterized by a 
C-terminal -helix. The loops connecting  strands of the OB-fold are variable in length 
and these insertions/deletions account for the unreliability of current bioinformatics tools 
for positively identifying OB-folds.  
The first well-characterized structure of the single-stranded G-overhang binding 
protein is O. nova TEBP [89]. The crystal structure of the heterotrimeric TEBP -TEBP -
ssDNA complex revealed a total of four OB folds. TEBP  consists of three OB folds, 
two tandem OB folds at the N-terminus (OB1 and OB2) that bind DNA and a third one at 
the C-terminus (OB3). The single OB-fold in TEBP  also interacts with DNA [89]. 
Together, the three DNA-binding OB folds form a deep DNA-binding cleft and the 3’-
terminal nucleotide is buried deep within the complex, making it inaccessible to 
telomerase, consistent with the finding that the TEBP -TEBP  complex blocks 
telomerase activity [95]. The interaction responsible for the TEBP -TEBP  association 
is established by an extended peptide loop contributed by TEBP  that wraps around the 
C-terminal OB of the  subunit.  
Lei et al. solved the crystal structure of the N-terminal part of S. pombe POT1 
complexed with single-stranded telomeric repeat GGTTAC [92]. The structure confirmed 
that the OB-fold at the N-terminus of POT1 mediates the specific binding to ssDNA with 
high affinity. By the two protruding loops at one side of the -barrel, the POT1 OB-fold 
clamps the single-stranded fission yeast telomeric DNA repeat “GGTTAC” tightly. The 
ssDNA was compactly folded and was buried in a basic pocket in the direction from 5’ to 
3’ across the OB-fold [92]. Later on, the crystal structure of the DNA-binding domain of 
human POT1 reveals two tandem OB folds bound the minimum binding sequence 
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(TTAGGGTTAG) that is more than one telomere repeat [93]. The two OB folds pack 
together and form a continuous DNA binding cleft.  Notably, the last nucleotide G10 is 
deeply buried in the binding pocket. It was hypothesized that the burying of G10 may 
prevent access by telomerase [93]. The superposition of the crystal structures of O. nova 
TEBP , S. pombe POT1 and human POT1shows that the three single-stranded G-
overhang-binding proteins bind to their cognate single-stranded telomere DNAs in a 
similar manner.  Taken together, both functional and structural studies strongly support 
the notion that POT1 proteins are indeed the homologue proteins of O. nova TEBP  
subunit as initial sequence analysis suggested. Whether higher eukaryotes have a TEBP  
subunit homologue, however, remains unknown. 
TPP1 is the most recently identified component of human telomere proteins that 
simultaneously interacts with both POT1 and another human telomere protein TIN2 [96-
98]. A 60-residue fragment at the C-terminus of TPP1 binds to the N-terminal half of 
TIN2, and a central region of TPP1 with ~ 100 amino acids binds to the C-terminal half 
of POT1. Database searches failed to identify any notable structure features in TPP1. 
Functional analyses suggested that TPP1 regulates the telomere recruitment of POT1 and 
TPP1 itself is a negative regulator telomere length [96-98] (reviewed in [99]). In order to 
explore the additional functions of TPP1 at the telomere, I determined the crystal 
structure of a portion of TPP1. The structure of TPP1 reveals an OB fold that is 
structurally most similar to the  subunit of O. nova TEBP. Furthermore, our biochemical 
studies demonstrated that, although itself does not bind ssDNA, TPP1 enhances the 
POT1-ssDNA interaction, exhibiting properties closely resembling those of TEBP  
[100]. Thus, our data clearly showed that TPP1 is the missing human homologue of the 
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O. nova TEBP  subunit and that capping of telomeres by a TEBP /  dimer is more 
conserved evolutionary than had been expected. These results will be discussed in detail 
in Chapter 2. 
 
1.6.2 Telomeric proteins that recognize the double-stranded telomeric DNA 
Just as the OB-fold is the signature of all single-stranded G-overhang binding proteins, 
the Myb motif is found in all telomere binding proteins that recognize double-stranded 
telomere DNA. The Myb motif is named after the transcription factor, c-Myb, a proto-
oncogene products that regulates differentiation and proliferation during hematopoiesis 
[101]. The Myb motif consists of three -helices arranged in an orthogonal bundle 
around a hydrophobic core (Fig. 1.6). The third helix presents residues that make 
sequence-specific contacts with bases in the major groove of B-form DNA [102-104]. 
For telomere proteins, these DNA recognition residues are especially well conserved and 
defined the so-called telobox sequence feature [105, 106].  
Budding yeast Saccharomyces cerevisiae Rap1 (repressor-activator protein 1) was 
the first identified double-stranded telomeric DNA-binding protein. Rap1 functions as a 
multifunctional protein that plays a crucial role in regulating telomere length, activating 
or repressing transcription [107-109]. Rap1 binds to the budding yeast irregular telomeric 
sequence (GTG1-3) directly via its two tandem Myb motifs in the center of the protein 
[110, 111]. Rap1 is a negative regulator of telomere length [107, 108], and the number of 
bound Rap1 molecules at a telomere seems to constitute a telomere-length measuring 
mechanism [112, 113].  
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The double-stranded telomeric DNA in mammals is bound sequence specifically 
by two closely related proteins, TRF1 and TRF2. TRF1 (telomere repeat binding factor 1) 
was first identified from Hela cell extracts by using tandem TTAGGG repeats as the 
probe [114]. TRF1 contains three domains: an N-terminal acidic region, a dimerization 
domain in the center, and a DNA-binding Myb domain at C-terminus [115, 116]. TRF1 
forms a dimer and remains a dimer when bound to the duplex TTAGGG repeats [116, 
117]. The dimerization is mediated via the central domain that is referred to as TRF 
homology (TRFH) domain [118]. TRF1 functions as a negative regulator of telomere 
length in telomerase-positive cell lines. Over-expression of TRF1 leads to telomere 
length shortening whereas removal of TRF1 from telomeres causes progressive 
elongation of the telomere length [119]. Not long after the discovery of TRF1, a novel 
protein TRF2, which shares high homology with TRF1, especially the C-terminal Myb-
domain sequence, was found in human and mouse [120, 121]. Structurally, both TRF1 
and TRF2 contain a Myb-domain at the C-terminus that is responsible for interacting 
with the TTAGGG telomeric dsDNA directly. TRF2 also has the central TRFH domain 
that mediates the homodimer formation. The N-terminal of TRF2 is a basic region that 
prevents telomeres from being engaged in homologous recombination (HR) mediated 
telomere attrition [122]. TRF2 functions as a recruiter to bring other protein factors to 
telomeres [123]. Although TRF2 is also involved in telomere length regulation [124], its 
primary role appears to be in capping and protecting chromosome ends (reviewed in 
[125]).  
The crystal structures of the TRFH domains from both human TRF1 and TRF2 
revealed that they have almost identical and entirely -helical dimeric structures [118]. 
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The overall structure of the TRHF domain resembles a twisted horseshoe and each 
monomer contains 10  helices. The dimer interface is formed by six  helices, 1, 2 
and 10 form each monomers (Fig. 1.7). The biological importance of a dimeric structure 
of the TRF proteins was highlighted by point mutations at the dimeric interface that 
prevent telomere localization in vivo [118]. Despite the structural conservation, the 
sequence divergence between TRF1 and TRF2 TRFH domains results in different dimer 
interfaces that prevent TRF1/TRF2 heterodimer formation. Consideration of domain 
architecture in Rap1, TRF1 and TRF2 supports the view that telomere double-stranded 
DNA-binding proteins are constrained to use two Myb motifs for recognition of telomeric 
DNA. The two Myb units can be arranged either as tandem repeats as seen in ScRap1 or 
as individual units as seen in TRF1 and TRF2 that are brought together by protein 
dimerization.  
Taz1 (telomere-associated protein in Schizosaccharomyces pombe) was identified 
as the double-stranded telomeric DNA-binding protein by using the one-hybrid screening 
in fission yeast [118, 126, 127]. Taz1 is involved in fission yeast telomere end protection, 
telomere length regulation, and 3’ overhang processing [128, 129]. Deletion of taz1
+
 in a 
trt1
+
 background (TRT1 is the catalytic protein subunit of S. pombe telomerase), results 
in dramatically increased telomere length as well as length hererogeneity [126, 130]. It 
has been proposed that by involving in a negative feedback control of synthesis of its 
own binding sites, Taz1 could count the telomeric repeats, and thus function in the 
similar “protein-counting” mechanism as budding yeast Rap1 and human TRF1 [113, 
119, 131]. In addition, similar to the TRF2-RAP1 interaction at human telomeres, Taz1 
also recruits Rap1 (the fission yeast ortholog of human RAP1) to telomeres by direct 
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interaction [132, 133]. Structurally, Taz1 forms a homodimer and binds to the fission 
yeast telomeric double-stranded DNA in a sequence-specific manner [106, 134]. Taz1 
contains a Myb domain at the C-terminus, which shares high sequence identity (29%) and 
similarity (66%) with TRF1 and TRF2 Myb domains [118, 126, 134]. Notably, Taz1 has 
a central predicted -helical region (residues 113-400) that has low sequence similarity 
and identity to the TRFH domains of human TRF1 and TRF2 [118]. Nevertheless, it was 
proposed that this region contains the TRFH domain and mediates homodimer formation 
in a similar way as TRF1/TRF2-TRFH [127]. Collectively, functional and biochemical 
studies all suggested that Taz1 is the fission yeast ortholog of mammalian TRF1 and 
TRF2. Similar TRF-like dsDNA binding protein is also found in Trypanosoma brucei 
[135], which suggests that TRFH domain might be an ancient component of the telomeric 
complex and could be another conserved feature in most dsDNA binding telomeric 
proteins. 
However, several key issues regarding Taz1 remains to be answered. Is the 
putative TRFH domain of Taz1 structurally similar to TRF1/TRF2-TRFH? Is this region 
indeed the dimerization domain of Taz1? How does Taz1 bind to Rap1 and does this 
interaction resemble the one between human TRF2 and RAP1? In Chapter 3, we will use 
both structural and functional approaches to address these questions. 
 
1.6.3 The telomere shelterin complex 
The core mammalian telomeric complex is called shelterin, for its role in telomere 
protection [136-138] (reviewed in [139]). It is delivered to telomeres by two of its 
components, TRF1 and TRF2. TRF2 recruits an additional factor, RAP1 [127]. The 
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mammalian G-overhang binding unit is a heterodimer of POT1-TPP1 [63]. A sixth factor, 
TRF1-interacting nuclear factor 2 (TIN2), interacts with three shelterin proteins, TRF1, 
TRF2 and TPP1, and thus has an important architectural role in bridging the duplex 
binding proteins, TRF1 and TRF2-RAP1, with the POT1-TPP1 complex at the single-
stranded G-overhang (Fig. 1.8). Sheltein is at telomeres throughout the cell cycle, it does 
not accumulate elsewhere in the nucleus, and its function is limited to telomeres. This is 
the major difference that distinguishes shelterin from several DNA damage-processing 
factors and various other proteins that are also found at telomeres. These telomere-
associated proteins can have crucial roles at telomeres, but also have nontelomeric 
functions. They often accumulate elsewhere in the cell, they are less abundant at 
telomeres than shelterin, and several are at telomeres transiently.  
Shelterin plays an important role in keeping telomeres away from DNA damage 
checkpoints and therefore protects chromosome ends from inappropriate DNA repair 
pathways [139]. In addition, shelterin affects the structure of the telomere terminus and 
controls the synthesis of telomeric DNA by telomerase. POT1 is implicated in telomerase 
recruitment and C-strand processing [67, 86, 87]. The different possible localizations of 
POT1 at the 3’ G-overhang may switch telomerase on and off by occupying different 
positions on the substrate DNA for telomerase extension [62]. At the duplex region, 
TRF1, TRF2 and TIN2 are part of the negative feedback loop that regulates telomere 
length. RAP1 may function as a negative regulator for telomere length (reviewed in [32]). 
But, recent data suggested that RAP1 also plays an important role in telomere end 
protection [140]. Collectively, shelterin helps maintain the proper length and structure of 
telomeres and protect chromosome ends from DNA damage surveillance and repair 
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pathways.  
A multi-protein telomeric complex with a shelterin-like architectural organization 
has been revealed in fission yeast S. pombe [141]. There are seven components in this 
complex, and many of them are the structural and functional homologues of the shelterin 
proteins (Fig. 1.9). Taz1 binds to the double-stranded telomeric DNA, regulates telomere 
homeostasis, and recruits another component Rap1 to telomeres. Thus, Taz1 functions as 
the S. pombe homolog of mammalian TRF1 and TRF2. At single-stranded G-overhangs, 
Pot1 and a Pot1-interacting partner, Tpz1, form a heterodimer that is the homolog of 
POT1-TPP1. Consistent with this notion, Pot1-Tpz1 protects telomeres and regulates 
telomerase activity [141]. Poz1, a small protein with no obvious sequence similarity to 
any components of the mammalian shelterin, interacts with both Tpz1 and Rap1, and thus 
connects the single-stranded and double-stranded binding proteins together (Fig. 1.9). 
This bridging function of Poz1 closely resembles the architectural role of TIN2 in the 
shelterin complex, raising the possibility that Poz1 might be a TIN2 homolog. One 
important difference is that Poz1 in S. pombe, unlike TIN2 in mammalian, interacts with 
Rap1. Another novel component is coiled-coil quantitatively enriched protein 1 (Ccq1). 
Ccq1 interacts with Tpz1 and plays a key role in recruiting telomerase to telomeres 
([141], reviewed in [142]). Further work is required to identify the telomeric complexes 
in other organisms that, with no doubt, will bring us more mechanistic insights in the 
functions of these essential complexes. 
 
1.7 Telomere higher-order structure, the t-loop  
Evidence from a large number of studies suggests that both yeast and mammalian 
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telomeres exist in higher-order structures. A lasso-like structure called the t-loop was 
isolated from human telomeres from DNA cross-linking carried out in vivo and 
subsequently visualized by electron microscopy [143] (Fig. 1.10). The t-loop contains 
thousands of base pairs of TTAGGG repeats and is proposed to form by the insertion of 
the G-overhang into the double-stranded region of telomeric DNA [143]. During the 
invasion, a D-loop structure is also formed (Fig. 1.10). The t-loop can be reconstituted by 
incubating purified human TRF2 with double-stranded telomeric DNA ending in a 
single-stranded G-overhang [144]. Subsequently, t-loop structures have been observed at 
the end of telomeres of many other organisms including mouse, chicken, pea, 
trypanosome and yeast mitochondria, and hence appear to be an evolutionarily conserved 
feature of telomere structure.  
Repetitive telomeric DNA and a homologous single-stranded 3’ G-overhang are 
structurally essential for t-loops to form. However, these elements also make the telomere 
a prime target for homologous recombination. The t-loop is structural mechanism that 
sequesters the ends of linear chromosomes, prevents recognition of the chromosome end 
as a double strand DNA break and inhibits exonulceolytic degradation; but the t-loop 
itself poses another problem. In particular, t-loops resemble homologous recombination 
intermediates and branch migration of a t-loop could generate a Holliday junction. This 
raises the question, how do telomeric DNA and its associated proteins prevent 
inappropriate recombination at the telomere or t-loop? Recent data suggest that double-
stranded telomeric DNA binding protein TRF2 and a newly identified BLM complex 
play important roles in telomere protection and maintenance. The structural study of the 
BLM complex is discussed in Chapter 4. 
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1.8 Telomere, telomerase and cancer 
Telomerase is highly expressed in cells that need to divide regularly. In embryonic stem 
cells and specific germ-line cells, telomerase is expressed and remains fully active, [48, 
49, 145, 146] (reviewed in [32, 147]). But, it is undetectable in most normal somatic cells 
except for proliferative cells of renewal tissues. Therefore, telomere length is shortened 
progressively in these nonproliferative somatic cells. Telomere shortening is 
hypothesized to be the direct cause for the “Hayflick limit” and a mechanism that 
prevents normal cells from developing to cancerous cells [148]. In 1998, Bodnar et al. 
demonstrated the relationship between telomere shortening and proliferative failure in 
human cells [149]. Transfection of hTERT into two telomerase-negative normal human 
cell lines successfully restored the telomerase activity. These hTERT transfected cells 
exhibited longer telomeres, indefinite life span and lower level of senescence.  
While telomerase activity is undetectable in most normal somatic cells, high 
levels of telomerase expression or re-expression and robust telomerase activity can be 
detected in more than 90% of tumor samples [150-156].  This discovery suggested that 
telomerase is a very good marker for cancer diagnosis and a potential target for anti-
cancer therapy [157-159]. The regulation of telomerase activity usually occurs at the gene 
transcription level. The transcription of hTERT gene is repressed by numerous factors, 
thus affecting telomerase assembly [160, 161] (reviewed in [161]). A genetic screen 
searching for the negative regulators of hTERT was performed by Lin and Elledge and 
identified three tumor suppressor/oncogene pathways that have the ability to repress 
hTERT, Mad1/c-Myc pathway (implicate in hTERT regulation), SIP1 (a transcriptional 
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target of TGF- pathway, mediates TGF-–regulated hTERT suppression) and Menin (a 
direct hTERT repressor) [162]. Although tumor cells require telomerase activity for 
keeping long-term proliferation, the hTERT gene itself is not an oncogene and is not 
sufficient to induce cell transformation [163, 164].  Thus, telomerase is controlled at a 
subtle balance between cellular senescence and immortalization.  
Not all the cancer cells and tumor tissues require telomerase to maintain the 
potential for proliferation. A telomerase-independent telomere maintenance pathway has 
been identified and named the “alternative lengthening of telomeres” (ALT) mechanism 
[165]. The available data indicate that ALT involves homologous recombination-
mediated DNA replication and requires the activity of many recombination complexes. 
Increased levels of various types of telomere recombination events in ALT cells suggest 
that the cellular mechanisms that normally regulate recombination at mammalian 
telomeres have been lost. Understanding how telomeres are maintained in ALT cells will 
help reveal the mechanisms that have evolved in mammalian cells (primary cells) to 
inhibit deregulated homologous recombination at the telomeres and thus prevent telomere 
elongation and cellular immortalization. 
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Figure 1.1 End replication problem 
The leading strand (green) is continuously synthesized from 5’ to 3’ by polymerase. The 
lagging strand (blue) synthesis is initialized by RNA primers (red) from 3’ to 5’. When 




Figure 1.2* Cavalier-Smith’s model for the synthesis of 5’ ends of a daughter DNA 
molecule (the 3’ end of a polynucleotide shown by an arrow, cyan and green lines 
are two complementary strands, newly synthesized DNA by a thick line). 
(a) Gap at 5’ end of new DNA; 
(b) The self complementary 3’ terminal strand of the palindromic sequence base pairs to 
form a hairpin loop; 
(c) 3’ OH end serves as a primer for a DNA polymerase to fill in the gap. 
(d) DNA ligase seals the remaining nick; 
(e) A sequence specific endonuclease nicks the old strand; 
(f) The loop unfolds; 
(g) DNA polymerase completes the old strand with new DNA. 




TABLE 1.1 Telomeric DNA Sequence  
 
Species Organism 5’ - Telomeric DNA Repeat Sequence - 3’ 
Vertebrates Human, mouse, Xenopus TTAGGG 
Higher plants Arabidopsis thaliana TTTAGGG 
Saccharomyces cerevisiae G(2-3)(TG)(1-6)T 
Candida albicans GGTGTACGGATGTCTAACTTCTT 
Candida glabrata GGGGTCTGGGTGCTG 




Candida tropicalis GGTGTA[C/A]GGATGTCACGATCATT 
Fission yeast Schizosaccharomyces pombe TTAC(A)(C)G(1-8) 
Tetrahymena TTGGGG Ciliate protozoa 
Oxytricha TTTTGGGG 
Kinetoplastid protozoa Trypanosoma TTAGGG 
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Figure 1.3* Structure illustrations of human TERT and TR 
(a) Domain organization of human TERT and comparison to RTs from retroviruses and 
retrotransposons. The RT domain (dark grey) includes conserved RT motifs 1 to E 
(fingers and palm) and the thumb domain, which is much more divergent among RTs 
(pink). The CTE (carboxyl-terminal extension) of telomerases contains three blocks of 
conserved amino acids. The amino-terminal half contains one or two RNA-binding 
domains (green). The region in blue may bind to another region in TR. Endonuclease 
(EN, orange) and RNase H (light gray) domains found in some retrotransposons and 
retroviruses have not been identified in TERT.  
(b) Model of a monomeric human telomerase RNP in the absence of hEST1A/B and 
other telomerase-associated proteins. The central RT structure (grey and pink) 
corresponds to murine leukemia virus RT [52] and includes its finger, palm, and thumb 
domains but not the RNase H domain. The colors are the same as those in (a).  
(c) Telomerase RNA secondary structure model for Homo sapiens. Different regions are 
highlighted by different color, as indicated.  
(* Figure 1.3a is made based on Fig. 2 from Chapter 2 The Telomerase 
Ribonucleoprotein Particle, Telomeres 2
nd
 edition 2006, Cold Spring Harbor Laboratory 
Press. Figure 1.3b and 1.3c are the photocopies of Fig. 3 and Fig. 1B from Chapter 2 The 
Telomerase Ribonucleoprotein Particle, Telomeres 2
nd











Figure 1.4 Telomerase elongates telomere in a processive manner. 
(a) Telomerase anneals to telomere via its RNA template;  
(b) Telomerase adds nucleotides (red) to the end of telomere; 
(c) Telomerase translocates to the next binding site without falling off the telomere; 
(d) Repeats step (b), the added nucleotides are colored in blue; 
(e) Repeats step (c) 








Figure 1.5 Cartoon illustration of OB-fold Structural architecture of a typical OB-fold 
(ref [94], Fig. 1); a typical OB-fold has the - - - - -  secondary structural 





Figure 1.6 Structure of a typical c-Myb domain Cartoon illustration of the mouse c-







Figure 1.7 Crystal structure of human TRF1-TRFH dimer Cartoon illustration of the 
TRFH domain of human double-stranded telomeric DNA binding protein TRF1 (PDB#: 
1H6O). TRF1-TRFH forms a homodimer through the interactions between six  helices, 
1, 2 and 10 from each of the two monomers.  
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Figure 1.8 Cartoon illustration of shelterin complex 
(a) Six shelterin complex components: TRF1 (cyan) and TRF2 (green) on the double-
stranded telomeric DNA; TIN2 (purple) binds to both TRF1 and TRF2; Rap1 (light 
green) interacts with TRF2; TPP1 (blue) interacts with both TIN2 and POT1 (red). POT1 
binds to single-stranded telomeric DNA.  








Figure 1.9* The shelterin-like complex in fission yeast S. pombe There are seven 
components in this complex: Taz1 (purple) on the duplex telomeric DNA, Rif1 (green) 
and Rap1 (orange) interact with Taz1. Pot1 (blue) binds to single-stranded telomeric 
DNA (not shown in this figure) and interacts with Tpz1 (cyan). Ccq1 (dark red) interacts 
with Tpz1. Poz1 (wheat) connects Tpz1 and Rap1. Some of them are the structural and 
functional homologues of the shelterin proteins.  
(* This figure is photocopied from Fig. 2 of the review paper by Bianchi and Shore. 
[142]) 
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Figure 1.10 Telomere and T-loop 
(a) Telomere region is divided into 2 regions: double-stranded telomeric DNA region and 
3’ G-overhang. Green and cyan lines are two complementary strands of DNA.  
(b) 3’ G-overhang folds back and invades into the double-stranded DNA track. D-loop 
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CHAPTER 2 
FUNCTIONAL AND STRUCTURAL ANALYSES OF POT1-TPP1 COMPLEX IN 
SINGLE-STRANDED TELOMERIC REGION 
 
 
POT1 proteins have been identified from many other organisms as the homologues of the 
 subunit of O. nova TEBP. It provides the most widespread solution to chromosome end 
protection in eukaryotes [1-8]. However, whether higher eukaryotes have a TEBP  
homologue remains unknown. TPP1 is a telomere protein that simultaneously interacts 
with both POT1 and TIN2 [9-11] (Fig. 1.8). In this chapter, I first focus on the functional 
and structural characterization of the POT1-TPP1 complex (Section 2.1). In Section 2.2, I 
extend the discussion to the studies of a budding yeast telomerase protein Est3 and its 
functional and structural connection to mammalian TPP1. The results of Section 2.1 have 
been published in Nature  (2007. 445(7127): p. 506-10) and part of the results in Section 
2.2 have been published in Nat Struct Mol Biol (2008. 15(9): p. 985-9) as a co-author 
paper with our collaborator Dr. Neal Lue at Weill Medical College of Cornell Universtiy. 
 
2.1 The POT1-TPP1 Telomere Complex is a Telomerase Processivity Factor  
2.1.1 Abstract 
Telomeres were originally defined as chromosome caps that prevent the natural ends of 
linear chromosomes from undergoing deleterious degradation and fusion events. POT1 
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(protection of telomeres) protein binds the single-stranded G-rich DNA overhangs at 
human chromosome ends and suppresses unwanted DNA repair activities. TPP1 is a 
previously identified binding partner of POT1 that has been proposed to form part of a 
six-protein shelterin complex at telomeres. Here, the crystal structure of a domain of 
human TPP1 reveals an oligonucleotide/oligosaccharide-binding fold that is structurally 
similar to the -subunit of the telomere end-binding protein of a ciliated protozoan, 
suggesting that TPP1 is the missing -subunit of human POT1 protein. Telomeric DNA 
end-binding proteins have generally been found to inhibit rather than stimulate the action 
of the chromosome end-replicating enzyme, telomerase. In contrast, we find that TPP1 
and POT1 form a complex with telomeric DNA that increases the activity and 
processivity of the human telomerase core enzyme. We propose that POT1–TPP1 
switches from inhibiting telomerase access to the telomere, as a component of shelterin, 
to serving as a processivity factor for telomerase during telomere extension.  
 
2.1.2 Introduction 
Telomeres, the specialized DNA-protein complexes found at the termini of all linear 
eukaryotic chromosomes, protect chromosomes from degradation and end-to-end fusion 
[12]. Telomeric DNA typically consists of tandem repeats of a short G-rich sequence 
oriented 5’ to 3’ towards the chromosome terminus, with the G-rich strand extending 
beyond its complement to form a 3’ overhang. In most eukaryotes, telomere length is 
maintained by telomerase, a specialized reverse transcriptase that adds telomeric DNA to 
the 3’ ends of chromosomes to ensure complete genome replication [13]. Telomerase is 
strongly upregulated in most cancer cells and has been studied as a plausible anti-caner 
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target [14].  
A six-protein complex is though to protect the telomeres of human chromosomes. 
TRF1 and TRF2 directly bind double-stranded telomeric DNA [15, 16]. POT1 directly 
binds the single-stranded 3’ extension at the chromosome end [1, 2, 5, 6, 8, 17], and these 
are bridged through protein-protein interactions involving TIN2 and TPP1 (refs [9-11, 
18-22]). The sixth protein, RAP1, binds mostly to TRF2 (refs [21, 23]). Two functions 
have been proposed for this complex: protecting the natural chromosome end from being 
mistaken for a broken end and being subjected to DNA repair, and negative regulation of 
telomerase by sequestration of its telomeric DNA substrate. Both functions of this 
complex are captured by the name shelterin [24].  
Because POT1-TPP1 has been viewed as a structural component of the telomere, 
we were surprised to find that it increases both the activity and processivity of core 
telomerase. This is the first protein complex shown to substantially activate telomerase 
processivity. The crystal structure of TPP1 shows high structural similarity to the -
subunit of TEBP (telomere end-binding protein) from Oxytricha nova, a ciliated 
protozoan [25-27]. Because POT1 is the human homologue of TEBP  [1, 2, 8, 28], it 
now appears that capping of telomeres by a TEBP -  dimer is more conserved 
evolutionary than had been expected.  
 
2.1.3 TPP1 and POT1 forms ternary complexes with ssDNA 
Recombinant human TPP1 protein with an N-terminal deletion, TTP1 (90-544) (Fig. 
2.1a), was overexpressed and purified from Escherichia coli. TPP1 (90-544) was chosen 
because the 87 N-terminal residues of TPP1 are functionally dispensable in human cells 
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[9, 11] and are not conserved among TPP1 proteins of different organisms [10, 11]. For 
simplicity, we hereafter use TPP1 to represent TPP1 (90-544) unless stated otherwise.  
TPP1 was first identified as the binding protein of POT1 [10, 11]. It binds to the 
C-terminal of POT1. In order to clarify the protein-protein interaction between TPP1 and 
POT1, a serial of constructs were designed that cover different regions of TPP1. These 
proteins were expressed and purified in E. coli and their binding ability to POT-C was 
judged by whether they could be eluted out as a complex through a gel filtration column. 
The results indicate that the domain in TPP1 that is responsible for binding to POT1 is 
from amino acid 250 to 334. The detailed domain interaction in POT1 and TPP1 is shown 
in Fig. 2.1a.   
POT1 is known as the single-stranded telomeric DNA binding protein. The 
detailed interaction between POT1 and human single-stranded telomeric DNA repeats 
has been studied thoroughly. However, how POT1-TPP1 complex binds to single-
stranded telomeric DNA as well as the detailed kinetic information is yet unknown. In 
order to test this, an 18-nucleotide single-stranded telomeric DNA (primer a, 
(TTAGGG)3) was incubated with increasing amounts of TPP1 with or without POT1, and 
binding was analyzed by electrophoretic mobility shift assay (EMSA). A previous study 
has already illustrated that primer contains two overlapped POT1 binding sites, as boxed 
in Fig. 2.2a. POT1 protein bound to the DNA, whereas TPP1 on its own did not, even at a 
high protein concentration (375nM) (Fig. 2.1b, lane 1-5). When TPP1 was added to the 
POT1-DNA mixture, however, an additional complex formed that migrated above the 
POT1-DNA complex (Fig. 2.1b, lane 6-11). By two criteria, this more slowly migrating 
complex contained TPP1. First, two size variants of TPP1, both of which contain POT1-
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binding domain (Fig. 2.1a), produced electrophoretically distinct complexes (Fig. 2.1c). 
Second, addition of the anti-His antibody confirmed that the slower complex contained 
His-tagged TPP1 (Fig. 2.1d). The amount of DNA in the ternary complex was increased 
compared with the amount of DNA bound to POT1 alone (compare lanes 5 and 11 in Fig. 
2.1b), suggesting higher affinity.  
The equilibrium dissociation constants (Kd) of the protein complexes with various 
telomeric single-stranded (ss)DNAs were determined by gel shift assays. Primer a (Fig. 
2.2a) bound POT1 with a Kd of 26 nM, and the stability of this complex was increased 
sixfold by addition of TPP1 (Fig. 2.3). Primers a5 and a3 (Fig. 2.2a) contain single-
nucleotide substitutions that force POT1 to bind either to a 5’ site (corresponding to an 
internal site on a long telomeric G-overhang) or to a 3’-proximal site (corresponding to 
end-capping) [29]. The POT1-TPP1 complex showed a substantial preference for 3’-end 
binding (Kd =0.7 versus 7.4 nM; compare circles in Fig. 2.2b, c). Notably, the 
dissociation constant of POT1-a5 is also tenfold higher than that of POT1-a3 (Kd =8.3 
versus 89 nM) (compare triangles in Fig. 2.2b, c), suggesting that the 3’ end preference of 
the POT1-TPP1 complex is mainly dictated by POT1. Measurements of the kinetic 
stabilities of the various complexes confirmed that the off rate of the POT1-TPP1 
complex was decreased by addition of equimolar TPP1 (Fig. 2.3). Furthermore, the 
complexes with a3 were kinetically about tenfold more stable than those with a5 (Fig. 
2.3). Taken together, these data indicate two POT1-TPP1 binding modes on telomeric 
DNA, a lower affinity one at internal sequences and a higher affinity one at the 3’ end.  
 
2.1.4 Structural conservation between TPP1 and TEBP  
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Functional and structural studies have established that POT1 is the human homologue of 
the O. nova TEBP -subunit [1, 2, 8, 28]. Although there has been no report of a TEBP 
-subunit in any organism besides O. nova and a related ciliate, Stylonychia mytilis[30], 
the DNA-binding properties of POT1-TPP1 closely resembled those of O. nova TEBP -
 [31], consistent with TPP1 being the human homologue of TEBP . In addition, their 
domain organizations reveled clear similarities (Fig. 2.1a). First, both TPP1 and TEBP  
use a central region (PBD in TPP1 and BD in TEBP ) to interact with the carboxyl-
terminal domains of their binding partners (POT1-C and TEBP -C). Second, primary 
sequence analysis of the N-terminal domain of TPP1 (residues 90-250) predicted a 
secondary structure pattern of - - - - - - - , where the bold region is characteristic of 
oligonucleotide/oligosaccharide-binding (OB) folds found in many telomere-binding 
proteins including TEBP  [8, 26]. Third, the C-terminal domains of both TPP1 and 
TEBP  (TPP1-C and TEBP-C) are not involved in the interaction with the -subunits 
(POT1 and TEBP ) and have evolved to have distinct functions [9, 10, 21, 31, 32] (Fig. 
2.1a). 
For crystallization studies, we first purified the N-terminal fragment TPP-N (Fig. 
2.1a), which can interact with POT1 and would correspond to the TEBP  fragment in the 
TEBP - -ssDNA crystal structure [26]. However, TPP1-N was unstable by itself. 
Limited proteolysis and matrix-assisted laser desorption/ionization (MALDI) mass 
spectrometry identified a protease-resistant core domain of TPP1-N containing residues 
89-260 (Fig. 2.4a); this domain corresponds to the predicted OB fold (Fig. 2.1a). 
Recombinant TPP1 (90-250) expressed from E. coli was crystallized (Fig. 2.4b), and the 
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structure was solved by single anomalous dispersion (SAD) and refined to a resolution of 
2.7 Å (Table 2.1). The final model contains residues 90-243 (Fig. 2.5a).  
The structure of TPP1 (90-250) reveals a typical OB-fold architecture comprising 
a highly curved five-stranded -barrel [33, 34](Fig. 2.5a). Hereafter, we will refer to 
TPP1 (90-250) as TPP1-OB (Fig.). An unbiased search for structurally homologous 
proteins using Dali [35] revealed that the structure of TPP1-OB is most similar to that of 
the OB fold of the O. nova TEBP -subunit [26]. The two structures can be superimposed 
with a root-mean-square deviation of 2.0 Å in the positions of 144 equivalent C  atoms 
(Fig. 2.5b). Notably, this structurally conserved region includes not only the central -
barrel, but also three peripheral -helices, suggesting that TPP1 and TEBP  are 
homologous proteins (Fig. 2.5b); other OB folds, such as that of TEBP , are more 
distantly related (Fig. 2.5c). In addition to the overall structural similarity, the OB folds 
of TPP1 and TEBP  share several unique features. First, the loop connecting 5 and C 
(L5C), unlike in the OB folds of POT1 and TEBP , adopts an extended conformation and 
packs across one side of the -barrel, forcing helix C to cap the bottom the barrel (Fig. 
2.5b). Second, helix B is in a modified position rotated almost 90° relative to the 
orientation normally observed in OB folds. Taken together, these structural similarities 
strongly support the notion that TPP1 is the human homologue of O. nova TEBP . Given 
that TPP1 has been identified in many other eukaryotes [10, 11], TPP1/TEBP  may be an 
evolutionarily conserved telomere protein.  
Despite the high degree of structural conservation, the sequences of OB folds of 
TPP1 and TEBP  are markedly divergent and share only 11% identity (Fig. 2.6). 
Significant sequence and structural variation is particularly evident in the connecting loop 
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regions. TPP1-OB has a very long loop (20 rediues), L12, between strands 1 and 2, 
which packs on helix A and covers one end of the barrel (Fig. 2.5a, b). In contrast, 
strands 1 and 2 of TEBP  are connected by a short two-residue turn (Fig. 2.5b). These 
marked variances in the loop regions explain the failure to detect the similarity between 
these OB folds by bioinformatics.  
 
2.1.5 POT1-TPP1 is a telomerase processivity factor 
We investigated the ability of telomerase to extended the POT1-TPP1-ssDNA ternary 
complex, expecting some inhibition consistent with the shelterin model [24]. Human core 
telomerase was reconstituted in vitro and immunopurified via the haemagglutinin (HA) 
tag on the telomerase catalytic subunit (TERT). Primer a5 has a single-nucleotide 
mutation that forces POT1 to bind to its 5’ end (Fig. 2.2a), leaving a telomerase –
extendible 3’ tail [29]. Addition of POT1 and TPP1 to primer a5 markedly increased the 
telomerase product size distribution. Primer a5 was extended via more than 30 cycles of 
template copying (Fig. 2.7a, lane 4), whereas in the absence of the POT1-TPP1 complex, 
the first three cycles accounted for most of the extension (lane 1). Under conditions of 
vast primer excess, longer extension products result from processive extension, not from 
rebinding of previously extended products [36]. We confirmed that this condition still 
pertained in the case of the ternary complexes by showing that the extension was 
independent of concentration over a 2,000-fold range (Fig. 2.8). 
These data emphasize the longer extension products, because 
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P-GMP 
incorporation increases with product size. Quantification showed that POT1-TPP1 
provided a threefold increase in activity (Fig. 2.7b) and, after dividing each product by 
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the amount of GMP incorporated, a fourfold increase in processivity (Fig. 2.7c). R1/2, the 
number of repeats synthesized before half of the chains have dissociated, increased from 
0.78 repeats with DNA primer a5 to 3.3 repeats with the POT1-TPP1-DNA complex. 
Because this fourfold increase in processivity is cumulative, it has a very large effect on 
the production of longer products (see double-headed arrows in Fig. 2.7c-e). POT1 by 
itself produced a more modest stimulation of processivity, consistent with earlier results 
[29], and TPP1 by itself had a similar effect (Fig. 2.7c-e).  
The increase in telomerase processivity with the POT1-TPP1 complex was 
unexpected, and we were concerned that it might be due to a small molecule 
accompanying the protein. However, when we fractionated TPP1 by gel filtration 
chromatography, the processivity activity clearly co-migrated with the main protein peak 
(Fig. 2.9), indicating that the enhanced processivity was TPP1-specific. 
The effects of POT1 and TPP1 were even more dramatic with other DNA 
primers. Primer a3 binds POT1 mainly at its 3’ end (Fig. 2.2a), as does primer b 
((GGTTAG)3) [29]. As expected, the addition of POT1 almost completely blocked the 
extension of these primers (Fig. 2.7a, lanes 6 and 10). When TPP1 was also added, 
however, telomere extension was rescued and processivity was increased five- to sixfold 
(Fig. 2.7a, lanes 8 and 12; also see Fig. 2.7d, e). To test the possibility that TPP1 induced 
sliding of POT1 from the preferred 3’ end binding site to the 5’ site, we mapped the 
position of the leading edge of the POT1-TPP1 complex on the DNA using snake-venom 
phosphodiesterase I, which degrades ssDNA exonucleolytically from the 3’ end. 
Complexes of primer a3 or primer a with the POT1-TPP1 heterodimer showed that the 
protein mostly occupied the DNA 3’ end, with a local change in accessibility relative to 
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the POT1-DNA complexes where the 3’ end of the DNA protrudes from the protein (Fig. 
2.10). Although TPP1 did not relocate the bulk of POT1 to an internal site on the DNA, 
we propose that the proteins are in fact binding internally in a minority of the complexes 
[29]; the resulting 3’ overhang is then extended by telomerase with the enhanced 
processivity characteristic of POT1-TPP1 complexes.  
Primer AGGG-a (AGGG(TTAGGG)3) has four blocks of GGG and therefore 
folds into Hoogsteen base-paired G-quadruplex structures, which are inhibitory for 
telomerase extension (Fig. 2.7a, lane 13) [37]. POT1 can trap an open form of this DNA, 
allowing telomerase extension (lane 4). TPP1 by itself (lane 15) gave the typical twofold 
incrase in telomerase activity seen with all the primers (Fig. 2.7b), but telomerase still 
stalled after every nucleotide added to the G-quadtrplex. POT1-TPP1 again stimulated 
highly processive extension by telomerase (lane 16). 
We next asked whether the enhanced telomerase processivity and activity were 
dependent on the POT1-TPP1 interaction by using a panel of POT1 and TPP1 deletion 
mutant proteins. POT1-N, which lacks the TPP1 interaction domain, and TPP1-OB, 
which lacks the POT1 interaction domain, both failed to endow telomerase with 
increased processivity and activity (Fig. 2.11). Only when both proteins had intact 
interaction domains was the processivity greatly stimulated (Fig. 2.11), confirming the 
important role of the POT1-TPP1 interaction in this activity. The purified POT1 
interaction domain of TPP1, TPP1-PBD, was insufficient to activate telomerase in the 




E. coli DNA polymerase achieves high processivity by means of an accessory protein that 
serves as a “sliding clamp’, encircling the DNA and preventing dissociation [38]. By 
analogy, the POT1-TPP1 complex might move with telomerase, binding the DNA just 
upstream from its 3’ end and inhibiting dissociation. Given the DNA sequence-specificity 
of POT1-TPP1 binding, the protein would not slide continuously along the DNA but 
would ratchet in 6- or 12-nucleotide steps. On the other hand, ssDNA is intrinsically 
much more flexible than double-stranded (ds)DNA. Thus, a clamp would not need to 
slide or ratchet to keep the ssDNA associated with telomerase, but could instead remain 
fixed while the newly synthesized telomeric repeats formed a larger and larger protruding 
loop. Another question for future research is whether a single POT1-TPP1 complex 
clamp is sufficient for increased processivity, or whether the protein must coat the 
elongating telomeric DNA.  
In normal human somatic cells that lack telomerase, telomeres shrink by about 
30-100 base pairs per replication cycle [39]. This provides a plausible estimate for the 
amount of DNA synthesized by telomerase at each chromosome end, and is similar to 
more direct measurements in yeast [40]. Whether such extension is processive or 
distributive in vivo is unknown. However, we note that the telomerase processivity 
achieved here in the presence of POT1-TPP1 is around four repeats or 24 nucleotides, 
which would mean that one or a few rounds of telomerase extension per cell cycle would 
be sufficient to maintain human telomeres.  
Given that POT1 and TPP1 are components of a negative feedback loop of 
telomere length control [9-11, 17], we were surprised to find that the POT1-TPP1 
complex can also function as a positive telomerase processivity factor. We propose a 
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three-state model of telomere length regulation that can reconcile the two apparently 
opposite functions of POT1-TPP1. (1) When POT1-TPP1 covers the 3’ terminus of the 
G-overhang, it sequesters the telomere and prevents binding of telomerase. (2) POT1-
TPP1 is removed from its high-affinity 3’ binding site by an unidentified mechanism, 
which might, for example, involve post-translational modification and disruption of the 
shelterin complex. (3) The POT1-TPP1 complex then serves as a telomerase processivity 
factor during telomere extension. As the telomere is elongated and reaches a certain 
threshold, the newly synthesized repeats bind shelterin complexes, the 3’ end of the 
overhang is re-bound by POT1-TPP1, and further telomerase extension is inhibited (back 
to state 1). Further work will be needed to understand how switching between such 
telomere and telomerase complexes is achieved and regulated in vivo.  
 
2.1.7 Methods and materials 
Oligonucleotide preparation 
Telomeric ssDNAs used in the DNA-binding assay were purchased from IDT and 
Invirogen and 5’ -end- labeled using polynucleotide kinase.  
 
Protein expression and purification 
Human TPP1 was expressed in E. coli BL21(DE3) using a modified pET28b vector with 
a SUMO protein fused at the N-terminus after the 6XHis tag. After induction for 16 hours 
with 0.1 mM IPTG at 25°C, the cells were harvested by centrifugation and the pellets 
were resuspended in lysis buffer (50 mM Tris-HCl pH 8.0, 50 mM NaH2PO4, 400 mM 
NaCl, 3 mM imidazole, 10% glycerol, 1 mM PMSF, 0.1 mg/ml lysozyme, 2 mM 2-
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mercaptoethanol, and home-made protease inhibitor cocktail). The cells were then lysed 
by sonication and the cell debris was removed by ultracentrifugation. The supernatant 
was mixed with Ni-NTA agarose beads (Qiagen) and rocked for 6 hours at 4˚C before 
elution with 250 mM imidazole. Then ULP1 protease was added to remove the His6-
SUMO tag. The protein was further purified by passage through Mono-Q and by gel-
filtration chromatography on Superdex200 equilibrated with 25 mM Tris-HCl pH 8.0, 
150 mM NaCl. The purified protein was concentrated to 2-10 mg/ml and stored at -80˚C. 
The TPP1 deletion mutants (TPP1-OB, TPP1N, and TPP1-PBD) were cloned, expressed, 
and purified following the same procedure as described above. POT1 and its splicing 
variant 2, POT1N, which contains the entire DNA-binding domain, and TPP1-N (residue 
89-334) were expressed by using baculovirus-insect cells and purified as described 
previously [8]. 
 
Limited protease (Glu-C) cleavage of TPP1N 
TPP1N was incubated with 0.2% w/w Glu-C (Roche) at room temperature in 25 mM 
Tris-HCl pH 8.0, 150 mM NaCl, and 2 mM DTT. At various time points, 8 μl aliquots of 
the reaction were withdrawn, diluted with 12 μl of water and 5 μl of SDS loading dye, 
and run on 15% SDS–PAGE visualized with Coomassie brilliant blue stain.  
 
MALDI mass spectrometry of the limited protease (Glu-C) cleavage products 
For MALDI mass spectrometric analysis, TPP1N was incubated with 0.2% w/w Glu-C in 
25 mM Tris-HCl pH 8.0, 150 mM NaCl, and 2 mM DTT at room temperature. Aliquots 
were withdrawn as described above for SDS–PAGE analysis. At the 60 min time point, 2 
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l of the reaction mixture was co-crystallized with 2 l sinapinic acid matrix. The 
samples were analyzed by MALDI-TOF-MS in linear mode. The major product by 
MALDI had an MH(+1) of 18,611 ± 30 Da. Examination of the map of predicted Glu-C 
sites revealed that this fragment corresponds to one predicted fragment: TPP190-260 
[MH(+1) 18,597 Da]. 
 
Crystallization, data collection and structure determination of TPP1-OB 
For crystallization, TPP1-OB was concentrated to 25 mg/ml in storage buffer. Crystals 
were grown by hanging drop vapor diffusion at 16ºC. The precipitant/well solution 
contained 100 mM trisodium citrate pH 5.6, 3.5 M sodium formate and 5 mM DTT. The 
crystals belong to space group I4122 with unit cell dimensions of a = b = 117.25 Å, and c 
= 171.58 Å. The asymmetric unit contains a dimer of TPP1-OB. All crystals were 
gradually transferred into a harvesting solution containing 100 mM sodium citrate pH 5.6 
and 5 M sodium formate, then flash-frozen in liquid nitrogen for storage and data 
collection under cryogenic conditions (100K). Data were collected at the Advanced 
Photon Source beamlines 23ID-D and processed using HKL2000 (Otwinowski and 
Minor, 1997). SAD data from the mercury derivative were used to obtain initial phases. 
Five mercury atoms were located and refined, and the SAD phases calculated using 
SHARP (E. d. La Fortelle, G. Bricogne, 1997); the initial SAD map was significantly 
improved by solvent flattening. A model was automatically built into the modified 
experimental electron density using ARP/WARP (V. S. Lamzin, A. Perrakis, K. S. 
Wilson, 2001); the model was then transferred into the native unit cell by rigid-body 
refinement and further refined using simulated-annealing and positional refinement in 
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CNS [41], with manual rebuilding (O) [42]. 
 
Electrophoresis Gel Mobility Shift Assay  
Proteins in binding buffer (25 mM HEPES/NaOH, pH 7.5, 50 mM NaCl, 40 mM KCl, 
7% glycerol, 1 mM EDTA, and 0.1 mM DTT) was mixed with 1 μM 32P-labeled 
telomeric ssDNAs in a total volume of 20 μL. The reaction mixtures were incubated at 
room temperature for 30 min. Then the mixtures were directly loaded onto a 4-20% 
nondenaturing polyacrylamide gel. Electrophoresis was carried out in TBE buffer at 150 
V for 85 min at 4 °C. The gels were dried, and radiolabeled ssDNA was visualized using 
a PhosphorImager. 
 
In vitro Reconstitution of Human Telomerase 
C-terminal HA-tagged human TERT was expressed from phTERT-HA2 and hTER from 
phTR [29, 36] by using the TnT quick-coupled transcription/translation system 
(Promega). Each 500-μl reaction contained 400 μl of TnT quick mix, 40 μl of PCR 
enhancer (Promega), 20 μl of 1 mM methionine, 20 μl of water, and 1.05 μg of each 
plasmid DNA. After incubation at 30 °C for 2 h, the reconstituted telomerase complex 
was affinity-purified on anti-HA F7-agarose beads (Santa Cruz Biotechnology). Anti-HA 
F7-agarose beads (150 μl), washed with TMG-100, were added for immunoprecipitation 
at 4 °C overnight. The beads were washed with 1× telomerase assay buffer (see below) 
four times and then resuspended in 1× telomerase assay buffer. The quantity of 35S-
hTERT was determined. 
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Telomerase Activity Assay 
Two types of telomerase activity assays, direct assay and telomeric repeat amplification 
protocol (TRAP) assay, have been developed and widely used in the studies of 
telomerase. In the direct assay, 
32
P-radioactive labeled nucleotides (usually dGTP) is 
incorporated into the 3’ end of the telomeric DNA primer. After the reaction is finished, 
the elongation products can be visualized in a denaturing polyacrylamide gel by 
autoradiograph [43]. When different telomeric primers with variant ending sequence are 
provided, the product’s pattern on the gel will change accordingly. Similar results will 
also appear if the RNA template sequence is mutated. Therefore, the direct assay is a very 
powerful tool for studying how telomerase behaves in various reaction systems. 
However, the direct assay requires abundant amount of telomerase materials with good 
processivity in order to observed the clear “ladder” pattern. For human tissue with very 
low amount of telomerase or mouse cells bearing low processivity telomerase, TRAP 
assay is more suitable. In the TRAP assay, telomerase first adds telomeric repeats to the 
primer during the reaction. Then the reaction products will be amplified through 
polymerase chain reaction (PCR) by using special designed primers [44, 45]. TRAP assay 
takes the advantage of the amplification power of PCR and magnifies the very low 
telomerase activity to a detectable level. Therefore, TRAP assay is ideal to deal with 
human tissue or tumor samples with really low levels of telomerase activity. Although 
TRAP assay results show the similar hexa-nucleotide “ladder” as the direct assay does, 
the banding pattern comes from the PCR amplification rather than from telomerase repeat 
addition.  
In this chapter, I applied the direct assay to monitor the change of telomerase 
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activity and processivity to study the function of the POT1-TPP1 complex. Activity of 
the immunopurified human telomerase complex reconstituted in vitro was determined by 
a direct assay modified from a published protocol [36]. Briefly, the reaction mixture (20 
μl) contained 1× telomerase assay buffer (50 mm Tris-HCl, pH 8.0, 50 mm KCl, 1 mm 
MgCl2, 5 mm 2-mercaptoethanol, and 1 mm spermidine), 100 nm telomeric DNA primer, 
0.5 mm dATP, 0.5 mm dTTP, 2 μm dGTP, and 1.25 μm [ -
32
P]dGTP (800 Ci/mmol) 
with 6 μl of immunopurified telomerase complex. The reaction was incubated at 30 °C 
for 1 h, and the products were precipitated with the addition of 100 μl of 3.6 m NH4OAc, 
20 μg of glycogen, and 450 μl of ethanol. After incubation at –80 °C for 1 h, samples 
were centrifuged at 4 °C for 20 min, and the pellets were washed with 70% ethanol and 
resuspended in 1× gel-loading buffer (40% formamide, 10 mm Tris-HCl, pH 8.0, 10 mm 
EDTA, and 0.05% xylene cyanol). The heat-denatured samples were loaded onto a 10% 
polyacrylamide, 1× TBE (Tris borate-EDTA), 7 M urea denaturing gel for 
electrophoresis. After electrophoresis, the gel was dried and quantified using a 
PhosphorImager. 
 
Snake-venom phosphodiesterase I (SVPI) digestion 
Protein-DNA complex was preformed before the addition of SVPI. The complex mixture 
(9 l) contained 1.1x telomerase assay buffer (50 mM Tris-HCl pH 8.0, 50 mM KCl, 1 
mM MgCl2, 5 mM 2-mercaptoethanol and 1 mM spermidine), 0.11x protein buffer (25 
mM Tris-HCl pH 8.0, 150 mM NaCl), protein or protein mixture (TPP1, POT1, or POT1-
TPP1) and 5’ labeled 
32
P-DNA and was incubated at room temperature for 30 min. Then 
0.3 g SVPI in 1 l stock solution (100 mM Tris-Cl pH 8.9, 100 mM NaCl and 15 mM 
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MgCl2) was added to start the digestion. The reaction was incubated at 30°C for 5 min 
and then stopped by the addition of 1 l 100 mM EDTA. After heat-inactivation at 95°C 
for 2 min, 10 l of 94% formamide, 1xTBE and loading dye were added to the sample.  
A portion (10 l) of the final mixture was loaded onto a 10% polyacrylamide/1xTBE/7 M 
urea denaturing gel for electrophoresis. 
 
2.2 Budding Yeast Est3 is a Putative Ortholog of Mammalian TPP1 
2.2.1 Abstract 
Ever shorter telomeres 3 (Est3) is an essential telomerase regulatory subunit thought to be 
unique to budding yeasts. Here we use multiple sequence alignment and hidden Markov 
model–hidden Markov model (HMM-HMM) comparison to uncover potential similarities 
between Est3 and the mammalian telomeric protein TPP1. Analysis of site-specific 
mutants of Candida albicans Est3 revealed functional distinctions between residues that 
are conserved between Est3 and TPP1 and those that are unique to Est3. Although both 
types of residues are important for telomere maintenance in vivo, only the former 
contributes to telomerase activity in vitro and facilitates the association of Est3 with 
telomerase core components. Consistent with a function in protein- protein interaction, 
the residues common to Est3 and Tpp1 map to one face of an OB-fold model structure, 
away from the canonical nucleic acid binding surface. We propose that Est3 and the OB-
fold domain of TPP1 mediate a conserved function in telomerase regulation. 
 
2.2.2 Introduction 
Telomeres are specialized nucleoprotein structures that maintain the integrity of 
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eukaryotic chromosomal termini by protecting them from fusion and recombination, and 
promoting their replication (for reviews, see refs. [12, 13, 24, 46]). In most organisms, 
telomeric DNA consists of short repetitive sequences that are rich in G residues on the 3’ 
end-containing strand. These repeats are maintained by a ribonucleo-protein (RNP) 
known as telomerase, which acts as an unusual reverse transcriptase (for reviews, see 
refs.[13, 47-49]). Both telomere binding proteins and telomerase are crucial for the 
maintenance of telomere integrity through multiple cell divisions, which in turn is pivotal 
in supporting genome stability and promoting cellular life span. 
Remarkably, components of both the telomeric protein complex and the 
telomerase complex have been observed to be evolutionarily malleable. For example, the 
terminal G-strand overhangs of mammalian telomeres are bound by POT1 and TPP1, 
which are subunits of a larger complex known as shelterin. In contrast, the budding yeast 
telomere overhangs evidently interact with a Replication protein A–like heterotrimeric 
complex consisting of Cdc13, Stn1 and Ten1 [50, 51]. Although each of the mammalian 
and yeast proteins consists of a variable number of OB-fold domains, no orthologous 
relationship has been established between any protein pairs from either sequence or 
functional comparison. Similarly, no telomerase subunit except the catalytic protein 
(telomerase reverse transcriptase (TERT)) and template RNA (TER) is universally 
conserved. Instead, both mammals and yeast possess species-specific factors that are 
crucial for telomerase assembly and function. Thus, the fundamental importance of the 
telomere-maintenance machinery is in striking contrast to its evolutionary plasticity. Est3 
is a small but functionally essential subunit of the yeast telomerase complex [52]. 
Deletion of EST3 leads to a progressive telomere-attrition phenotype that mimics closely 
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deletion of TERT or TER [52, 53]. Yet the protein is not essential for the catalytic 
activity of telomerase in vitro [52, 54, 55]. Recent experiments, however, point to a role 
for Candida albicans Est3 in promoting holoenzyme assembly and stimulating the 
polymerization activity of telomerase in a primer substrate–dependent fashion [56]. To 
gain further insights into Est3 mechanisms, we used a combination of bioinformatic 
analysis and site-specific mutagenesis to identify structural attributes of the protein 
necessary for its biochemical functions. Our results reveal unexpected similarities 
between Est3 and mammalian TPP1. 
 
2.2.3 Similarities between Est3 and TPP1 
To delineate the structure and function of Est3, a multiple sequence alignment was first 
performed against 12 EST3 homolog genes from different Saccharomyces and Candida 
species (5 from Saccharomyces and 7 from Candida) (Fig. 2.13a). The result was then 
used to query the HHpred server [57], which exploits comparison of hidden Markov 
models (HMMs) profiles for the identification of distantly related proteins. Notably, the 
top-scoring hit from this analysis was the mammalian telomeric protein TPP1 (E-value = 
0.71, P-value = 91.5), indicating a possible connection between Est3 and TPP1. This 
result is consistent with our previous data that revealed an interaction between TPP1 and 
telomerase as well as a stimulatory effect of TPP1 on telomerase activity and processivity 
(Section 2.1).  
 
2.2.4 Effects of CaEst3 mutations on telomeres, telomerase assembly and activity 
To further illustrate the connection between Est3p and TPP1, we proceeded to generate a 
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series of site-specific C. albicans EST3 mutants designed on the basis of a composite 
sequence alignment between Est3 and TPP1 homologs (Fig. 2.13a). This sequence 
alignment highlights three residues that are well conserved in all Est3 and TPP1 family 
members (Trp36, Asp91 and Asp/Glu169 in C. albicans Est3 and Trp98, Asp148 and 
Glu215 in human TPP1), as well as residues that are conserved only in Est3 homologs 
(Arg72, Ser92, Phe109, Arg116, Thr121 and Gln170). These residues were replaced with 
alanine. The resulting mutants were reintegrated into an C. albicans est3 /est3  strain 
and subjected to functional analyses in Dr. Neal Lue’s laboratory at the Weill Medical 
College of Cornell University. 
Dr. Lue and colleagues first examined the impact of mutations on telomere 
lengths and contents by telomere Southern (Fig. 2.14). All of the mutants, with the 
exception of D59A, R72A and S92A, manifested substantial defects in telomere 
maintenance. Notably, both the D91A and D91A/S92A mutants behaved as null alleles 
with regard to telomere maintenance (Fig. 2.14a, b). Then, the levels of mutant Est3 
proteins and their association with telomerase RNA (Ter1) were investigated by IgG-
Sepharose pull-down, western blotting and reverse-transcription PCR (RT-PCR). All of 
the mutant proteins were present at near wild-type levels, except for D91A and DS91AA, 
which were reduced by approximately five-fold (Fig. 2.14c). On the other hand, 
quantitative RT-PCR revealed no detectable Ter1 in the D91A and DS91AA pull-down 
samples, and Ter1 levels were reduced to ~20% of the normal Ter1 levels in the W36A 
and D169A samples (Fig. 2.14d, e). Titration of the wild-type extract indicates that the 
absence of Ter1 in the D91A pull-down sample cannot be explained by reduced protein 
level. In particular, the D91A protein level is reduced approximately 5-fold, whereas the 
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associated Ter1 is reduced more than 25-fold (Fig. 2.14e). Thus, Asp91 enhances the 
stability of Est3 and is essential for telomerase association, whereas Trp36 and Asp169 
are not required for protein stability but promote telomerase association. The other 
mutated residues seem dispensable for both functions. Finally, primer-extension activity 
was measured using the IgG-Sepharose precipitates to determine the effect of EST3 
mutations on telomerase activity in vitro (Fig. 2.15). Notably, mutations in the residues 
conserved only in Est3 generally had little effect on telomerase activity on either primer 
(Fig. 2.15b). Telomerase from the W36A and D169A mutants showed greatly reduced 
activity (Fig. 2.15b). For both mutants, the magnitude of reduction in activity 
(approximately 50-fold) was far greater than that of telomerase RNA (approximately 5-
fold) (compare Figs. 2.14d and 2.15c), indicating a dramatic reduction in specific 
activity. Thus, Trp36 and Asp169 must have a function in stimulating telomerase activity 
that goes beyond their role in promoting telomerase association of Est3, possibly through 
an allosteric effect. As expected, no telomerase activity was detected in the D91A and 
DS91AA IgG-Sepharose precipitates as a result of their lack of telomerase association 
(Fig. 2.15b). (detailed data refer to ref. [58]Fig. 2 and 3)  
 
2.2.5 Effects of TPP1 mutations on telomerase activity  
We generated three TPP1N (amino acid 89-334) mutants in E. coli: W98A, D148A, and 
E215A, which are equivalent to Trp36, Asp91 and Asp/Glu169 in C. albicans Est3. Both 
D148A in TPP1 and D91A in Est3 resulted in insoluble proteins, suggesting that this Asp 
is important for protein stability. The other two mutant proteins as well as the wild type 
TPP1N were then purified and used in the in vitro telomerase activity assay. The addition 
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of POT1 to the wild type TPP1N and primer a5 gave us a typical increased telomerase 
product size distribution. As expected, primer a5 was extended via more than 30 cycles of 
template copying when both POT1 and TPP1N are present. (Fig. 2.16, lane 1-3) Notably, 
when W98A was introduced, it greatly abolished POT1-TPP1 complex’s processive 
effect on telomerase for about 50 folds (Fig. 2.16, lane 4), which is similar as Est3 when 
mutating Trp36. However, the other mutant (E215A) didn’t have such an effect. The 
DNA primer was extended just like the wild type did (Fig. 2.16, compare lane 3 with lane 
5). So far, two of the mutations (Trp and Asp) at the well-conserved residues in Est3p and 
TPP1 have detectable phenotypes. In the contrast, the other mutants mutating at the sites 
only shared by Est3 family members just function similar to wild type (The data are 
summarized in Table 2.2). These results further revealed the functional connection 
between TPP1 and CaEst3.  
 
2.2.6 Studies towards the structure of Est3 
The most direct approach to prove the Est3-TPP1 connection is to determine the three-
dimensional structure of Est3. To this end, full-length Est3 proteins from several different 
budding yeast species including S. cerevisiae, C. albicans, and C. tropicalis were 
expressed, purified and used in extensive crystallization trials. However, we failed to 
obtain any crystals of these proteins. The full-length S. cerevisiae Est3 (ScEst3) presents 
dual bands in SDS-PAGE, which suggest that it is not stable in solution. Limited 
proteolysis and mass spectrometry analyses identified a protease-resistant core of ScEst3 
(residues 2-181). ScEst32-181 was then prepared and subjected to crystallization screening. 
A cluster of needle shaped tiny crystals showed up after more than 100 days under the 
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condition of HEPES pH 7.5 100 mM, PEG 4000 30%, NaCl 200 mM (Fig. 2.17a) at 4 
°C. During the protein purification process, I noticed that there was a monomer-dimer 
equilibration for ScEst3 in solution. I hypothesized that it was this equilibration process 
that caused the heterogeneity of the sample and the difficulties in crystallization. Further 
work is needed to solve this issue to obtain Est3 crystals suitable for structure 
determination. 
As an alternative approach to X-ray crystallography, I also employed NMR 
spectrometry to study the solution structure of Est3 (with the help from Dr. Erik 




N 2D spectrum analysis for the 
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N isolated peaks nicely distributed on the spectrum, suggesting that the 
CtEst3 protein is well folded. The positions of these peaks also indicate a -strand-rich 
structure. This is consistent with our prediction that CtEst3 is an OB-fold containing 
TPP1-like protein. However, the CtEst3 protein tends to precipitate after ~ 5 hours at 25° 
(at which NMR data were collected), preventing us from obtaining the 3D spectra for 
structure determination. Further work in needed to improve the thermal stability of 
CtEst3. Alternatively, Est3 proteins from other budding yeast strains will also be used in 
the NMR study. 
 
2.2.7 Discussion 
Altogether, functional analysis of Est3 mutants has revealed three classes of important 
residues (class I to III in Table 2.2). Class I, represented by Asp91, is essential for both 
the in vivo and in vitro function of Est3. Substitution of Asp91 results in the concurrent 
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dissociation of Est3 and Est1 from the telomerase complex and primer-dependent loss of 
telomerase activity, thus leading to progressive telomere attrition. Class II residues, 
including Trp36 and Asp169, are less important functionally. Substitution of these 
residues results in partial dissociation of Est3 and Est1 from telomerase and partial loss of 
telomerase activity. The extent of telomere loss in these mutants is accordingly less 
severe than in the D91A mutant. Class III residues, including Phe109, Arg116, Thr121 
and Gln170, are also required for normal telomere maintenance. However, mutations in 
these residues have little effect on the telomerase association of Est3 and telomerase 
activity. The existence of class III residues points to an additional molecular function for 
Est3 that is not revealed by the current in vitro assay. 
Notably, class I and II residues are conserved between Est3 and Tpp1, whereas 
class III residues are shared only by Est3 family members. The crystal structure of TPP1-
OB allows us to locate the three TPP1 residues that are equivalent to those in Candida. 
albicans Est3. All three residues (Trp98, Asp148 and Glu215 in TPP1, equivalent to 
Trp36, Asp91 and Asp169 in C. albicans Est3) stay at one face of the OB-fold, which is 
away from the classical oligomer-binding site (Fig. 2.18b). This suggests that these 
residues are not crucial for interacting with DNA but may be involved in protein-protein 
interactions. Asp148 (equivalent to Asp91 in C. albicans Est3), which is localized at the 
end of 2 in TPP1-OB, is able to form four hydrogen bounds with the backbone amino 
groups (W98, I99, T150 and H151) through its side chain. Thus, the helix A at the end 
of the 2 of the OB-fold is stabilized. By analogy, this will explain the biological 
significance of Asp91 in C. albicans Est3. Remarkably, Asp91 is well conserved through 
many other OB-fold-containing proteins besides TPP1 and Est3.  It seems that the 
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conserved Asp91 is important for the correct folding of the OB-fold. In contrast, class II 
residues (Trp36 and Asp169) are shared only by Est3 and TPP1 (Fig. 2.18a). Consistent 
with this notion, Lue’s group has been unable to detect DNA binding by Est3 using 
various substrates. A plausible protein target of Est3 may be the N-terminal domain of 
TERT, which is conserved between yeast and human telomerase, and has been linked to 
Est3 genetically [59].  
The structural and functional similarities uncovered in this study suggest that Est3 
could be orthologous to the OB-fold domain of TPP1. This then begs the question as to 
how orthologous proteins can be components of different macromolecular complexes in 
different organisms. A speculative evolutionary scenario is as follows (Fig. 2.19): the 
ancestral TPP1/Est3 was a component of the telomeric protein complex and, as such, a 
stimulatory factor for telomerase action. It has been suggested that, during budding yeast 
evolution, POT1 might have been lost from telomeres as a result of mutations in the 
telomere repeat sequence [23], thus resulting in the concomitant dissociation of TPP1. 
The yeast mutant would be expected to face profound selection pressures for alternative 
mechanisms of telomere protection and telomerase stimulation. The telomere protective 
function was apparently assumed by the Cdc13–Stn1–Ten1 complex. The telomerase-
stimulatory function, on the other hand, was rescued by new interactions between Est3 
and the telomerase protein Est1, which stabilized the association between Est3 and TERT 
[56, 60]. In this scenario, Est3 is orthologous to only the telomerase-stimulatory domain 
of TPP1, having lost the region(s) required for telomere localization (for example, the 
TIN2 and POT1 binding domain). The fact that budding yeast has retained Est3 despite 
the drastic remodeling of its telomere-maintenance machinery suggests that this 
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telomerase-stimulatory function may be universally required. In this regard, it would be 
interesting to determine whether the ciliate TEBP  and S. pombe Tpz1, which are 
homologous to TPP1 (refs. [61-64], also mediate telomerase stimulation. Moreover, an 
apparent homolog of Est3 and TPP1 has not been identified in plants. Instead, a POT1 
homolog is reportedly associated with the telomerase RNP. Understanding the shared and 
distinctive properties of these factors would surely provide valuable insights on telomere 
evolution. 
 
2.2.8 Methods and materials  
Protein expression and purification 
Human TPP1 was expressed in E. coli BL21(DE3) using a modified pET28b vector with 
a SUMO protein fused at the N-terminus after the 6XHis tag. After induction for 16 hours 
with 0.1 mM IPTG at 25°C, the cells were harvested by centrifugation and the pellets 
were resuspended in lysis buffer (50 mM Tris-HCl pH 8.0, 50 mM NaH2PO4, 400 mM 
NaCl, 3 mM imidazole, 10% glycerol, 1 mM PMSF, 0.1 mg/ml lysozyme, 2 mM 2-
mercaptoethanol, and home-made protease inhibitor cocktail). The cells were then lysed 
by sonication and the cell debris was removed by ultracentrifugation. The supernatant 
was mixed with Ni-NTA agarose beads (Qiagen) and rocked for 6 hours at 4˚C before 
elution with 250 mM imidazole. Then ULP1 protease was added to remove the His6-
SUMO tag. The protein was further purified by passage through Mono-Q and by gel-
filtration chromatography on Superdex200 equilibrated with 25 mM Tris-HCl pH 8.0, 
150 mM NaCl. The purified protein was concentrated to 2-10 mg/ml and stored at -80˚C. 
The Est3 proteins (ScEst3, CaEst3 and CtEst3) were cloned into pET28b vector 
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with a SUMO protein fused at the N-terminus after the 6XHis tag.  Proteins were 
expressed and purified following the same procedure as described above. The CtEst3 
protein for the NMR study, cells were allowed to grow overnight in 5 ml of LB media at 
37 °C and subsequently transferred into 2 L of M9 minimal media containing 
15
NH4Cl 
(1.5 g/L) (Cambridge Isotope Laboratories, Inc.) for preparation of 
15
N-labeled protein.  
 
In vitro telomerase activity assay 
Telomeric ssDNAs used in the DNA-binding assay were purchased from IDT. For in 
vitro telomerase activity assays [29], C-terminal HA-tagged HA-tagged human TERT 
was expressed from phTERT-HA2 and hTR from phTR [36] using the TnT quick-
coupled transcription/translation system (Promega). And the reconstituted core 
telomerase was affinity-purified on anti-HA F7-agarose beads (Santa Cruz 
Biotechnology) [29].  
 
Sequence alignment and structure prediction 
The sequences of 12 Est3 homologues from budding yeast were culled from the National 
Center for Biotechnology Information (NCBI) and Broad Institute databases and aligned 
using T-coffee (http://tcoffee.vital-it.ch/cgi-bin/Tcoffee/tcoffee_cgi/index.cgi). The 
alignment was used to query the HHpred server, resulting in the identification of human 
TPP1 as a potential ortholog [57]. A composite alignment of the 12 Est3 and 3 TPP1 
homologs (from humans, mice and Xenopus laevis) was then generated using the 





Figure 2.1 TPP1 binds to the POT1-ssDNA complex and enhances the POT1-ssDNA 
interaction.  
a) Human POT1-TPP1 and O. nova TEBP -  complexes share similar domain 
organization. In POT1 and TEBP , the N-terminal ssDNA-binding domains are colored 
in red, and the C-terminal TPP1/TEBP -binding domains are in light blue. In TPP1 and 
TEBP , the N-terminal OB folds are in orange, the central -subunit-binding region 
(PBD in TPP1 and BD in TEBP ) is in cyan, and the C-terminal domains are in yellow. 
Numbers indicated amino acid positions at the boundaries of various subdivisions.  
b) TPP1 requires POT1 in order to interact stably with telomeric DNA. Primer a (50 nM) 
was incubated with increasing amounts of TPP1 (2, 10 and 50 nM in lanes 2-4, 2-100 nM 
in lane 6-11) in the absence or presence of POT1. 
c) Both TPP1 and TPP1-N generate super-shifted species but with different mobility; use 
of a longer primer enhanced the separation.  
d) The addition of anti-His antibody detected the existence of His-tagged TPP1 in the 





Figure 2.2 The POT1-TPP1 complex binds to the single-stranded telomeric 
overhang with 3’ end preference.  
(a) Sequence of primers a, a5 and a3. The bold letters are the point mutations. The POT1-
binding sites are denoted by boxes [29].  
(b,c) Equilibrium binding curves for primers a3 (b) and a5 (c) binding to POT1 and the 
POT1-TPP1 complex. The solid and dashed lines represent theoretical binding curves fit 
to the data for POT1 and POT1-TPP1, respectively. The calculated equilibrium 
dissociation constant (Kd) values are indicated. The binding curves and Kd values for 
primers a, b and hT10 (TTAGGGTTAG) are shown in Fig. 2.3.   
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Figure 2.3 TPP1, POT1, and ssDNA form a ternary complex with enhanced stability 
relative to POT1-ssDNA.  
 (a, b, and c) Equilibrium binding curves for primers a ((TTAGGG)3) (a), b 
((GGTTAG)3) (b) and hT10 (TTAGGGTTAG) (c) binding to POT1 and the POT1-TPP1 
complex. The red and blue lines represent theoretical binding curves fit to the data for 
POT1 and POT1-TPP1, respectively. The calculated equilibrium dissociation constant 
(Kd) values are indicated.  
(d,e) Kinetic stability of the POT1-TTP1-ssDNA and POT1-ssDNA complexes for 
primers a3 ((TTTGGG(TTAGGG)2) (d) and a5 (TTAGGGTTAGCGTTAGGG) (e). 
Reactions containing 500 nM protein and 50 nM labeled ssDNA were incubated at room 
temperature for 30 min prior to challenge with 250-fold excess unlabeled ssDNA. Zero 
time points were taken prior to competitor addition. Bound and free DNA were separated 
by EMSA and quantified by PhosphorImager analysis. Data could not be adequately fit 







Figure 2.4 Determination of TPP1-OB from TPP1N 
(a) SDS–PAGE time course of limited protease (Glu-C) cleavage of TPP1N. Lanes in 
minutes of time of the reaction as labeled.   
(b) SDS-PAGE of purified TPP189-260 protein 
(c) Crystals of TPP189-260 
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Figure 2.5 The crystal structure of TPP1-OB indicates that TPP1 is the homologue 
of O. nova TEBP .  
(a) Ribbon diagram of TPP1-OB with b-strands coloured in blue, a-helices green, and 
loops orange. The secondary structure elements are labelled.  
(b) Superposition of TPP1-OB on the crystal structure of the OB fold of TEBP  [26]. 
TPP1 is in red and TEBP  in blue.  
(c) Superposition of TPP1-OB on the crystal structure of the first OB fold of TEBP  
[26]. TPP1 is in red and TEBP  in cyan. Figures were generated by using the program 




Figure 2.6 Structure-based sequence alignment of the OB-folds of human TPP1 and 
its homologues.  
Secondary structure assignments from the TPP1 crystal structure are shown as colored 
cylinders (  helices) and arrows (  strands) above the aligned sequences. Red dots 
indicate the conserved residues in the OB folds of TPP1 and TEBP . The dotted lines 




Figure 2.7 The POT1–TPP1 complex functions as a telomerase processivity factor.  
(a) Direct telomerase activity assays [36] were performed with 100 nM primer a5 (lanes 
1–4), a3 (lanes 5–8), b (lanes 9–12), or AGGG-a (lanes 13–16) in the presence of a 
saturating concentration of POT1, TPP1, or POT1–TPP1. Reaction products were then 
analyzed by gel electrophoresis (LC, loading control). Three independent sets of 
experiments gave equivalent results.  
(b) Quantification of total DNA synthesis relative to synthesis in the presence of protein 
buffer alone.  
(c–e) Activity in each repeat shown in (a) was measured, corrected for the number of 
radiolabelled nucleotides incorporated, and then plotted.  
*Processivity= R1/2= -ln2/(2.303k), where k is the slope and R1/2 is the number of repeats 







Figure 2.8 Effect of primer concentration on the processivity of telomerase.  
(a) Direct telomerase activity assays were performed under standard conditions with 
primer a5 at concentrations of 5, 20, 50, 100, 500, 1,000, 5,000 and 10,000 nM in the 
presence of POT1 (500 nM) and TPP1 (500 nM). Reaction products were then analyzed 
by gel electrophoresis.  
(b) A bar-representation of the telomerase processivity values. 
*Processivity= R1/2= -ln2/(2.303k), where k is the slope and R1/2 is the number of repeats 





Figure 2.9 The enhanced processivity of telomerase is TPP1 specific.  
(a) Upper panel: Gel filtration chromatography profile of TPP1N. Lower panel: SDS-
PAGE gel of TPP1 fractions corresponding to the peak of TPP1N in gel filtration profile. 
(b) Direct telomerase activity assays were performed using 100 nM primer a5 and an 
equimolar amount of purified POT1 protein with the central TPP1N peak fractions in 
panel a.  
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Figure 2.10 TPP1 does not substantially relocate POT1 to an internal site on the 
DNA.  
(a) SVPI digestion of primers a, a3, and a5 in the presence of protein buffer (-), TPP1, 
POT1, or POT1-TPP1 was carried out under the same conditions as that of the direct 
telomerase activity assay.  
(b) SVPI digestion results of primer a in the presence of TPP1, POT1, or POT1-TPP1 
with increasing amount of SVPI. TPP1 binds to POT1-ssDNA and enhances the POT1-
ssDNA interaction (compare the amounts of the 1 nt degradation products in lanes 3, 5, 7, 








Figure 2.11 POT1-TPP1 interaction is necessary for the enhanced processivity and 
activity of telomerase.  
Direct telomerase activity assays were performed using 100 nM primer a5 with protein 
buffer (-), TPP1-OB, TPP1N, or TPP1 in the presence of POT1N (lanes 1-4) or POT1 







Figure 2.12 The POT1-binding domain of TPP1, TPP1-PBD, is insufficient to 
activate telomerase in the presence of POT1.  
Direct telomerase activity assays were performed using 100 nM primer a5 with protein 
buffer (-), TPP1-PBD, or TPP1 in the presence of POT1.  
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Figure 2.13 Sequence and structural similarity between Est3 and Tpp1 homologs. 
(a) Sequence comparison between Est3, TPP1 and TEBP . The secondary- structural 
elements derived from the human TPP1 crystal structure are illustrated as follows: -
helices, green cylinders; -strands, blue arrows. Blue and cyan letters highlight mutated 
residues that are conserved between Est3 and TPP1. Note that these residues are also 
conserved in the recently identified S. pombe homolog Tpz1 (ref. [64] and data not 
shown). Green dots highlight mutated residues that are conserved only in Est3.  
(b) A hypothetical structure of Est3 based on the TPP1 crystal structure. Residues 
predicted to be important for telomerase interaction based on structure-function analysis 







Figure 2.14 The effects of C. albicans Est3 mutations on telomere maintenance and 
telomerase association. (Done by Dr. Lue’s group) 
(a) Left, est3 /est3  strains containing the wild-type and mutant alleles of protein A 
(ProA)- tagged EST3 were passaged on plates by successively streaking for single 
colonies. Chromosomal DNAs were prepared from either streaks 16 or 20 of each 
indicated strain and subjected to telomere Southern blotting (above). The blot was then 
stripped and reprobed using a labeled RAD52 fragment (below). Right, the telomere-
hybridization signals and the RAD52 signals obtained from the Southern blots shown and 
from three other independent blots were quantified using a PhosphorImager. The relative 
ratios of the telomere to RAD52 signals were calculated and plotted for the wild-type and 
all mutant samples. Shown are means ± s.d. from four independent experiments.   
(b) Effects of Candida EST3 mutations on telomere lengths. Telomeres from successive 
streaks of est3 / est3  strains with different mutant alleles of protein A-tagged EST3 
were analyzed by Southern blotting. The chromosomal DNAs were derived from streaks 
4, 8, 12, 16 and 20 of each indicated strain. One streak corresponds to ~ 25 generations of 
growth. The results are representative of at least two independent clones.  
(c) Est3 and associated Ter1 in wild-type and mutant strains were analyzed by IgG-
Sepharose pull-down followed by western analysis (right) and RT-PCR (20 cycles) (left), 
respectively.  
(d) Extracts from strains containing ProA-tagged wild- type EST3 (WT), the W36A 
mutant and the D169A mutant were subjected to IgG-Sepharose pull-down and RT-PCR 
to detect Est3-associated Ter1. To facilitate quantitative comparison, the WT sample was 
subjected to three-fold serial dilution before RT-PCR. Thermocycling was performed for 
20 or 23 cycles to ensure the linearity of the signals.  
(e) The Est3 protein and associated Ter1 in the wild-type and D91A mutant strains were 
analyzed by IgG-Sepharose pull-down followed by western blotting and RT-PCR (below 
and above, respectively). The WT sample was subjected to five-fold serial dilution before 








Figure 2.15 The effects of C. albicans Est3 mutations on telomerase primer extension 
activity in vitro. (Done by Dr. Lue’s group) 
(a) All primer extension assays were performed using two different 12-nt primers, P6 and 
P20, which correspond to different regions of the C. albicans telomere repeat and support 
the synthesis of primer+1 or primer+2 products in the presence of labeled dTTP (T*).  
(b) Telomerase isolated from the indicated strains by IgG-Sepharose pull-down were 
assayed for primer extension activity using primers P6 and P20 in the presence of labeled 
dTTP.  
(c) The activities for the W36A, F109A and D169A mutants relative to the wild-type 
enzyme on the P6 and P20 primer were quantified and plotted; shown are means ± s.d. 
from three independent experiments.  
(d) Telomerase isolated by DEAE chromatography from the indicated strains was tested 
for enzyme activity using primers P6 and P20 in the presence of labeled dTTP (above). 







2.16 Effects of TPP1 mutations on telomerase activity  
Three mutant and the wild type TPP1N proteins are used in the in vitro telomerase 
activity assay. When m1: W98A (lane 4) was introduced, it greatly abolished POT1-
TPP1 complex’s processive effect on telomerase. However, the other two mutants (m2: 
E215A and m3: E215A/Q216A, lane 5 and 6) didn’t have such effect. The DNA primer 
was extended just like the wild type (lane 3) did. 
107




Figure 2.17 Structural study (crystallography and NMR) of Est3 
(a) ScEst3 (2-181) crystallizes in the condition of HEPES pH 7.5 100 mM, PEG 4000 





N 2D spectrum analysis for the 
15
N-labeled Candida. tropicalis Est3 




N isolated peaks nicely distributed on the 







Figure 2.18 The conservation of an Asp residue in OB-fold proteins and its 
structural role.  
(a) The backbone structure of TPP1 is shown in a ribbon representation. Residue D146, 
located at the end of 2, is shown as sticks that make four hydrogen bounding 
interactions with residues in the L2-3 loop (T150 and H151) and residues near A (W98 
and I99).  
(b) A local alignment of sequences near the end of 2 from many OB-fold proteins 
(including Est3, TPP1, POT1, TEBP  and RPA) illustrates the conservation of this 




Figure 2.19 A possible evolutionary scenario for yeast telomere binding proteins and 
telomere. 
The precursor of TPP1/Est3 may be part of the telomeric protein complex and a 
stimulatory factor for telomerase. During budding yeast evolution, this precursor may be 
lost from the telomeres and its function in telomere protection and telomerase activation 
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CHAPTER 3 
STRUCTURAL STUDIES OF TAZ1, THE DOUBLE-STRANDED TELOMERIC 
DNA BINDING PROTEIN IN FISSION YEAST 
 
 
Taz1 is the double-stranded telomeric DNA binding protein in fission yeast and is 
proposed to be the homologue of human TRF1 and TRF2. Functionally, Taz1 mimics 
TRF1 and TRF2 in several aspects. However, there is no structural information of Taz1 
to support such proposal. In this chapter, the structural analyses of several domains in 
Taz1 (TRFH domain, dimerization domain and Rap1-interaction domain) as well as the 
solution structure of Taz1-Rap1 complex are introduced. Besides, by collaborating with 
Dr. Julia Cooper’s group, the functions of Taz1 dimerization and Taz1-Rap1 complex are 
also tested in vivo and the results are also introduced in this chapter.   
 
3.1 Abstract 
Duplex telomeric DNA repeats in fission yeast Schizosaccharomyces pombe are bound 
by Taz1, the proposed homologue of human double-stranded telomeric DNA binding 
proteins TRF1 and TRF2. By recruiting other yeast telomeric proteins, Taz1 is important 
for telomere maintenance and regulation. Secondary structural prediction result indicates 
that Taz1 contains a -helix-rich region and this region may cover the conserved TRFH 
domain, which is responsible for dimerization and protein recruitment in TRF1 and 
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TRF2. By solving the high-resolution crystal structures of TRFH domain (Taz1TRFH) and 
dimerization the domain (Taz1D) in Taz1, we report that Taz1TRFH is structurally different 
from TRFH domain in TRF1 and TRF2. Rather than using the TRFH domain, Taz1 
dimerizes via the formation of a four-helix-bundle. Structural comparison of Taz1D with 
the TRFH domains of TRF1 and TRF2 reveals that they employ different architectural 
principles for homodimerization. The disruption of dimerization interface greatly 
abolishes Taz1’s dsDNA binding ability, as indicated by in vitro DNA binding assay and 
in vivo analyses. We also report the solution structure of Taz1-Rap1 complex. Taz1 
interacts with Rap1 in a similar way as TRF2-Rap1 complex in human. The recruitment 
of Rap1 to yeast telomere by Taz1 will greatly regulate telomere length. In summary, 
Taz1 functionally represents both TRF1 and TRF2 in fission yeast. We conclude that 
Taz1 is not the structural homologue but the functional homologue of TRF1 and TRF2. 
 
3.2 Introduction 
Telomere, the natural end of linear eukaryotic chromosome, is a specialized DNA-protein 
complex. Telomeric DNA, synthesized by telomerase, contains several hundreds of non-
coding repetitive Guanidine-riched DNA sequences that are unique in different organisms 
(e.g. GGTTAG in vertebrates and GGTTAC(A)(C)G(0-6) in fission yeast), terminating a 
3’ G-overhang at the very end. Telomere is usually bound with sequence-specific binding 
telomeric proteins and their interacting partners. At human telomere, six telomeric 
proteins form a telomere-end-capping complex (shelterin) to protect telomere from 
degradation, end-to-end fusion and prevent inappropriate DNA repair pathways, such as 
non-homologous end joining (NHEJ) and homologous recombination (HR). Recently, 
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several components of a shelterin-like telomere-associated protein complex are also 
identified in fission yeast Schizosaccharomyces pombe [1]. It has been suggested that 
shelterin complex is evolutionarily conserved from yeast to human. Besides protecting 
chromosome ends, telomeric protein complex plays an important role in regulating 
telomerase activity and controlling telomere length.  
Taz1 was identified by the one-hybrid screening in fission yeast 
Schizosaccharomyces pombe and it has been proposed to be the homologue of human 
double-stranded (ds) telomeric DNA binding proteins TRF1 and TRF2[2-4]. Taz1 stays 
on yeast telomeric DNA track and is important in yeast telomere end protection and 
telomere length regulation. Deletion of taz1 gene leads to the release of single-stranded 3’ 
G-overhang regulatory machinery, massive elongation of double-stranded telomeric 
repeats, and eventually causes the loss of telomeric chromatin structure and de-repression 
of telomere-adjacent transcription [2]. Taz1 is also involved in 3’ overhang processing 
and protecting yeast cells from cold sensitivity [5, 6]. Several proteins have been found to 
interact with Taz1 directly, including yeast telomeric proteins Rif1 and Rap1 [7, 8]. By 
recruiting Rif1 and Rap1 to telomere, Taz1 negatively regulates telomere length through 
different independent pathways [6, 7].  
Taz1 highly resembles TRF1 and TRF2 in several aspects. Taz1 is able to count 
the telomeric repeats, and thus function in the similar “protein-counting” model as 
budding yeast Rap1 and TRF1 [9-11]. Both Taz1 and TRF1 are important for gene 
transcription regulation. Taz1 recruits Rap1 to yeast telomere region, in a similar way as 
TRF2 brings Rap1 to human telomere. Functional assay results already show that similar 
to TRF1 and TRF2, Taz1 dimerizes on the telomere track [12]. Based on sequence 
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alignment with TRF1 and TRF2, Taz1 contains the highly conserved Myb domain in the 
C-terminus. The Myb domain, shared by all the telomeric dsDNA binding proteins, is 
responsible for mediating dsDNA-binding activity. In budding yeast S. cerevisiae, Rap1 
binds to dsDNA via its two tandem Myb domains. Human TRF1 and TRF2 only contain 
one Myb domain per molecule. In order to arrange two Myb domains for dsDNA 
recognition as ScRap1 does, TRF1 and TRF2 homodimerize via the central TRFH (TRF 
Homology) domain [4]. Crystal structures of TRFH domain in TRF1 and TRF2 indicate 
that this -helix-rich domain is responsible for dimerization [4]. Mutations that disrupt 
the dimerization interface of TRFH domain will greatly reduce TRF1/TRF2’s binding 
affinity to dsDNA, as suggested by in vitro dsDNA binding assay. So far, TRFH-like 
proteins have been found not only in human, but also in some simple organisms such as 
Trypanosoma [13]. It even has been proposed that besides Myb-domain, TRFH domain is 
another signature motif that is conserved through all the dsDNA binding telomeric 
proteins. This hypothesis is supported by the discovery of a 270-aa region locating in the 
center of Taz1. Secondary structural prediction indicates that this region is made up of -
helices and the helix arrangement is very close to TRF1/TRF2-TRFH domain. Therefore, 
it was suspected that this region is the TRFH domain of Taz1 and that it may mediate 
Taz1 homodimerization. However, there has been no structural evidence to support such 
hypothesis.  
We were very curious about the structure of Taz1. Specifically, we want to test 
whether that 270-aa-long region is indeed the Taz1 TRFH domain and is responsible for 
dimerization. We are also interested in the Taz1-Rap1 complex since our recent discovery 
indicates that human TRF2-Rap1 complex plays an essential role in telomere end 
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protection (Chen Y et al., 2009, submitted). In order to address these questions, structural 
studies on the potential TRFH domain in Taz1 were preformed. The solution structure of 
the interacting domains of Taz1-Rap1 complex was determined by NMR. Based on this 
structural information, the biological relevance of Taz1 dimerization and the function of 
Taz1-Rap1 complex were also tested in vivo.  
 
3.3 Structural determination of the TRFH domain of Taz1 
Sequence alignment and secondary structure prediction analyses suggested that Taz1 
contains a putative TRFH domain (residues 117 – 391) [3]. However, Taz1117-391 only 
showed a low sequence similarity to the TRFH domains of human TRF1 and TRF2, and 
the size of Taz1117-391 was significantly larger than those of TRF1TRFH and TRF2TRFH (~ 
200 amino acids), resulting in big gaps in the sequence alignment [14]. In addition, unlike 
TRF1TRFH and TRF2TRFH that form stable homodimmers, purified Taz1117-391 is a 
monomor in solution as revealed by gel filtration chromatographic analysis (Fig. 3.1a). 
Thus, the decisive answer to the similarity between Taz1117-391 and the TRFH domains of 
TRF proteins required a structural approach. Taz1113-400 was cloned into the SUMO-His6-
pET28 vector and the protein was overexpressed and purified to homogeneity. Intensive 
crystallization screening and optimization only yielded twisted needle crystals of Taz1113-
400 that were not suitable for diffraction. Therefore, Taz1113-400 was subjected to limited 
proteolysis analysis using four different proteases (elastase, Glu-C, trypsin, and 
subtilisin) (Fig. 3.1b). A stable digestion product was obtained after 90-minute treatment 
of trypsin (Fig. 3.1c). The stable fragment was identified by mass spectrometry to contain 
residues 127-388 of Taz1 (Fig. 3.1d). Taz1127-388 was then expressed, purified and 
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successfully crystallized in space group P41212 with one molecule per asymmetric unit 
(Fig. 3.2a-c) (Table 3.1). The protein was phased to 2.7 Å resolution by the multi-
wavelength anomalous dispersion (MAD) method by using selenium-methionine 
substituted crystals, and the phases were extended with the native data set to 2.3 Å 
resolution (Table 3.1). In the refined structure, C-terminal residues 362-388 were not 
represented in the electron density and therefore we presume that this region is disordered 
in solution. Hereafter, we will refer to Taz1127-361 as the TRFH domain of Taz1, Taz1TRFH.   
 
3.4 Crystal structure of Taz1TRFH  
Taz1TRFH adopts a compact globular fold, with 14 -helices tightly packed around a 
central hydrophobic core (Fig. 3.3a). The helices are organized so that the entire domain 
resembles the shape of a slightly curved hockey puck with a diameter of ~ 50 Å (Fig. 
3.3b). Of the 14 helices, 1B, 3, 6, 7, 8, 9, 12, and 13 form an eight-helix 
bundle, while the other six short helices 1A, 2, 4, 5, 10, and 11, cap the exposed 
hydrophobic surface from the sides of the central helical bundle (Fig. 3.3a). The eight-
helix bundle can be further divided in to four groups of helix pairs ( 1B and 3, 6 and 
13, 7 and 8, 9 and 12). Hydrophobic contacts between the helices within each 
pairs are the main driving force to maintain the central helical core. For instance, the 
aromatic side chains of three phenylalanine residues (Phe263 from 8, and Phe350 and 
Phe354 from 13) stack with one another to help holding helix 8 and 13 together (Fig. 
3.3c). In contrast to the hydrophobic nature of the central core, an analysis of surface 
electrostatic potential reveals a large stripe of strongly electronegatively charged surface 
on the convex side of the structure (Fig. 3.3d), consisting of a cluster of 13 acidic 
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residues that are distributed in several peripheral short helices (Fig. 3.3e). This negatively 
charged surface can potentially mediate protein-protein interactions with other telomeric 
factors. Further investigation on Taz1 and its binding partners is needed to test this 
hypothesis.  
 
3.5 Comparison of Taz1TRFH with the TRFH domains of TRF1 and TRF2 
Taz1TRFH and the TRFH domains of TRF1 and TRF2 are all -helical structures. The 
topology of the helical core of Taz1TRFH is similar to TRF1TRFH and TRF2TRFH (Fig. 3.4a, 
d). Despite this topology similarity, Taz1TRFH is not the structural homolog of the TRFH 
domains of TRF1 and TRF2. There are significant structural differences between 
Taz1TRFH and the TRFH domains of TRF1 and TRF2 (Fig. 3.4a, d). Only six of 14 
Taz1TRFH helices can be matched in the TRF1/2 TRFH domains and the rest eight helices 
in Taz1TRFH cannot be superimposed with TRF1TRFH and TRF2TRFH. Consequently, the 
root-mean-square deviation (r.m.s.d.) between Taz1TRFH and the TRFH domains of TRF1 
and TRF2 is over 4.5 Å, suggesting that Taz1TRFH and the TRF1/2 TRFH domains are 
not structurally closely related. Consistent with this notion, structural based sequence 
alignment show a less than 6 % identity between TRF1TRFH and the TRFH domains of 
TRF1 and TRF2 with many large gaps (Fig. 3.4d). 
Notably, as indicated by biochemical analysis (Fig. 3.1a, Fig. 3.2a), the most 
prominent difference between Taz1TRFH and the TRFH domains of TRF1 and TRF2 is 
that Taz1TRFH adopts a monomeric conformation, whereas TRF1/2 TRFH domains are 
homodimers. In both TRF1TRFH and TRF2TRFH, the 1 helix is only slightly bent (< 5°) 
and retains its integrity as a single -helix through maintenance of all intra-helical 
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hydrogen bonds (Fig. 3.4a). The N-terminal portion of 1 extends outside of the helical 
core and interacts with helix 10 from the other molecule in the dimer (Fig. 3.4b). In 
contrast, the 1 helix of Taz1TRFH is severely bent (~ 70°), and is stretched between 
residues 138 and 140, resulting in the disruption of hydrogen bonds between the carbonyl 
oxygen atoms of residues 138 and 139, and the amide nitrogen atoms of residues 142 and 
143, respectively. Consequently, the 1 helix in Taz1TRFH is now composed of two 
helices 1A and 1B, with a one-residue intervening linker (Fig. 3.3a, Fig. 3.4a). The 
bended 1A helix and the N-terminal tail of Taz1TRFH fits into a hydrophobic groove 
formed by helices 3, 4, and 5 (Fig. 3.4c). This conformation is further stabilized by a 
pair of hydrogen bonding interactions between main-chain atoms of Trp129 and the 
hydroxyl groups of Tyr206 and Tyr213, respectively (Fig. 3.4c). Because of the bending, 
Taz1TRFH lacks the dimeric interface mediated by helices 1 and 10 in the structures of 
the TRFH domains of TRF1 and TRF2 [4]. In addition, the C-terminal tail of Taz1TRFH 
(residues 362-388) that corresponds to helix 10 in TRF1 and TRF2 is also disordered in 
the Taz1TRFH structure. Thus, the structural features of both the bending of 1 and the 
lack of 10 explain why Taz1TRFH adopts a monomeric conformation. 
 
3.6 Identification and structure determination of the dimerization domain of Taz1 
Both our structural and biochemical analyses reveal that, unlike the TRFH domain of 
human TRF1 and TRF2, Taz1TRFH adopts a monomeric conformation (Fig. 3.1a, Fig 3.2a, 
Fig. 3.3a). However, previous studies indicated that Taz1 binds to telomeric DNAs as a 
homodimer [12], suggesting that the dimerization of Taz1 must be mediated by another 
region outside of the TRFH domain. To identify the dimerization domain of Taz1, 
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various fragments were evaluated for their ability to form a homodimer in solution by gel 
filtration chromatography and chemical cross-linking analysis (Fig. 3.5a). We found that 
a fragment of Taz1 containing residues 395 – 490 of Taz1 constitutes the minimal 
structural core that is necessary and sufficient for dimerization (Fig. 3.5a).  
To understand the mechanism of Taz1 dimerization, we reconstituted and 
crystallized the Taz1395-490. We determined the crystal structure at a resolution of 1.5 Å 
by single isomorphous replacement (SIR) using an iodide compound (NaI) (Table 3.2). 
The final model contains residues 409 – 478 of Taz1, and has been refined to an R-value 
of 25.40% (Rfree = 26.95%). No electron density is observed corresponding to the N-
terminal residues 395 – 408 or the C-terminal residues 479 – 490, and we presumed that 
these two regions are disordered in solution. Hereafter we refer to Taz1409-478 as the 
dimerization domain of Taz1 (Taz1D) (Fig. 3.5b-e). 
 
3.7 Crystal structure of the dimerization domain of Taz1 
In the crystals, two molecules of Taz1D form a homodimer, resulting the burial of a total 
of 2514.96 Å
2
 of the solvent accessible surface area (Fig. 3.6a, c). Each Taz1D monomer 
consists of three helices. Helices D 2 and D 3 pack closely against each other forming 
an antiparallel coiled-coil that dimerizes through a two-fold axis of crystallographic 
symmetry (Fig. 3.6b). The symmetry related D 2 helices pack against each other 
parallelly while the two D 3 helices open up at the C-terminal end resulting in a slightly 
deformed four-helix bundle (Fig. 3.6b). The N-terminal helix of Taz1D, D 1, contains 
only two helical turns and packs perpendicularly on D 2 and D 3 opposite the dimeric 
interface (Fig. 3.6a, b). D 1 is linked with D2 through an eleven-residue loop, which 
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together with helix D1 is attached to the coiled-coil through van der Waals contacts. 
Particularly, the side chains of L415, L417, I420, and I425 insert into a hydrophobic 
groove formed by residues from helices D 2 and D 3 (Fig. 3.6d). The position of D1 is 
further stabilized by two hydrogen-bonding interactions; the hydroxyl group of S411 and 
the main chain carbonyl oxygen of L415 on D 1 accept two hydrogen bonds from the 
side chain amino groups of Q456 and K440, respectively (Fig. 3.6d).  
The hydrophobic packing contact at the dimeric interface of Taz1D is extensive, 
with 12 residues from one molecule interacting with those from the other molecule. The 
interface consists of seven planes of twofold symmetry related interdigitating residues 
from helices D 2 and D 3 (Fig. 3.7a). Hydrophobic residues stack closely against each 
other both within and between adjacent planes. Within each plane, the interface is 
contributed by the residues at positions a and d of the heptad repeats, a characteristic of 
coiled-coil proteins (reviewed in [15-17]). Although the dimeric interface is 
predominantly hydrophobic, intermolecular electrostatic interactions provide additional 
specificity and stability to the structure. At the end of the helix bundle, the side chain of 
Arg471 makes two salt bridge interactions with the carboxyl group of Glu427 from the 
other molecule, and the aliphatic portions of the side chains of the two symmetry-related 
Glu427 stack with each other connecting the two electrostatic interaction networks 
together (Fig. 3.7a, b). These intermolecular interactions are further buttressed by three 
hydrogen bonds formed by Arg471 and the main-chain carbonyl groups of Ile420, 
Asn422 and Ile425 (Fig. 3.7a, b). At the center of the helix bundle, Ser461 at position a 
in plane 3 accepts a hydrogen bond from the side chain hydroxyl group of Thr442 while 
donates another one to the main chain carbonyl of Leu438 from plane 4 (Fig. 3.7a, b). 
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Structural comparison of Taz1D with the TRFH domains of TRF1 and TRF2 
reveals that they employ different architectural principles for homodimerization. In TRF1 
and TRF2, helices 1 and 2 from both monomers interact with each other to generate an 
anti-parallel four-helix bundle with the symmetry-related dyad perpendicular to the 
helical axes (Fig. 3.4b). The third helix 10 at the C-terminus of the TRFH domain 
protrudes outside of the TRFH domain and packs with the N-terminal portion of helix 1 
forming a cross-brace to stabilize the four-helix bundle (Fig. 3.4b). In contrast, although 
Taz1D also consists three helices, its dimer interface only involves helices D 1 and D 2, 
which form a parallel four-helix bundle with the symmetry-related dyad parallel to the 
helical axes (Fig. 3.6a, b, Fig. 3.7a, b).  
 
3.8 Biochemical and functional analyses of the Taz1 dimerization interface 
To corroborate our structural analysis, we assessed the contribution of the residues at the 
Taz1D dimeric interface to the stability of Taz1 dimer structure. Four single point 
mutations, L431R, V434W, L438W, and L445R were generated and tested in a yeast 
two-hybrid assay. All these residues are in the center of the hydrophobic dimer interface, 
and we predicted that substitution of them with charged residue arginine or large 
hydrophobic residue tryptophan would disrupt the packing within the dimer structure. 
Indeed, compared with the wild-type Taz1, three mutants (L431R, V434W, and L445R) 
completely abolished the dimeric interaction of Taz1 (Fig. 3.8a). Notably, tryptophan 
substitution of Leu438 still maintained a detectable dimeric interaction (~ 10% of the 
wild type level), consistent with the observation that the binding pocket for Leu438 in the 
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crystal structure is deeper than that for Val434 (Fig. 3.8b). These results confirmed that 
the interface observed in the Taz1D crystal structure is responsible for Taz1 dimerization. 
A common feature of the telomeric dsDNA binding proteins is that they all bind 
to the duplex DNA via multiple Myb domains. In budding yeast S. cerevisiae, Rap1 
contains two tandem Myb domains. Whereas in humans, although TRF1 and TRF2 
contain only one Myb domain, their DNA binding activities require formation of 
homodimers in vivo and in vitro [4, 18, 19]. Based on the facts that Taz1 also exists as a 
homodimer [12](Fig. 3.6) and that each monomer contains only one Myb domain, we 
hypothesized that Taz1 homodimerization is also essential for its telomere association. To 
test this idea, the L445R mutant that disrupted the Taz1 dimerization in the yeast two-
hybrid assay was studied for its effect on the DNA binding activity by an electrophoretic 
mobility shift assay (EMSA) with a duplex (GGTTACA)3 probe. Because attempts to 
express recombinant full-length Taz1 yielded insoluble protein, a C-terminal fragment 
that includes both the dimerization and the Myb domains (Taz1D-Myb, residues 408–663) 
was instead used in the assay. To determine the equilibrium dissociation constant (Kd) of 
the Taz1D-Myb–DNA complex, the binding of a trace amount of DNA probe with 
increasing Taz1D-Myb was measured. Wild-type Taz1D-Myb bound to DNA in a simple 
hyperbolic binding equilibrium with a Kd of ~ 600 nM (Fig. 3.9a). In contrast, the 
substitution of L445 with an arginine reside caused a 10-fold decrease in DNA binding 
with a Kd of ~ 7 μM (Fig. 3.9b). Notably, the Myb domain of Taz1 (Taz1Myb) exhibits a 
similar level of reduction in DNA binding affinity (Kd ~ 60 μM) (data not shown). 
Collectively, we conclude that similar to TRF1 and TRF2, homodimerization of Taz1 is 
required for its efficient association with the telomeric duplex DNA.  
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To determine the in vivo roles of Taz1 dimerization in telomere maintenance, we 
examined the telomere length in yeast cells expressing wild-type Taz1 versus Taz1 
mutants that are deficient in dimerization (a collaboration with Dr. Julia P. Cooper at 
Cancer Research UK). Consistent with the published results, deletion of taz1
+
 from yeast 
cells resulted in dramatic increase in telomere length and length heterogeneity compared 
to wild-type cells (Fig. 3.10a). Notably, three Taz1 single mutations (L431R, V434W, 
and L445R) that showed no detectable dimerization ability in yeast two-hybrid assay 
exhibited significant loss of function in telomere length regulation and manifested 
phenotypes that were as severe as that is in Taz1  cells (Fig. 3.10a, lane 3, 4 and 6). 
Intriguingly, the L438W mutant that retained partial dimerization ability in the yeast two-
hybrid assay also retained partial function in suppressing telomere elongation (Fig. 3.10, 
lane 5). Thus, these data suggested that Taz1 dimerization is critical for telomere length 
regulation.  
 
3.9 Characterization of the Taz1-Rap1 interaction  
Fission yeast Rap1 is recruited to telomeres by binding to Taz1. Both Taz1 and Rap1 are 
involved in regulating telomere length homeostasis, 3’ G-overhang processing and 
preventing NHEJ-medicated chromosome end-to-end fusion [6]. Like budding yeast and 
mammalian Rap1 proteins, S. pombe Rap1 contains a N-terminal BRCT (BRCA-1 
carboxyl-terminal) domain and a central Myb domain [7, 8]. However, the RCT (Rap1 
carboxyl-terminal) domain in pombe Rap1 is not similar as those in ScRap1 and huma 
Rap1 according to the sequence alignments. The RCT domain of mammalian RAP1 
mediates the interaction with TRF2. Thus, it was unknown how S. pombe Rap1 is 
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recognized and recruited to the chromosome ends by Taz1. 
To determine the mechanism of Rap1 recognition by Taz1, we characterized the 
Taz1-Rap1 interaction (Fig. 3.11a). Various fragments of the GST-Rap1 protein were 
evaluated for their ability to interact with Taz1. The N-terminal half (residues 1–570) of 
Rap1 did not show detectable binding to Taz1. In contrast, the C-terminal half (residues 
567–693) formed a stable complex with Taz1 (data not shown). Further mapping 
revealed that, similar to the mammalian TRF2-RAP1 interaction, the C-terminus of Rap1 
(resides 639-693) is sufficient for interaction with Taz1 (Fig 3.11b). Using a similar 
strategy, a 32-residue fragment of Taz1 immediately after the TRFH domain (residues 
365-396) was found to be the minimal structural core that is necessary and sufficient for 
binding to Rap1. Hereafter, Taz1365-396 and Rap1639-693 will be referred to as Taz1RBD 
(Rap1-binding domain) and Rap1RCT, respectively (Fig. 3.11c). 
 
3.10 Solution structure of the Taz1RBD-Rap1RCT complex 
To reveal the structural basis of Rap1 recognition by Taz1, we reconstituted the Taz1RBD-
Rap1RCT complex. However, after extensive constructs and crystallization screening, we 
failed to obtain crystals suitable for structural study. Based on the facts that the Taz1RBD-
Rap1RCT complex is very stable at 25°C and that the size of the complex is ~ 9.6 kDa that 
falls well into the feasible range for NMR technique, we set up a collaboration with Dr. 
Hongyu Hu’s laboratory (Institute of Biochemistry and Cell Biology, Chinese Academy 
of Sciences, Shanghai, China) to determine the solution structure of the Taz1RBD-Rap1RCT 





NMR sample preparation, we linked Rap1RCT to Taz1RBD with a 14-residue linker, which 
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contains four Gly-Gly-Ser repeats with one Hind III restriction enzyme site in the middle 
(Fig. 3.11c). The linker is flexible and long enough so that it does not influence the 
proper interaction between Rap1RCT and Taz1RBD. The high-resolution structure of the 
Taz1RBD-Rap1RCT complex (Fig. 3.12) was calculated from a total of 2420 NMR restrains 
(Table 3.3). 
The solution structure of the Taz1RBD-Rap1RCT complex reveals a compact 
globular fold, except for the linker region that is unstructured. Taz1RBD contains a single 
helix Taz1, while RAP1RCT consists of three  helices (Fig. 3.12a, b). Together, these 
helices are arranged into an intermolecular four-helix bundle. The helix from Taz1RBD 
packs against helices 1 and 2 of RAP1RCT to form an intermolecular three-helix bundle 
(Fig. 3.12a, b). The formation of the binary complex involves an extensive set of 
interactions and causes the burial of 1,682 Å
2
 of surface area at the interface. The driving 
force for the binding of Taz1 to Rap1 is van der Waals interactions (Fig. 3.12c, d). Four 
hydrophobic residues of Taz1RBD (Ile379, Leu380, Leu383 and Val387) make extensive 
contacts with the hydrophobic wedge between helices 1 and 2 of Rap1RCT (Fig. 3.12c, 
d). Located at the center of the hydrophobic interface, the side chain of Ile379 and 
Leu383 of Taz1 are deeply buried in a hydrophobic groove formed by a group of 
hydrophobic residues of Rap1 (Fig. 3.12e). In addition to hydrophobic contacts, 
electrostatic interactions also contribute to the formation of the Taz1RBD-Rap1RCT 
complex. On one side of the Taz1 helix, the guanidinium group of Arg386 of Taz1 is 
directed towards a negative charged depression of Rap1 and anchored in place through a 
network of electrostatic interactions: three salt bridges and one hydrogen bond to the 
carboxyl groups of three residues of Rap1 (Asp652 and Asp656 from 1 and Glu666 
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from 2) (Fig. 3.12c). On the other side the Taz1 helix, another arginine residue of Taz1, 
Arg384, makes two direct hydrogen bonds to the side chain of Rap1 Glu674 (Fig. 3.12c). 
Collectively, these electrostatic contacts function as the two arms of a clamp to help 
Rap1RCT hold the Taz1RBD helix.  
The structure of Rap1RCT closely resembles the N-terminal three-helix bundle of 
the RCT domains of both budding yeast ScRap1 and human hRAP1 even with no 
apparent sequence similarity (Fig. 3.13a). An unbiased search for structurally 
homologous proteins using the Dali server [20] revealed that the structure of Rap1RCT is 
most similar to that of human RAP1RCT; the two RCT domains can be superimposed with 
an rmsd of 2.7 Å for 104 equivalent C  pairs (Fig. 3.13b). In addition to the structurally 
conserved helix bundle, the RCT domains of ScRap1 and hRAP1 contain an additional 
three-helix bundle at the C-termini of the proteins (Fig. 3.13b). Notably, the sequence of 
this extra helix bundle is highly conserved in budding yeast and mammalian Rap1 
proteins but is not present in fission yeast Rap1 (Fig. 3.13a). This explains the failure to 
detect the RCT domain of S. pombe Rap1 by bioinformatics. The structural similarity 
does not only limit to the Rap1RCT moiety of the complex. Strikingly, when the structures 
of the Taz1RBD-RapRCT and the human TRF2RBD-RAP1RCT complexes were superposed 
based on the RCT domains of Rap1 proteins, it is evident that the helix A of Taz1RBD 
packs against the hydrophobic groove of Rap1RCT in a very similar fashion as the 1 
helix of TRF2RBD in the TRF2RBD-Rap1RCT complex (Fig. 3.13b). Taz1RBD lacks the 
second helix 2 in TRF2RBM, which makes less contribution to the TRF2RBD-Rap1RCT 
interaction (Fig. 3.13b). Taken together, these structural similarities strongly support the 
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notion that Taz1 and Rap1 are the fission yeast homologues of human TRF2 and RAP1, 
respectively.  
 
3.11 Biochemical and functional analyses of the Taz1-Rap1 interface 
To corroborate our structural analysis, we examined whether missense mutations of the 
interface residues of Taz1RBD or Rap1RCT could weaken or disrupt the Taz1-Rap1 
interaction. Consistent with the crystal structure, substitution of Taz1 Ile379 and Leu383 
with a positively charged and bulkier arginine residue completely abolished the 
interaction with Rap1 in a yeast two-hybrid assay (Fig. 3.14a). Similarly, Rap1 mutations 
I655R on the other side of the interface also impaired the interaction (Fig. 3.14a). These 
results indicated that a single point mutation at the hydrophobic interface is sufficient to 
disrupt the Taz1-Rap1 interaction. In contrast, two point mutations (Taz1L380R and 
Rap1V651R) only partially disrupted the interaction and another one Taz1V387R maintained 
a wild-type binding with Rap1 (Fig. 3.14a), suggesting these residues are not essential for 
binding.  
To further examine the in vivo roles of the Taz1-Rap1 interaction in telomere 
length regulation, we analyzed the phenotypes of four Taz1 mutations (Taz1I379R, 
Taz1L380R, Taz1L383R, and Taz1L387R) that showed varying degrees in disruption of the 
Taz1-Rap1 interaction in the yeast two-hybrid assay. Notably, all four point mutants of 
Taz1 exhibited partial to complete loss of telomere length regulation, in a manner that is 
entirely consistent with the severity of the Rap1-binding defect (Figs. 3.14b, lane 4-7). 
The two mutants (Taz1I379R and Taz1L383R) that completely lost the Rap1-binding activity 
in the yeast two-hybrid assay showed a rap1 -like telomere length defect (Fig. 3.14b, 
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lane 4, 6). Furthermore, the Taz1L387R mutant that retained almost wide-type Rap1-
binding ability in the yeast two-hybrid assay also exhibited the mildest defect in 
suppressing telomere length elongation (Fig. 3.14b, lane 7). Taken together, our 
mutagenesis analyses suggest that the hydrophobic interface is necessary for both in vitro 
and in vivo binding of Taz1 to Rap1. 
 
3.12 Discussion 
As one important component of yeast telomere-associated protein complex, Taz1 is 
previously thought to mimic its human homologues TRF1 and TRF2 in many aspects, as 
supported by the following evidence. 1.) By sequence alignment and secondary structural 
prediction, Taz1 contains the conserved C-terminal Myb-domain, which is the feature 
motif of all the known double-stranded telomeric DNA binding proteins. The TRFH 
domain is also considered to locate in the center of Taz1, although the sequence identity 
and similarity is low compared with TRFH domain in TRF1 and TRF2 [4]. 2.) Similar to 
TRF1 and TRF2, Taz1 functions as a homodimer on the fission yeast telomeric dsDNA 
[12]. Through direct interaction, Taz1 recruits Rap1 to telomere, reassembles the human 
TRF2-Rap1 complex in fission yeast [7, 8]. Before our structural results are reported, it 
has been widely proposed that Taz1 homodimerizes through its TRFH domain, which 
shares the similar structural architecture as TRF1 and TRF2. However, to our great 
surprise, Taz1 adopts a novel method for dimerization. Due to the different helix 
arrangements, Taz1TRFH forms a more compact helix-bundle and lacks the two extended 
 helices ( 1 and 10 in TRF1/TRF2-TRFH) that are required for the cross-brace-like 
homodimerization interface in TRF1 and TRF2. Alternatively, Taz1 dimerizes via two  
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helices outside Taz1TRFH, which are paralleled packed to form a four-helix-bundle with 
the symmetry-related dyad parallel to the helical axes.  
So far, the dsDNA binding telomeric proteins have been found in many 
organisms, from the simple Trypanosoma [13] to yeast and higher vertebrates. All the 
functional evidences suggest that they are very crucial in telomeric pathways, such as 
telomere end protection, proper telomere structure maintenance, as well as facilitating 
efficient telomere replication. Although Myb domain is shared by all the known dsDNA 
binding telomeric proteins, the TRF-like complex, rather than Myb domain, is previously 
considered to represent the ancestral scenario. In fission yeast and higher vertebrates, 
duplex telomeric DNA repeats are bound by TRFH containing proteins and Rap1 is 
directed to telomere via interactions with TRF homologues. In budding yeast, Rap1 
orthologue stays on telomeric DNA track and the TRF homologue is missing. This 
exception may be caused by a duplication of Myb domain gene during the revolution. 
ScRap1 accidentally obtained two Myb domains, which made it possible to bind duplex 
telomeric DNA by itself. Meanwhile, the TRF homologue got lost for some unknown 
reasons. Therefore, before our structural studies on Taz1 TRFH domain, it has been 
hypothesized that TRFH domains in all the TRF homologues bear the same structural 
architecture and mediate dimerization. However, our crystal structures of Taz1TRFH and 
Taz1D challenge this hypothesis. Future structural studies of the potential TRF 
homologues in other species will help further clarify the debate.  
Nevertheless, despite the structural differences in TRFH domain, we still consider 
Taz1 as the homologue of TRF1 and TRF2 because of the common functions. Being the 
only telomeric protein that binds yeast dsDNA, Taz1 carries out several biological 
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functions that have been distinctively distributed to two players in human: TRF1 and 
TRF2. For example, both Taz1 and TRF1 are actively involved in efficient replication of 
telomeric repeats [21, 22]. The N-terminal domains of both proteins are very acidic 
(pITRF1N=3.5, pITaz1N=4.8), although the function is still unknown [23]. On the other hand, 
Taz1 provides a landing platform for other yeast telomeric proteins, just similar as TRF2 
does in human. Our solution structure of Taz1-Rap1 complex clearly reveals that the 
TRF2-Rap1 complex is similarly reassembled in fission yeast. In the Taz1-Rap1 
complex, Taz1 shares the similar  helix as that in TRF2, which contributes most to the 
Rap1-interacting interface. In vivo analyses also indicate that the recruiting of Rap1 to 
yeast telomere is important for telomere length regulation, which match our recent 
discoveries about TRF2-Rap1’s function on human telomere protection (Chen, Y et. al, 
2009, submitted) Furthermore, although Taz1 dimerizes differently from TRF1 and 
TRF2, the purpose of the dimerization remains the same: to assemble two Myb domains 
that are required for binding to dsDNA with high affinity, as suggested by our EMSA 
data. Collectively, we draw the conclusion that rather than a structural homologue, Taz1 
is the functional homologue of TRF1 and TRF2. Taz1 represents both TRF1 and TRF2 in 
fission yeast and plays an important role in the telomere length regulatory mechanism. 
 
3.13 Methods and materials 
Protein expression and purification  
The TRFH domain of Taz1 (residues 128 – 388) and dimerization domain of Taz1 
(residues 395 – 490) were cloned into a modified pET28b vector with a SUMO protein 
fused at the amino-terminus after the His6 tag [24]. The TRFH domain of Taz1 was 
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expressed in E. coli. BL21(DE3). After induction for 16 hours with 0.1 mM IPTG at 25 
°C, the cells were harvested by centrifugation and the pellets were resuspended in lysis 
buffer (50 mM Tris-HCl pH 8.0, 50 mM NaH2PO4, 400 mM NaCl, 3 mM imidazole, 10% 
glycerol, 1mM PMSF, 0.1 mg/ml lysozyme, 2 mM 2-mercaptoethanol, and home-made 
protease inhibitor cocktail). The cells were then lysed by sonication and the cell debris 
was removed by ultracentrifugation. The supernatant was mixed with Ni-NTA agarose 
beads (Qiagen) and rocked for 6 hours at 4 °C before elution with 250 mM imidazole. 
The ULP1 protease was added to remove the His6-SUMO tag.  Finally the Taz1
TRFH
 
protein was further purified by passage through Mono-Q ion-exchange column and by 
gel-filtration chromatography on Hiload Superdex 75 equilibrated with 25 mM Tris-HCl 
pH 8.0, 150 mM NaCl and 5 mM dithiothreitol (DTT). The purified Taz1
TRFH
 protein 
was concentrated to 25 mg/ml and stored at -80 °C. The Seleno-Met substituted Taz1
TRFH
 
protein was similarly purified.  
 The protein of dimerization domain of Taz1 was expressed in E. coli. and purified 
following the same procedures as described above.  
 The Rap1RCT and Taz1RBD were artificially linked together with a 14-residue 
linker, which contains 4 Gly-Gly-Ser repeats with one Hind III restriction enzyme site in 
the middle. The fusion protein of Rap1RCT-Taz1RBD was expressed in E. coli. and purified 
following the same procedures as described above. 
 
Expression and Purification of the Fusion Protein Taz1RBD-Rap1RCT (spRT6) 
The spRT6 construct was expressed in E. coli BL21(DE3) strain. 10 mL of overnight 














respectively.  When the culture reached an OD600 of 0.6, the expression of spRT6 fusion 
protein was induced by adding IPTG to a final concentration of 0.2 mM.  The proteins 
were purified by Ni-NTA affinity chromatography. The SUMO-tag was removed by on-
column cleavage with ULP1.  The proteins were further purified by gel filtration on a 
Superdex-75 column (Amersham Biosciences). 
 
Limited protease (Trypsin) cleavage of Taz1113-400 
The protein of Taz1113-400 was incubated with 0.2% w/w Trypsin (Roche) at 25 °C in 25 
mM Tris-HCl pH 8.0, 150 mM NaCl, and 5 mM DTT. At various time points, 10 μl 
aliquots of the reaction mixture were withdrawn, diluted with 10 μl of water and 5 μl of 
SDS loading dye, and run on 15% SDS-PAGE visualized with Coomassie brilliant blue 
stain.  
 
MALDI mass spectrometry of the limited protease (Trypsin) cleavage products 
Fro MALDI mass spectrometry analysis, Taz1113-400 was incubated with 0.2 % w/w 
Trypsin (Roche) at 25 °C in 25 mM Tris-HCl pH 8.0, 150 mM NaCl, and 5 mM DTT. 
Aliquots were withdrawn as described above for SDS-PAGE analysis. At the 90 min time 
point, 2 μl of the reaction mixture was co-crystallized with 2 μl sinapinic acid matrix. 
The samples were analyzed by MALDI-TOF-MS in linear mode. The major product by 
MALDI had an MH(+1) of 29360.2 + 30 Da. Examination of the map of predicted 
Trypsin sites revealed that this fragment corresponds to the predicted fragments: Taz1127-
383 [MH(+1) 29394.6 Da].
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Electrophoretic mobility shift assay (EMSA) 
The protein of Taz1408-663 in binding buffer (25 mM Tris-HCl pH 8.0, 150 mM NaCl, and 
5 mM DTT) was mixed with 1 μM 32P-labeled telomeric dsDNAs (32mer) in a total 
volume of 20 μL. The reaction mixtures were incubated at 4 °C for 30 min. Then the 
mixtures were directly loaded onto a 4 20% nondenaturing polyacrylamide gel. 
Electrophoresis was carried out in TBE buffer at 150 V for 85 min at 4 °C. The gels were 
dried, and radiolabeled dsDNA was visualized using a PhosphorImager. (32mer dsDNA 
was annealed by the following ssDNA with its complementary strand: 5’ -
GATCTCAGCT GGTTACA GGTTACA GGTTACA G- 3’) The signal of the 
radiolabeled dsDNA was quantified by using ImageQuant (GE Healthcare Life Sciences). 
The dissociation constant was determined by using the software of GraphPad Prism.  
 
Cross linking of Taz1D  
The protein of Taz1D was incubated with various concentration of DSS cross-linker 
(Disuccinimidyl suberate, Thermo Scientific) at 25 °C in PBS. After incubation for 30 
min, 10 μl aliquots of the reaction mixture were withdrawn, diluted with 10 μl of water 
and 5 μl of SDS loading dye, and run on 15% SDS-PAGE visualized with Coomassie 
brilliant blue stain.  
 
Crystallization, data collection and structure determination 
The Taz1TRFH protein was crystallized by hanging-drop-vapor-diffusion at 4 °C. The 
precipitant/well solution contained 100 mM Tris-HCl pH7.0, 18% PEG 3350, 300mM 
141
KNO3, 10 mM Co(NH4)6Cl3 and 10 mM DTT. Crystals were gradually transferred to a 
harvesting solution containing 100 mM Tris-HCl pH7.0, 25% PEG 3350, 300mM KNO3, 
10 mM Co(NH4)6Cl3 and 25% glycerol before flash-frozen in liquid nitrogen for storage 
and data collection under cryogenic conditions (100 K). Se-Met-MAD datasets with the 
resolution of 2.7 Å were collected at beam line 21ID-D at APS and processed using 
HKL2000 (Otwinowski and Minor, 1997). Crystals belong to space group C222 and 
contain one Taz1TRFH per asymmetric unit. Two selenium sites were located and refined, 
and MAD phases calculated using SHARP (E. d. La Fortelle, G. Bricogne, 1997). A 
model was automatically built into the modified experimental electron density using 
ARP/WARP (V. S. Lamzin, A. Perrakis, K. S. Wilson, 2001); the model was then further 
refined in CNS [25] with manual rebuilding using program O [26]. 
 The Taz1D protein was crystallized by sitting-drop-vapor-diffusion at 4 °C. the 
precipitant/well solution contained 2.3 M (NH4)2SO4, 100 mM Bicine pH 8.5 and 10 mM 
DTT. Crystals were gradually transferred to a harvesting solution. Final concentration of 
125 mM NaI was added into harvesting solution 1 minute before the flash-frozen in 
liquid nitrogen for storage and data collection under cryogenic conditions (100 K). 
Crystals belong to space group P43212 with one Taz1D monomer per asymmetric unit. 
Datasets with the resolution of 1.5 Å were collected at beam line 21ID-D at APS and 
processed using HKL2000 (Otwinowski and Minor, 1997). Native-/I- datasets were 
combined and scaled in ccp4i and then were input into SHARP (E. d. La Fortelle, G. 
Bricogne, 1997). The initial SIR map was significantly improved by solvent flattening. A 
model was automatically built into the modified experimental electron density using 
ARP/WARP (V. S. Lamzin, A. Perrakis, K. S. Wilson, 2001); the model was then further 
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refined using simulated-annealing and positional refinement in CNS [25] with manual 
rebuilding using program O [26]. 
 
Yeast two-hybrid assay  
The yeast two-hybrid assays were performed using L40 strains harboring pBTM116 and 
pACT2 (Clonetech) fusion plasmids. The colonies containing both plasmids were 
selected on –Leu –Trp plates. The -galactosidase activities were measured according to 




The NMR experiments were carried out at 25 ºC on Bruker 600- and 800-MHz 
spectrometers equipped with four RF channels and triple resonance pulsed-field gradient 
cryoprobes. The chemical shifts were referenced to internal 2, 2-dimethyl-2-
silapentanesulfonic acid (DSS). The samples were prepared with 1.5 mM protein 
dissolved in a buffer of 90%H2O/10% D2O containing 20 mM sodium phosphate (pH 
6.5) and 50 mM NaCl. All NMR spectra were processed with NMRPipe [27] and 
analyzed with Sparky (T.D. Goddard and D.G. Kneller, SPARKY 3, University of 





(HB)CB(CGCD)HD, (HB)CB(CGCDCE)HE, and three-dimensional HNCACB, 
CBCA(CO)NH, HNCO, HN(CA)CO, C(CCO)NH, H(CCCO)NH,  HCCH-TOCSY and 
CCH-COSY spectra were recorded to obtain the chemical shift assignments of backbone 




C-edited NOESY-HSQC spectra 
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(mixing time 100 ms) were collected to generate the distance restraints for structure 
calculations.   
 
Structure Calculation 
Initial structures were calculated using the program ARIA 2.2 [28], NOE peaks were 
assigned with SANE [29] and CYANA 2.1 [30], and the final structures were refined 
with Amber 9.0 (D.A. Case et al. 2006). Distance restraints were derived from 
interproton NOEs. Backbone dihedral angle (  and ) restraints were generated from 
chemical shift data using TALOS [31]. Hydrogen bond restraints were determined using 
the secondary structure information from CSI [32] and confirmed by intermediate range 
NOEs. The 20 lowest energy structures from ARIA were selected as models for SANE to 
extend the NOE assignments. The final set of distance restraints were obtained after 
several rounds of SANE/CYANA calculations. Two hundred structures from CYANA 
were refined by restrained molecular dynamics calculations with Amber using 
generalized Born salvation model to account for solvent effects. The 20 refined structures 
with the lowest energy were analyzed using [33] and the averages from three individual 




A region of taz1
+
 open reading frame (from bases pair 315 to 501) has been replaced by 
ura4
+
 gene to generate a taz1::ura (Tomita K., unpublished data). Vectors pACT2-taz1-
L431R / taz1-V434W / taz1-L438W / taz1-L445R as well as vectors pET-SUMO-Taz1 I379R / 
Taz1-L380R / Taz1-L383R / Taz1-L387R were digested with BamHI / XhoI, generating a 
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taz1 full length fragment containing a set of point mutation in Taz1 dimerization domain 
(taz1-L431R / taz1-V434W / taz1-L438W / taz1-L445R) and Taz1-Rap1 interaction domain 
(taz1 I379R / taz1-L380R / taz1-L383R / taz1-L387R). taz1::ura strain was transformed with 
the BamHI / XhoI fragments from pACT2 and pET-SUMO and plated on replica-plated 
twice on EMM + FOA to select for the loss of ura4+ gene. Transformants were screened 
by PCR using two sets of primers. Primers 59/60 hybridize outside taz1+ ORF; primers 
146/60 hybridize inside and outside taz1+ ORF respectively. 
 
Measurement of telomere length 
 
Telomere length was measured by Southern hybridization according to the procedure 
described by Cooper J.P. et al 1997 [34]. Briefly, genomic S.pombe DNA was prepared 
by glass beads lysis method, digested with EcoRI, resolved on 1% agarose gel, 
transferred to Hybond membrane (Amersham) and hybridized at 65°C to 
32
P random 
primed telomeric probe (SacI-PstI fragment from pIRT2-TELO vector). 
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Figure 3.1 Characterization of Taz1TRFH 
(a) Taz1117-391 is a monomor in solution. Gel filtration chromatography profile (Hiload 
Superdex 75) of the Taz1117-391 protein. Elution positions of 15 and 32 KDa protein 
markers are indicated.  
(b) Limited proteolysis of Taz1113-400 by Trypsin, Elastase, Subtilisin and Glu-C. 
Reaction time and different proteases as labeled.  
(c) SDS-PAGE time course of Trypsin cleavage of Taz1113-400. Lanes in minutes of time 
of the reaction as labeled.  
(d) The molecular weight of the stable fragment resulted from (c) was identified by mass 










Figure 3.2 Purification and crystallization of Taz1TRFH 
(a) Gel filtration chromatography profile (Hiload Superdex 75) of the Taz1127-388 protein. 
Elution positions of 15 and 32 KDa protein markers are indicated.  
(b) SDS-PAGE of purified protein of Taz1127-388 for crystallization. 
(c) Crystals of Taz1127-388. 
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Table 3.1 Data collection, phasing and refinement statistics for Taz1TRFH 
 
 Taz1TRFH  
Data collection  
 Se Peak Se Inflection Native 
Space group C222 C222 
Cell dimensions   
    a, b, c (Å) 68.006, 160.354, 49.941 68.008, 160.097, 50.080 
    , ,   (º) 90, 90, 90  90, 90, 90 
Wavelength (Å) 0.97935 0.97951 0.97935 
Resolution (Å)  50-2.7 50-2.7 100-2.25 
Rmerge (%) (high res. shell) 0.063 (0.518) 0.055 (0.368) 0.043 (0.373) 
I/  (high res. cell) 52.5 (4.9) 55.7 (8.6) 57.6 (3.6) 
Completeness (%) (high res. shell) 99.4 (96.8) 99.6 (98.8) 96.6 (80.3) 
Redundancy (high res. shell) 16.4 (12.9) 16.8 (15.6) 6.7 (5.4) 
Phasing   
 Anomalous Anomalous Isomorphous  
Acentric Phasing Power 2.051 1.471 0.625  
Centric Phasing Power   0.608  
Acentric reflections FOM 0.304   
Centric reflections FOM 0.117   
Refinement   
Resolution (Å)   50-2.3 
No. reflections   12401 
Rwork/ Rfree (%)   23.66/28.57 
B-factors (Å
2
)   
    Protein   77.6 
    Water   66.9 
R.m.s deviations   
    Bond lengths (Å)    0.006820 
    Bond angles (º)   1.28085 
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Figure 3.3 Crystal structure of Taz1TRFH 
(a), (b) Overall structure of Taz1TRFH. Taz1TRFH consists 14  helices: 1B, 3, 6, 7, 
8, 9, 12, and 13 form an eight-helix bundle, while the other six short helices 1A, 
2, 4, 5, 10, and 11, cap the exposed hydrophobic surface from the sides of the 
central helical bundle. The helices are organized so that the entire domain resembles the 
shape of a slightly curved hockey puck with a diameter of ~ 50 Å. 
(c) Three phenylalanines (Phe263 from 8, Phe350 and Phe354 from 13) stack with 
other and keep the interaction between helix 8 and 13. 
(d) Taz1TRFH is in surface representation and colored according to its electrostatic 
potential (positive potential, blue; negative potential, red). Taz1TRFH surface is highly 
negative charged. 
(e) On the surface of Taz1TRFH, there is a cluster of 13 acidic residues that are distributed 






Figure 3.4 Comparison of Taz1TRFH with TRF1/TRF2TRFH 
(a) Superposition of the Taz1
TRFH
 structure on the crystal structure of TRF2 [35]. Taz1 is 
colored in green and TRF2
TRFH
 is colored in cyan. The 1 helix of Taz1TRFH is severely 
bent (~ 70°). 
(b) The dimerization of TRF1TRFH. The N-terminal portion of 1 extends outside of the 
helical core and interacts with helix 10 from the other molecule in the dimer. 
(c) The bended 1A helix and the N-terminal tail of Taz1TRFH fits into a hydrophobic 
groove formed by helices 3, 4, and 5. Two hydrogen bonding interactions are formed 
between main-chain atoms of Trp129 and the hydroxyl groups of Tyr206 and Tyr213, 
respectively. 
(d) Secondary structure assignments from the crystal structure of Taz1TRFH and 
TRF1/TRF2TRFH are shown as colored (Taz1TRFH is green, TRF1/TRF2TRFH are blue) 
cylinders (  helices,) above the aligned sequences. Highlighted areas indicate the 
conserved residues in the TRFH domain of Taz1 and TRF1/TRF2. The dashed lines show 








Figure 3.5 Characterization of Taz1 dimerization domain 
(a) Various constructs are designed for determination of Taz1D. Dimerization is tested 
via gel filtration chromatography and chemical cross-linking analysis.  
(b) Gel filtration chromatography profile (Hiload Superdex 75) of the Taz1395-490 protein. 
Elution positions of 15 and 32 KDa protein markers are indicated. 
(c) Dimerization of Taz1395-490 protein that cross-linked by DSS cross-link reagent 
(Disuccinimidyl suberate, Thermo Scientific). With increased amount of DSS added, 
more Taz1395-490 protein is cross-linked as the dimer. 
(d) SDS-PAGE of Taz1395-490 protein fractions from (b). 






Table 3.2 Data collection, phasing and refinement statistics for Taz1D 
 
 Taz1D 
Data collection   
 NaI Native 
Space group P43212 P43212 
Cell dimensions  
    a, b, c (Å) 45.170, 45.170, 79.341 45.078, 45.078, 78.687 
    , ,   (º) 90, 90, 90 90, 90, 90 
Wavelength (Å) 0.97872 0.97872 
Resolution (Å)  100-1.3 100-1.5 
Rmerge (%) (high res. shell) 0.086 (0.355) 0.046 (0.271) 
I/  (high res. cell) 54.7 (2.63) 38.6 (2.1) 
Completeness (%) (high res. shell) 95.3 (64.7) 97.1 (85.9) 
Redundancy (high res. shell) 11.6 (4.1) 6.5 (4.0) 
Phasing  
Acentric Phasing Power 0.623  
Centric Phasing Power 0.634  
Acentric reflections FOM 0.129  
Centric reflections FOM 0.185  
Refinement  
Resolution (Å)  50-1.5 
No. reflections  12913 




    Protein  24.4 
    Water  40.9 
R.m.s deviations  
    Bond lengths (Å)   0.003554 
    Bond angles (º)  1.02094 
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Figure 3.6 Crystal structure of Taz1 dimerizatin domain 
(a)-(c) Taz1 dimerization domain is a four-helix bundle structure, resulting the burial of a 
total of 2514.96 Å
2
 of the solvent accessible surface area. In (a) and (b), one monomer is 
colored yellow and the other monomer is colored light red. In (c), one monomer is in 
surface representation and colored according to its electrostatic potential (positive 
potential, blue; negative potential, red).  
(d) The side chains of L415, L417, I420, and I425 insert into a hydrophobic groove 
formed by residues from helices D 2 and D 3. L415 has two hydrogen-bonding 






Figure 3.7 Dimerization interface of Taz1D 
In (a, b), the hydrophobic packing contact at the dimeric interface of Taz1D is extensive, 
with 12 residues from one molecule interacting with those from the other molecule. 
Besides, intermolecular electrostatic interactions and three hydrogen-bonding interactions 
provide additional specificity and stability to the structure. In (a), one monomer is in 
surface representation and colored according to its electrostatic potential (positive 




Figure 3.8 Effects of the mutations on the Taz1 dimerization interface  
(a) In yeast two-hybrid, interaction of LexA-Taz1D with GAD- Taz1D was measured as 
-galactosidase activity. Data are averaged of three independent -galactosidase 
measurements. 
(b) Yeast two-hybrid results consistent with the observation that the binding pocket for 
Leu438 in the crystal structure is deeper than that for Val434. One monomer is in surface 
representation and colored according to its electrostatic potential (positive potential, blue; 




Figure 3.9 Disruption of Taz1 dimerization abolishes Taz1’s dsDNA binding activity 
(a), (b) Equilibrium binding curves for the proteins of Taz1408-663 wide type or L445R 
mutant. The dsDNA primer contains three pombe telomeric repeats “GGTTACA”. The 
blue and red lines represent theoretical binding curves fit to the data for wild type and 
L445R mutant protein, respectively. The calculated equilibrium dissociation constant 




Figure 3.10 In vivo effects of the mutations on the Taz1 dimerization interface (Done 
by Dr. Julia Cooper’s group.) 
(a) Three Taz1 single mutations (L431R, V434W, and L445R) that showed no detectable 
dimerization ability in yeast two-hybrid assay exhibited significant loss of function in 
telomere length regulation as that in Taz1  cells (compare lane 2 with lane 3, 4 and 6). 
L438W mutant that retained partial dimerization ability in the yeast two-hybrid assay also 
retained partial function in suppressing telomere elongation. 
(b) Two Taz1 mutants (L431R, L445R) and wild type are tagged. By ChIP, mutants 
L431R and L445R do not bind telomeric dsDNA (lower panel). On the dot blot (upper 
panel) of WCE (whole cell extract) that both mutants give a stronger signal with the 
TELO probe, indicating longer telomeres.  
(c) Quantitative PCR is applied to monitor the telomere proximal position by using 




Figure 3.11 Fusion protein of Rap1RCT - Taz1RBD complex 
(a) Schematic illustration of domain organization of Taz1 and Rap1. Taz1RBD interacts 
with Rap1RCT as indicated. 
(b) SDS-PAGE of Taz1148-408-Rap1639-693 complex.   
(b) Rap1RCT and Taz1RBD was linked by a 14-residue peptide linker. The purified fusion 




Figure 3.12 NMR structure of Rap1RCT-Taz1RBD complex (Done by Dr. Hongyu Hu’s 
group) 
(a) Superposition of 20 energy-minimized structures of the Rap1RCT-Taz1RBD complex. 
Rap1 (yellow) contains three  helices and Taz1 (cyan) contains one  helix.  
(b) Overall structure of Rap1RCT-Taz1RBD complex.  
(c), (d) Rap1RCT-Taz1RBD interaction interface. Rap1RCT in (d) is in surface representation 
and colored according to its electrostatic potential (positive potential, blue; negative 
potential, red). Four hydrophobic residues on helix A of Taz1RBD (Ile379, Leu380, 
Leu383 and Val387) wedge in between the two -helices of Rap1RCT: 1 and 2. Arg386 
was deeply buried into a negative charged pocket of Rap1RCT, which is made up by 
Asp652, Asp656 on 1 and Glu666 on 2. Arg384 forms two strong hydrogen bonds 
with the side chain of Glu674 on helix 2 of Rap1RCT. Arg384 and Arg386 function as 
the two arms of a clamp to fix Taz1RBD on Rap1RCT.  
(e) Rap1RCT is in surface representation and colored according to its electrostatic potential 
(positive potential, blue; negative potential, red). The side chains of Ile379 and Leu383 of 
Taz1RBD are deeply buried in a hydrophobic groove made of a group of hydrophobic 








Table 3.3 Statistics for the structure of Rap1RCT-Taz1RBD complex 
 
No. of experimental restraints  
Total unambiguous distance restraints 1044 
Intra-residual  521 
 Sequential (|i-j| = 1) 224 
Medium (2 |i-j|  4) 157 
Long range (|i-j|  5) 142 
   Total ambiguous distance restraints 268 
   Hydrogen bond restraints 31 
   Dihedral angle restraints  
 54 
 54 
Structure model statistics   
Coordinate precisions (Å)
 a
, residues 11-52, 85-97 (1-104)  
Backbone (N, C , CO) 0.51 ± 0.10 (4.85 ± 0.86) 
Heavy atoms 1.46 ± 0.18 (5.05 ± 0.76) 
RMSD from experimental restraints  
      NOE distances (Å) 0.0834 ± 0.0173 
Dihedral angles (deg.) 0.7398 ± 0.1493 
RMSD from idealized geometry  
      Bond lengths (Å) 0.0051 ± 0.0002 
      Bond angles (deg.) 0.6274 ± 0.0262 
      Impropers  1.6428 ± 0.1593 
   Energies (kcal/mol)  
Etotal -3711.0 ± 114.8 
Restraint violations  
   Distances (> 0.2 Å)  10 
   Dihedral angles (> 5 deg.)  0 
   Hydrogen bonds  0 
Ramachandran analysis
b
, residues 11-52, 85-97 (1-104)  
Residues in most favored regions 97.5 (75.8) 
   Residues in additionally allowed regions 2.5 (19.6) 
Residues in generously allowed regions 0.0 (2.5) 
Residues in disallowed regions 0.0 (2.1) 
a
The coordinate precision is defined as the average RMS deviation between the 20 structures and their 
mean coordinate positions. 
b
Exception of Gly residues. 
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Figure 3.13 Comparison of SpRap1RCT, ScRap1RCT and human Rap1RCT 
(a) Sequence alignment of the RCT domains of human Rap1, ScRap1 and SpRap1. The 
alignment is based on the crystal structures of ScRap1RCT and human Rap1RCT and 
solution structure of SpRap1RCT. SpRap1 lacks the last three helices ( 4, 5 and 6). The 
identical residues are highlighted by green and the similar residues are highlighted by 
yellow.  
(b) Superposition of the crystal structure of pombe Rap1RCT-Taz1RBD complex and human 
TRF2RBD-Rap1RCT complex (Chen et al, 2009, submitted). Helices are shown as colored 





Figure 3.14 Effects of the mutations on the Rap1RCT - Taz1RBD interaction interface. 
(a) In yeast two-hybrid, interaction of LexA-Rap1RCT with GAD-Taz1RBD was measured 
as -galactosidase activity. Data are averaged of three independent -galactosidase 
measurements. 
(b) In vivo roles of the Taz1-Rap1 interaction in telomere length regulation. All four 
point mutants of Taz1 (Taz1I379R, Taz1L380R, Taz1L383R, and Taz1L387R) exhibited partial to 
complete loss of telomere length regulation, in a manner that is entirely consistent with 
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CHAPTER 4 
STRUCTURAL ANALYSES OF BLM-TOPOIII -RMI1-RMI2 COMPLEX, THE 
DOUBLE HOLLIDAY JUNCTION DISSOLVASOME. 
 
 
The BLM-TOPOIII -RMI1-RMI2 (BTR) complex plays an important role in dissoluting 
homologous recombination (HR) intermediate double Holliday junctions (dHJs). Recent 
data suggest that the dHJ dissolvasome BTR complex is also involved in telomere 
maintenance in telomerase-negative ALT (alternative lengthening of telomeres) cells. 
However, the detailed dissolution mechanism of the BTR complex is unclear. In this 
chapter, I focus on the structural and functional characterization of the RMI1-RMI2 




Telomeres in most cancer cells and tumor tissues are maintained by telomerase for long-
term proliferation. While in some types of cancer cells, telomeres could be maintained by 
a mechanism named ALT (alternative lengthening of telomeres) in the absence of 
telomerase. BLM, the RecQ helicase mutated in the Bloom Syndrome, is found in a 
special nuclear structure called ALT-associated PML (promyelocytic leukemia) bodies 
(APBs). BLM associates with TOPOIII  and RMI1-RMI2 to form the BTR (BLM-
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TOPOIII -RMI1-RMI2) complex. This complex can specifically resolve the double 
Holliday junction (dHJ), a homologous recombination (HR) intermediate, without 
crossover recombinants. The BTR complex may also function in telomere maintenance in 
ALT cells because 1) telomeres in ALT cells could be processed through the HR 
pathway, and 2) BLM and double-stranded telomeric DNA binding proteins TRF1 and 
TRF2 are found in APBs. Direct interactions between BLM and TRF1/TRF2 have been 
reported, and 3) the BTR complex associates human telomeric chromatin from ALT cells. 
Collectively, the dHJ dissovalsome BTR complex may play an important role in telomere 
metabolism in ALT cells. In order to elucidate the structural basis of dHJ dissolution 
mechanism of the BTR complex, I first solved the crystal structure of the RMI1-RMI2 
complex. The RMI1-RMI2 complex contains three OB folds (two in RMI1 and one in 
RMI2), which interact in a similar way as RPA1 and RPA2 in the RPA complex. 
Structural study of BLM was also performed. I have already successfully obtained 
crystals of the catalytic core of BLM. Functional interpretations based on the structural 
information are also tested in an in vitro dHJ dissolution assay. 
 
4.2 Introduction 
4.2.1 Alternative Lengthening of Telomere in Mammalian Cells 
Telomerase plays an important role in cells of the germ line and in normal somatic 
biology, especially in those tissue compartments that depend on extensive cellular 
proliferation. Nevertheless, in normal somatic cells telomerase is not expressed at 
sufficient levels to prevent telomere shortening due to the end replication problem. In 
contrast, telomere length maintenance in most cancer cells requires dysregulated 
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telomerase activity [1]. A substantial minority of immortalized mammalian cell lines and 
tumors are telomerase-negative, however, and in these cells telomere length maintenance 
can be achieved instead by a telomerase-independent mechanism, called Alternative 
Lengthening of Telomeres (ALT) [2]. The existence of ALT was deduced from 
observations of telomere length maintenance over many hundreds of population 
doublings in the absence of detectable telomerase activity.  
ALT-positive human cells can be recognized on the basis of a number of 
hallmarks. One unique feature of ALT cell lines and tumors is the presence of special 
nuclear structure called ALT-associated promyelocytic leukemia (PML) bodies (APBs). 
PML bodies are found in several different cellular processes including cell cycle 
regulation, senescence, apoptosis, tumor suppression, and immune and inflammatory 
responses [3-8] (reviewed in [4]). APBs appear to be special since in addition to 
recombination proteins RAD52, RAD51, RPA, RecQ helicase WRN and BLM, they also 
contain the telomeric DNA and duplex telomeric DNA binding proteins TRF1 and TRF2 
[9]. ALT cells can also be distinguished from other cells by the extremely heterogeneous 
telomere length, the increased number of extra-chromosomal telomeric DNA repeat 
(ECTR) circles (or T-circles) and dramatic telomere lengthening and shortening events 
[10-14]. Under normal conditions, cultured human somatic cells lose about 40 – 200 bp 
during each cell cycle [15-18].  In human germ line cells, the telomere length is 
maintained at the level of ~ 15 kb by telomerase [19, 20], and in human cancer cells the 
telomeres are normally homogeneous and the average length is below ~ 10 kb [20-22]. In 
contrast, telomeres in ALT cells are very heterogeneous, ranging from < 3 kb to > 50 kb 
with the average length of ~ 20 kb [2, 10, 11, 23, 24].  
189
The rapid dynamics of telomere length and the increased number of T-circles in 
ALT cells suggest that telomere maintenance mechanism in these cells involves 
homologues recombination (HR). HR is a conserved mechanism in which the exchange 
of genetic information (nucleotide sequences) between two similar (homologous) or 
identical strands of DNA sequences. During the process of HR, several HR intermediates 
appear, including D-loops and double Holliday Junctions (dHJs). Coincidently, the T-
loop, the reshaped telomere structure by the shelterin complex, resembles an intermediate 
of HR (see Chapter 1, Figure 1.10), and provides a substrate for telomere deletion 
through the HR pathway. Previous studies showed that the N-terminal basic domain (B-
domain) of TRF2 prevents the T-loop from undergoing HR mediated deletion [25]. 
Expression of TRF2 B in cells induced catastrophic deletions of telomeric DNA, and the 
number of T-circles increased to a level similar to that in ALT cells [25]. These T-circles 
are very likely the resolution products of T-loops as electron microscopy data showed 
that these T-circles and T-loops were of similar size[25, 26] (Fig. 4.1). 
 
4.2.2 The BLM-TOPOIII -RMI1-RMI2 (BTR) complex, a dHJ dissolvasome that 
associated with telomeres 
BLM belongs to the RecQ helicase family, named after the E.coli recQ gene product. 
There are five RecQ helicase members in humans: RECQ1, RECQ4, RECQ5, WRN and 
BLM [27-32]. Defects in three RecQ helicases cause genome instability and premature 
aging [32]. Specifically, defects in BLM gene result in cancer predisposition disorders BS 
(Bloom’s syndrome) [33]. BS is an autosomal recessive genetic disorder in human. BS 
patients have a very high risk of most types of cancers at the early age of onset (usually at 
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about 24 years of age). It has been identified that the mutated gene (BLM) in BS patients 
locates on chromosome 15q26.1 [33, 34]. The BLM gene encodes a protein of 1417 
amino acids, which is expressed in all active proliferation tissues, such as testis, ovary, 
thymus and spleen [32, 35]. There is a high BLM protein expression level in S phase and 
it reaches a peak in G2 phase [36, 37].  
As a member of the RecQ helicase family, BLM is able to unwind various HR 
intermediates in vitro, including D-loops and Holliday Junctions [38-40]. It has been 
observed experimentally that in human cells BLM functionally associates with a type IA 
topoisomerase, topoisomerase III  (TOPOIII ), which unknots the two DNA strands by 
introducing transient nicks [41, 42]. Through the combined and cooperative nicking and 
unwinding activities, one particular HR intermediate, known as a double Holliday 
Junction (dHJ) that arises from reciprocal exchanges of single stranded sequence during 
the process of HR, is processed by the BLM complex without leaving any crossover 
recombinants, in a process termed ‘double Holliday junction disolution’ (Fig. 4.2) [43-
46](reviewed in [47]). Thus, the BLM complex prevents the formation of hybrid 
recombinant DNA molecules called crossovers that could lead to a phenomenon known 
as loss of heterozygosity, which significantly contributes to cancer.  
Under physiological conditions, the dissolution activity of BLM-TOPOIII  
requires a third member of the BLM complex, RMI1 (RecQ mediated genome instability 
1 or BLAP75) [46, 48]. Since RMI1 has ssDNA binding ability, it has been proposed that 
RMI1 acts as an accessory factor to load TOPOIII  onto the substrate and stimulate 
TOPOIII  activity in dHJ dissolution [43, 49]. Recently, a novel component of the 
dissolvasome complex, RMI2 (or BLAP18), was identified [50, 51]. RMI2 helps 
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maintain the stability of the BLM-TOPOIII -RMI1 complex and plays a key role in 
mitotic phosphorylation of BLM and suppressing sister-chromatid exchange (SCE) [50]. 
Through interacting with the carboxyl-terminus of RMI1, RMI2 associates with BLM-
TOPOIII -RMI1 to form a stable BLM-TOPOIII -RMI1-RMI2 (BTR) complex (also 
called the “dissolvasome”) [50, 51]. Notably, TOPOIII , RMI1 and RMI2 could also 
form a stable protein complex in vivo without BLM. Deletion of any one of the three 
components by RNA interference will result in the disruption of the complex, while the 
BLM expression level is unaffected [50, 51].  
Several lines of evidence suggested that the BTR complex is required for telomere 
maintenance in ALT cells. First, both BLM and telomeric DNA were found in APBs [9]. 
Second, the telomeric DNA structure T-loop resembles the HR intermediates D-loop and 
Holliday junction, which are the substrates of the BTR complex (Fig. 4.1). Third, it has 
been shown that BLM directly interacts with telomere binding protein TRF2, indicating a 
connection between BLM and telomere maintenance [52-54]. Last but not least, a newly 
developed technique called proteomics of isolated chromatin segments (PICh) revealed 
that all four components of the BTR complex were found to associate with human 
telomeric chromatin in ALT cells, but not in telomerase-positive cancer cells  [55]. 
Therefore, we proposed that the dHJ dissolvasome BTR complex plays a role in telomere 
maintenance in the absence of telomerase. The detailed molecular mechanism of dHJ 
dissolution catalyzed by BTR remains unclear. In order to address this question and 
elucidate the potential functions of the BTR complex at telomeres, I set up a project to 
study the structure of the BTR complex. 
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4.3 Structural determination of the RMI1-RMI2 complex 
Sequence alignment analysis predicted that both RMI1and RMI2 are OB-fold-containing 
proteins [51]. RMI1 has two putative OB-folds at both termini and RMI2 has one. The C-
terminal OB-fold of RMI1 (RMI1C) shares limited similarity to the C-terminal OB-fold 
of RPA1 (RPA1C), the largest subunit of the RPA complex. The OB-fold in RMI2 is 
most similar to the OB-fold of another RPA protein, RPA2. However, the sequence of the 
N-terminal OB-fold of RMI1 (RMI1N) shows no apparent similarity to any OB-fold in 
the RPA complex [50]. RPA is a three-subunit complex that binds single-stranded DNA 
and plays an essential role in DNA replication, DNA recombination, and DNA repair 
[56-58]. RPA contains six OB-folds in total: four in RPA1 (RPA1-F, RPA1-A, RPA1-B, 
RPA1-C), one in each of RPA2 and RPA3 [56-58].  
There is a 280-residue unstructured fragment between the two OB-folds of RMI1, 
which has no secondary structural feature based on secondary structural prediction 
analysis. Consistently, initial attempt to express full-length RMI1 yielded no soluble 
protein. Therefore, two fragments of RMI1 that correspond to the two OB-folds, RMI1N 
(residues 2 – 213) and RMI1C (residues 475 – 625), were cloned separately into the 
His6-SUMO vector and both proteins were expressed and purified from E. coli.  
The RMI1N construct produced soluble and stable proteins, which allowed me to 
obtain enough material of high purity for crystallization trails (Fig. 4.3a-c). Thin plate 
crystal clusters started to show up two days after the initial screening. After several 
rounds of optimization, I obtained good quality crystals that are suitable for structural 
study (Fig. 4.3d). Diffraction data were collected at the Advanced Photon Source (APS). 
The space group is P3121 with one molecule per asymmetric unit. The structure of 
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RMI1N was solved by single-wavelength anomalous dispersion (SAD) using Seleno-Met 
substituted crystals and refined to 2.0 Å resolution (Table 4.1).  
In contrast to the N-terminal OB-fold of RMI1, the expression of RMI1C yielded 
insoluble protein. Since RMI2 interacts with the RMI1C, we reasoned that the correct 
folding and/or the stability of RMI1C might need the existence of RMI2. Then we cloned 
full-length RMI2 into the pGEX-6p-1 vector, and His6-SUMO-tagged RMI1C and GST-
tagged RMI2 were co-expressed in Rosetta DE3 strain under a Kana/Amp double 
selection. The RMI1C-RMI2 complex is well expressed and kept in a soluble and mono-
dispersed form. The heterodimeric interaction was strong enough that the RMI1C-RMI2 
complex was able to tolerate several rounds of size exclusion and ion-exchange 
chromatographic steps, and still maintain a 1:1 stoichiometry. The RMI1C-RMI2 
complex with > 99% purity was subjected to crystallization trial and chunky crystal 
clusters were obtained one week after initial screening (Fig. 4.4). High-resolution data 
sets were collected at APS and the phase information was obtained by diffracting Seleno-
Met substituted derivative crystals. The structure of the RMI1C-RMI2 complex was 
solved by SAD method and refined to 1.9 Å resolution. The space group is P212121 with 
one complex per asymmetric unit (Table 4.2). 
 
4.4 Crystal structure of RMI1N  
The crystal structure reveals that RMI1N indeed contains a single OB-fold core, as 
expected from secondary structural prediction results (Fig. 4.5a). N-terminal to the OB-
fold core (residue 2 – 56) is a three-helix-bundle motif, which packs on the OB-fold 
though hydrophobic van der Waals contacts and buries a total surface area of 2453.8 Å 
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(Fig. 4.5c). This observation and our previous unsuccessful attempt to purify the RMI1 
N-terminal OB-fold without the three-helix bundle suggest that this motif is crucial for 
the OB-fold stability (Section 4.3). Although bioinformatics analysis failed to detect any 
substantial sequence similarity between RMI1N and RPA proteins, comparison of the 
structures of RMI1N and the N-terminal OB-fold of RPA1 (RPA1Nl residue 1 – 120) 
clearly reveals a high degree of structural similarity (Fig. 4.5d). In fact, RPA1N is one of 
the top solutions revealed by Dali that are structurally most similar to RMI1N with an 
rmsd of 2.5 Å for 118 equivalent C  atoms. This close structural similarity is rather 
unexpected given that the sequences of the OB folds of Ten1 and Rpa3 share only 15% 
identity.  
Despite these similarities, the structure of RMI1N contains several unique 
features. Neither end of the RMI1N OB-fold -barrel is covered by -helix, which is 
often observed in OB-fold-containing structures, leaving a -barrel with an open hole in 
the center (Fig. 4.5b). Notably, there is a large 35-residue insertion (residue 97 – 131) 
between strands 1 and 2 (Fig. 4.5a, b, d). This large insertion, which contains one -helix 
and a long loop (partially disordered), extends out from the protein perpendicular to the 
axis of the OB-fold -barrel. The substitution of the insertion by a four-residue-linker 
“SGGS” between 1 and 2 did not affect the protein stability and generated well-folded 




 will be used in 
various biochemical assays to investigate the function of this large insertion in RMI1. By 
collaborating with Dr. Patrick Sung’s lab from Yale University, we test the RMI1N and 
RMI1N
loop
 in pull down assays and in vitro dHJ dissolution assay. RMI1N interacts with 
both BLM and TOPOIII  in pull down assay (Fig. 4.6a) and is active in dHJ dissolution 
195
assay. With BLM- TOPOIII , RMI1N can dissolute 50% of the dHJ substrate, even 
higher than the RMI1 full-length protein (40% dissolution) at similar concentration (Fig. 
4.6b). However, although RMI1N
loop
 retains the binding ability to BLM and TOPOIII  
(Fig. 4.6a), it fails to enhance the dissolution activity of BLM-TOPOIII  (Fig. 4.6b). 
Therefore, the N-terminal of RMI1 is responsible for stimulating BLM-TOPOIII  and 
the loop region outside the OB-fold may play an essential role in dHJ dissolution. Further 
investigations need to be applied in order to elucidate more detailed information. 
 
4.5 Crystal structure of the RMI1C-RMI2 complex 
The RMI1C-RMI2 complex structure reveals a 1:1 stoichiometry between RMI1C and 
RMI2, consistent with the observed molecular weight of the complex as determined by 
gel filtration chromatography (~38 kDa, Fig. 4.4b, c). The crystal structure shows that 
each protein indeed comprises a single OB-fold (Fig. 4.7a). In addition to the central -
barrel, there are several structural features common to the OB folds of RMI1C and RMI2. 
First, both proteins contain a C-terminal  helix ( 4 in RMI1C and 3’ in RMI2), which 
contributes most of the contact interface between RMI1C and RMI2 (Fig. 4.7a, b). 
Second, short  helices ( 3 in RMI1C, and 2’ in RMI2) that cover the bottom of the -
barrels of the OB folds are found between strands 3 and 4 (Fig. 4.7a). Third, the other 
end of the -barrel of both proteins is closed by  helix ( 2 in RMI1C and 1’ in RMI2) 
N-terminal to the OB folds (Fig. 4.7a). Notably, compared to RMI2, RMI1C contain a 
unique segment in the connecting region between 3 and 4. This segment, which 
consists of resides 558-587 of RMI1, folds into two helices 4 and 5, extending outside 
of the OB-fold core (Fig. 4.7a).  
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The interface between RMI1C and RMI2 in the crystal structure is mainly 
hydrophobic. The interactions are mediated primarily by the C-terminal amphipathic 
helices of both proteins; hydrophobic residues from RMI1C (Met613, Leu616 and 
Leu619) and RMI2 (Ile130, Met134 and Leu137) inter-digitate with one another to form 
the core of the hydrophobic interface (Fig. 4.7b). The 3’ helix of RMI2 makes a 30° 
kink that bends the helix towards helix 4 of RMI1C, extending the interaction surface 
between the two OB folds. In addition to hydrophobic contacts, hydrogen-bonding 
interactions between the two C-terminal helices appear also to strengthen the interface 
and contribute to the specificity of the RMI1C-RMI2 complex. Specifically, at the C-
terminal end of the RMI1C 6 helix, the side chain of R622 makes two salt-bridge 
interactions with the carboxylate group of D141 in the middle of RMI2 3’ helix (Fig. 
4.7c). A panel of missense mutations designed to disrupt the interface have been 
generated and their effects on the RMI1-RMI2 interaction will be examined using yeast 
two-hybrid assay.  
The crystal structure of the RMI1C-RMI2 complex closely resembles that of the 
RPA1C-RPA2N complex (Fig. 4.8a) [51]. Consistent with previous sequence alignment 
predictions, the structure of RMI1C and RNI2 OB-folds are most similar to those of the 
OB-folds of RPA1C and RPA2N, with rmsd values of 3.2 Å and 2.0 Å, respectively (Fig. 
4.8b) [51]. Notably, the structurally conserved region includes not only the central -
barrel of the OB fold, but also peripheral -helices including the three helices between 
strands 3 and 4 (Fig. 4.8a-c). In addition to similarities between the individual 
components, the RMI1C-RMI2 and the RPA1C-RPA2N complexes exhibit another 
common feature; in both cases, the two subunits heterodimerize mainly through 
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hydrophobic contacts mediated by the two C-terminal helices (Fig. 4.8a). Taken together, 
we concluded that RMI1C-RMI2 is structurally similar to the RPA1C-RPA2N complex.  
 Despite the high degree of overall structural conservation, there are substantial 
differences between the RMI1C-RMI2 and the RPA1C-RPA2N complexes. Most 
notably, the relative orientations between the two components are different in the two 
complexes. When both complex structures are overlaid based on the OB folds of RMI1C 
and RPA1C, RMI2 exhibits a ~ 16° rotation relative to the position of RPA2N (Fig. 
4.8a). Second, RMI1C lacks a zinc-binding motif between strands 1 and 2 (Fig. 4.8a). 
Instead 1 and 2 are connected by a short seven-residue loop (residues 522-528). The 
zinc-binding motif in RPA1 is essential for the in vivo function of the RPA complex [59, 
60]. Nevertheless, we conclude that the RMI1C-RMI2 complex is a structural homologue 
of RPA1C-RPA2.  
The RPA complex contains three components: RPA1C, RPA2 and RPA3 [56-58]. 
Given the structural similarity between RMI1-RMI2 and RPA1-RPA2, I speculated that it 
is likely that there exists an unidentified protein that binds to RMI1-RMI2 to form an 
RPA-like trimer. Indeed, a potential candidate RMI1-RMI2 binding protein that 
reassembles RPA3 has been cloned in Dr. Patrick Sung’s laboratory at Yale University 
(personal communications with Dr. Patrick Sung). 
 
4.6 Detection interactions between BLM and TRF2 
FRET (Fluorescence Resonance Energy Transfer) and co-immuoprecipitation results 
suggested that TRF2 and BLM interact with each other in ALT cells [52]. Purified TRF2 
and BLM protein (BLM full-length protein was expressed and purified from budding 
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yeast S. cerevisiae) also could bind in vitro with high affinity (apparent Kd = 2.5 nM) as 
suggested by ELISA assay results [61]. Therefore, it was believed that BLM is involved 
in telomere maintenance and processing. To further characterize the direct interaction 
between BLM and TRF proteins, I performed a direct binding assay between purified 
BLM-core and TRF1 and TRF2 using EMSA. As shown in Fig. 4.9, incubation of BLM-
core with TRF2 resulted in a slower migration band, compared with BLM-core or TRF2 
alone, suggesting a direct interaction between BLM-core and TRF2. In contrast, no 
difference was observed between BLM-core and TRF1 (Fig. 4.9). Thus, BLM-core only 
mediates the interaction with TRF2. Further mapping will be performed to identify the 
BLM-core binding domain of TRF2 before I can carry out structural study to establish the 
connection between the BTR complex and telomeres at atomic resolution by X-ray 
crystallography. 
 
4.7 Progress towards the structure of the BTR complex 
Human BLM protein contains three domains that are conserved throughout the RecQ 
helicase family. From the N- to the C-termini, these domains are the helicase domain, the 
RecQ carboxy-terminal (RQC) domain, and the Helicase and RNase D C-terminal 
(HRDC) domain [62] (Fig. 4.11). The helicase domain is essential for ATP binding and 
hydrolysis and defines the RecQ family. The RQC domain is also restricted to RecQ 
family members and is considered important for both the structural integrity of the 
protein and dsDNA binding. The HDRC domain has an auxiliary role in nucleic acid 
binding. These domains form the catalytic core of BLM (hereafter referred to as BLM-
core, residues 646-1292). BLM-core was cloned into the His6-SUMO vector for protein 
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expression. However, initial purification of BLM-core yielded soluble aggregate. Slightly 
increase of the salt concentration from 150 to 250 mM NaCl helped prevent the 
aggregation. BLM-core with high purity then was subjected to intensive crystallization 
screening trial. Small needle crystals started to show up after 10 days of incubation at 4 
°C (Fig. 4.10). Additional screening and optimization BLM-core will be performed to 
obtain crystals suitable for diffraction analysis.  
The N-terminal half of BLM (BLM-N, residues 1-645) mediates the interactions 
with TOPOIII  [42, 63]. However, primary sequence analysis indicated that BLM-N is 
mostly unstructured. Probably not surprisingly, expression of BLM-N alone failed 
because of low yield and insolubility. To address this issue, I am using both biochemical 
and yeast two-hybrid methods to map the interactions between BLM-N and TOPOIII . 
Similarly, the BLM-RMI1 and the TOPOIII -RMI1 interactions are also studied by the 
same approaches. (More detailed protein-protein interactions of BTR complex is shown 
in Fig. 4.11) The resulting information will be used to reconstitute the BTR complex in 
vitro for the structural study. 
 
4.8 Methods and materials 
Protein expression and purification 
The C-terminal domain of RMI1 (residues 475 – 625) was cloned into a GST fusion 
protein expression vector, pGEX6p-1 (GE Healthcare). RMI1 (residues 6 – 147) was 
cloned into a modified pET28b vector with a SUMO protein fused at the amino-terminus 
after the His6-tag [64]. The RMI1C-RMI2 complex was expressed in E. coli. Rosetta DE3 
strain. SUMO-tagged RMI1C-OB and GST-tagged RMI2-OB plasmids were co-
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transformed into Rosetta DE3 strain and the colonies carrying two plasmids were picked 
by Kana/Amp double selection. After induction for 16 hours with 0.1 mM IPTG at 25 °C, 
the cells were harvested by centrifugation and the pellets were resuspended in lysis buffer 
(50 mM Tris-HCl pH 8.0, 50 mM NaH2PO4, 400 mM NaCl, 3 mM imidazole, 10% 
glycerol, 1mM PMSF, 0.1 mg/ml lysozyme, 2mM 2-mercaptoethanol, and home-made 
protease inhibitor cocktail). The cells were then lysed by sonication and the cell debris 
was removed by ultracentrifugation. The supernatant was mixed with glutathione 
sepharose beads (GE Healthcare) and rocked for 6 hours at 4 °C before elution with 15 
mM reduced glutathione. The protease 3C was added to remove the GST-tag. The 
complex was then mixed with Ni-NTA agarose beads (Qiagen) and rocked for 8 hours at 
4 °C before elution with 250 mM imidazole. The ULP1 protease was added to remove 
the His6-tag. Finally the RMI1C-RMI2 complex was further purified by passage through 
Mono-Q ion-exchange column and by gel-filtration chromatography on Hiload Superdex 
75 equilibrated with 25 mM Tris-HCl pH 8.0, 150 mM NaCl and 5 mM dithiothreitol 
(DTT). The purified RMI1C-RMI2 complex protein was concertrated to 25 mg/ml and 
stored at -80 °C. The Seleno-Met substituted RMI1C-RMI2 complex protein was 
similarly purified.  
 The protein of N-terminal domain of RMI1 and BLM-core (rediues 646 – 1292) 
were expressed in E. coli. and purified following the same procedures as described above 
except for only one affinity chromatography step (Ni-NTA agarose) was used for 
RMI1N. 
 The protein of hTOPOIII -N was expressed in the insect cells (Sf9 and Hifive) 
expression system. The protein was purified following the same procedures as described 
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above except for only one affinity chromatography step (glutathione sepharose beads) 
was used for hTOPOIII -N. 
 
Crystallization, data collection and structure determination 
RMIN: The RMI1N protein was crystallized by sitting-drop-vapor-diffusion at 4 °C. The 
precipitant/well solution contained 100 mM Tris-HCl pH 8.5, 18% PEG 3350, 300 mM 
NaSCN, 10 mM NiCl2 and 10 mM DTT. Crystals were gradually transferred to a 
harvesting solution containing 100 mM Tris-HCl pH 8.5, 25% PEG 3350, 25% glycerol, 
300 mM NaSCN, 10 mM NiCl2 and 10 mM DTT before flash-frozen in liquid nitrogen 
for storage and data collection under cryogenic conditions (100 K). Se-Met-SAD (at Se 
peak wavelength) dataset with the resolution of 2.0 Å was collected at beam line 21ID-D 
at APS and processed using HKL2000 (Otwinowski and Minor, 1997). Crystals belong to 
space group P3121 with one complex per asymmetric unit. Five selenium sites were 
located and refined, and SAD phases calculated using SHARP (E. d. La Fortelle, G. 
Bricogne, 1997). A model was automatically built into the modified experimental 
electron density using ARP/WARP (V. S. Lamzin, A. Perrakis, K. S. Wilson, 2001); the 
model was then further refined using simulated-annealing and positional refinement in 
CNS [65] with manual rebuilding using program O [66].  
 
RMI1C-RMI2 complex: The RMI1C-RMI2 complex protein was crystallized by 
hanging-drop-vapor-diffusion at 4 °C. The precipitant/well solution contained 18% PEG 
3350, 300 mM NaSCN, and 10 mM DTT. Crystals were gradually transferred to a 
harvesting solution containing 25% PEG 3350, 25% glycerol, 300 mM NaSCN, and 10 
202
mM DTT before flash-frozen in liquid nitrogen for storage and data collection under 
cryogenic conditions (100 K). Se-Met-SAD (at Se peak wavelength) dataset with the 
resolution of 2.0 Å was collected at beam line 21ID-D at APS and processed using 
HKL2000 (Otwinowski and Minor, 1997). Crystals belong to space group P212121 with 
one complex per asymmetric unit. Eleven selenium sites were located and refined, and 
SAD phases calculated using SHARP (E. d. La Fortelle, G. Bricogne, 1997). A model 
was automatically built into the modified experimental electron density using 
ARP/WARP (V. S. Lamzin, A. Perrakis, K. S. Wilson, 2001); the model was then further 
refined using simulated-annealing and positional refinement in CNS [65] with manual 
rebuilding using program O [66].  
 
BLM-core: The BLM-core protein was crystallized by sitting-drop-vapor-diffusion at 4 
°C. The precipitant/well solution contained 50mM HEPES pH 7.0, 1.6 M Li2SO4, 50 mM 
MgCl2 and 10 mM DTT. 
 
Pull down assays:  
For pull-down assays, (His)6-BLM (5 μg), (His)6-TOPOIII  (5 μg), RMI1N (5 μg), or 
RMI1N
Loop
 (5 μg) were used. The indicated proteins were incubated in 30 μl of Buffer B 
(25 mM Tris-HCl, pH 7.5, 0.005% Triton, 80 mM KCl, and 1 mM DTT) for 30 min at 
4°C. The reactions were mixed with 11 μl of Ni-NTA agarose beads (which recognize the 
His-tag at the N-terminus of BLM and TOPOIII ) at 4°C for 30 min. After washing the 
beads twice with 200 μl of the same buffer, bound proteins were eluted with 25 μl of 2% 
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SDS. The supernatant (S), wash (W), and SDS eluate (E), 10 μl each, were analyzed by 
15% SDS-PAGE and Coomassie Blue staining. 
 
dHJ dissolution assay:  
The dHJ dissolution reaction is carried out in the presence of BLM (10 nM), TOPOIII  
(125 nM), and RMI1 (MBP-RMI1, RMI1N, RMI1
Loop
) (140, 280 and 420nM) were 
incubated for 10 min on ice in 12 μl of reaction buffer (50 mM Tris-HCl, pH 7.8, 1 mM 
DTT, 0.8 mM MgCl2, 200 μg/ml bovine serum albumin, 2 mM ATP, 80 mM of KCl, and 
an ATP regenerating system consisting of 10 mM creatine phosphate and 50 μg/ml 
creatine kinase) followed by the addition of the dHJ substrate (1nM). After a 5-min 
incubation at 37 °C, 2 μl of 1% SDS and 1 μl of proteinase K (10 μg/μl stock) were 
added to the reaction mixtures, followed by a 10 min incubation at 37 °C. The 
deproteinized reactions were mixed with an equal volume of sample loading buffer (20 
mM Tris-HCl, pH 7.5, 50% glycerol, and 0.08% Orange G) containing 50% urea, 






Figure 4.1* Speculative Model for T-loop HR 
(Top) Proposed structure of t-loops. (Middle) Branch migration at the strand invasion site 
of the telomere terminus results in the formation of a Holliday junction. (Bottom) Two 
steps lead to t-loop deletion. Cleavage of the C strand at two positions by HJ resolvase 
(green arrowheads). This process is proposed to require XRCC3. The second step 
involves nicking of the D loop by an unknown nuclease (open arrowhead). The products 
are a shortened telomere and a relaxed telomeric circle. The shortened telomere might 
reform a small t-loop in a TRF2-dependent manner (left) or, if the deletion is too 
extensive, might activate a DNA damage response and induce senescence. TRF2 is 
proposed to promoted t-loop formation, thereby crating the substrate for t-loop HR. The 
basic domain of TRF2 is proposed to suppress t-loop HR by inhibiting branch migration 
and/or strand cleavage. In ALT cells, the telomeric circles resulting from t-loop HR could 
function as a template for rolling circle replication and allow telomeric-independent 
telomere maintenance.  
(* This figure is photocopied from ref. [25], Fig. 7)  
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Figure 4.2* Proposed roles of the BTR complex in processing HR intermediates. 
Diagrammatic representation of the putative roles of the human BTR (BLM-TOPOIII -
RMI1-RMI2) complex in processing HR intermediates during S-phase. Two homologous 
chromosomes are shown, labelled red and black. In this example, the initiating lesion is a 
ssDNA gap (on the red chromosome), such as is predicted to arise during discontinuous 
DNA synthesis (e.g. following bypass of a lesion on the lagging strand template). 
(a) RAD51 catalyses the early strand invasion step of HR repair of ssDNA gaps to create 
a D-loop intermediate. At this stage, the human RecQ helicase, BLM, could prevent HR 
from progressing any further by disrupting D-loops.  
(b) If homologous recombination repair does proceed, a key HR intermediate known as 
the ‘double Holliday junction’ (dHJ) forms. These dHJ intermediates are processed by 
either the BLM-TOPOIII -RMI1-RMI2 complex or putative HJ resolvases. If the latter 
occurs, then, depending on the relative orientation of HJ resolvase cleavage and re-
joining of DNA fragments, crossing over of genetic material flanking the original repair 
site might occur. Alternatively, the BLM-TOPOIII -RMI1-RMI2 complex catalyses a 
reaction known as ‘dHJ dissolution’, which acts to resolve dHJs without any crossing 
over of genetic material flanking the repair site. This reaction encompasses two key steps: 
(c) convergent branch migration of individual HJs to create a hemicatenane intermediate, 
and (d) the decatenation of this structure. RMI1 stimulates TOPOIII  activity, and 
probably performs a DNA-targeting function in vivo. Note, for simplicity the figure only 
shows the human proteins and mechanism, where BLM is the RecQ helicase homologue. 
Therefore the BTR complex is BLM-TOPOIII -RMI1-RMI2 in this figure. 




Figure 4.3 Protein purification and crystallization of RMI1N 
(a) Schematic diagram of purification procedure of RMI1N. 
(b) Gel filtration chromatography profile (Hiload Superdex 75) of RMI1N protein. 
Elution positions of 15 and 55 KDa protein markers are indicated. 
(c) SDS-PAGE of purified protein of RMI1N for crystallization. 










Data collection  
 Se Peak 
Space group P3121 
Cell dimensions 
    a, b, c (Å) 57.896, 57.896, 117.475 
    , ,   (º) 90, 90, 120 
Wavelength (Å) 0.97872 
Resolution (Å)  100-2.0 
Rmerge (%) (high res. shell) 0.073 (0.409) 
I/  (high res. cell) 48.9 (4.5) 
Completeness (%) (high res. shell) 99.1 (94.7) 
Redundancy (high res. shell) 14.0 (11.3) 
Phasing 
Acentric Phasing Power 1.734 
Acentric reflections FOM 0.385 
Centric reflections FOM 0.114 
Refinement 
Resolution (Å) 50-2.0 
No. reflections 34177 




    Protein 42.8 
    Water 41.0 
R.m.s deviations 
    Bond lengths (Å)  0.005823 
    Bond angles (º) 1.43358 
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Figure 4.4 Protein purification and crystallization of RMI1C-RMI2 complex 
(a) Schematic diagram of purification procedure of RMI1C-RMI2 complex. 
(b) Gel filtration chromatography profile (Hiload Superdex 75) of RMI1C-RMI2 
complex. Elution positions of 15 and 32 KDa protein markers are indicated. 
(c) SDS-PAGE of purified protein of RMI1C-RMI2 complex for crystallization. 










Data collection  
 Se Peak 
Space group P212121 
Cell dimensions 
    a, b, c (Å) 41.682, 42.365, 157.734 
    , ,   (º) 90, 90, 120 
Wavelength (Å) 0.97934 
Resolution (Å)  100-2.0 
Rmerge (%) (high res. shell) 0.112 (0.279) 
I/  (high res. cell) 33.1 (6.4) 
Completeness (%) (high res. shell) 98.4 (89.7) 
Redundancy (high res. shell) 12.0 (7.1) 
Phasing 
Acentric Phasing Power 1.990 
Acentric reflections FOM 0.477 
Centric reflections FOM 0.139 
Refinement 
Resolution (Å) 50-2.0 
No. reflections 35460 




    Protein 14.584 
    Water 30.612 
R.m.s deviations 
    Bond lengths (Å)  0.008171 
    Bond angles (º) 2.25049 
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Figure 4.5 Crystal structure of RMI1N 
(a) RMI1N-OB adopts a typical OB-fold structure.  
(b) Bottom view of RMI1N-OB structure. Neither side of the RMI1N OB-fold is covered 
by any  helices. 
(c) The N-terminal three-helix-bundle motif of RMI1N packs on the OB-fold though 
hydrophobic van der Waals contacts. The OB-fold is in surface representation and 
colored according to its electrostatic potential (positive potential, blue; negative potential, 
red). 









Figure 4.6 In vitro tests of RMI1N and RMI1N
loop
 (Done by Dr. Patrick Sung’s 
group) 
(a) RMI1N and RMI1N
loop
 interact with both BLM and TOPOIII . RMI1N and 
RMI1N
loop
 can be detected in elution (E) lanes after incubating with His6-BLM /His6-
TOPOIII  on Ni-NTA. RMI1N and RMI1N
loop
 cannot be seen in supernatant (S), wash 
(W) and Ni-NTA control lanes.  
(b) RMI1N enhances the dissolution activity of BLM- TOPOIII , while RMI1N
loop
 
doesn’t. Increased amount of RMI1N and RMI1N
loop
 proteins together with BLM-
TOPOIII  are incubated with radioactive labeled dHJ substrates (upper band). The 
dissolution products (lower band) are detected by Phosphorimager. The percentage of the 




Figure 4.7 Crystal structure of RMI1C-RMI2 complex 
(a) Both RMI1C and RMI2 contain an OB-fold. The C-terminal -helices from RMI1C 
and RMI2 medicate the protein interaction.  
(b) Hydrophobic residues locating on each  helix from RMIC (Met613, Leu616 and 
Leu619) and RMI2 (Ile130, Met134 and Leu137) interdigitate with one another and form 
the major hydrophobic interface. 








Figure 4.8 RMI1C-RMI2 complex is structural conserved with RPA1C-RPA2 
complex. 
(a) Superposition of RMI1C-RMI2 complex (RMI1C: green, RMI2: cyan) on the crystal 
structure of human RPA1C-RPA2 complex (RPA1C: blue, RPA2: red). 
(b) Superposition of RMI2 (RMI2: cyan) on the crystal structure of human RPA2 (RPA2: 
red). 
(c) Amino acid sequence alignment of RMI1C-RMI2 complex and human RPA1C-RPA2 
complex*. Upper panel: sequence alignment of the C-terminal OB-fold regions of RMI1 
and human RPA1. Lower panel: sequence alignment of OB-fold regions of RMI2 and 
human RPA2. The sequence alignments with RPA1C and RPA2 are based on the crystal 
structure of the human RPA trimerization core complex [67]. Secondary structural 
assignments from our RMI1C-RMI2 complex are shown as colored cylinders (  helices, 
green: RMI1C and RPA1) and arrows (  strands, cyan: RMI2 and RPA2) above the 
sequences. The highlighted areas indicate the conserved amino acids. (*The  strands ( a 
and b) in RPA1C and  helix ( 2) in RMI2 are not shown in the alignment since there 











Figure 4.9 BLM interacts with TRF2 in vitro. Purified BLM-core protein is incubated 
with GST-TRF1 or GST-TRF2 protein for native gel. Only the incubation of BLM-core 







Figure 4.10 Protein purification and crystallization of BLM-core (646-1292) 
(a) Gel filtration chromatography profile (Hiload Superdex 200) of BLM-core. Elution 
position of 63 KDa protein markers is indicated. 
(b) SDS-PAGE of purified protein of BLM-core for crystallization. 
(c) Crystal picture of BLM-core. 
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Figure 4.11 Schematic diagram of BLM-TOPOIII -RMI1/2 (BTR) complex and 
other potential interacting protein in human cells. Individual domain of each 
component of BTR complex is coloured and labeled. Direct interactions between two 
proteins are indicated by solid black double arrows; and the potential interactions are 
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Chapter 5 
Conclusions and perspectives 
 
 
Being synthesized and extended by telomerase, telomeres make sure chromosomes can 
be completely replicated during cell divisions. Functionally, telomeres keep the genome 
integrity and protect chromosome ends from degradation and being processed by 
inappropriate DNA repair pathways (reviewed in [1-3]). Telomeric proteins, the 
permanent residents at telomere region, play an important role in regulating telomerase 
activity and protecting telomere (reviewed in [2-4]). In my studies, my aim is to reveal 
the biological functions of the telomere-associated proteins by structural and biochemical 
analyses. So far, I have performed structural studies on three different telomere-
associated protein complexes: human POT1-TPP1 complex, fission yeast Taz1 and Taz1-
Rap1 complex, and human RMI1-RMI2 complex in the BLM-TOPOIII -RMI1-RMI2 
(BTR) complex.  
 
5.1 POT1-TPP1 complex on 3’ G-overhang 
By solving the crystal structure of the N-terminal portion of human TPP1, I found out 
that TPP1 contains one OB-fold that is structurally conserved with that in N-terminus of 
Oxytricha nova TEBP-  subunit (see Chapter 2). Since human POT1, TPP1’s binding 
partner, was previously identified as the homologue of Oxytricha nova TEBP -subunit 
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[5, 6], I concluded that human POT1-TPP1 complex is structurally conserved with 
Oxytricha nova TEBP /  complex. However, beyond our anticipation, unlike the TEBP 
/  complex that has a negative regulatory effect on telomerase extension [7, 8], human 
POT1-TPP1 complex showed a dramatic stimulation effect on telomerase activity as well 
as processivity in the in vitro telomerase activity assay (see Chapter 2). Therefore, a new 
question arises: what is the mechanism for human POT1-TPP1 up-regulates telomerase 
activity and processivity?  
 Previous studies already showed that POT1 could negatively and positively 
regulate telomere extension [9]. Generally, POT1 tends to bind to the 3’-terminal 
sequence GGTTAG and functions as a strong telomerase inhibitor. However, if POT1 
was fixed to the 5’ sequence (by mutation on the telomeric sequence) and released the 
unbound 3’ G-overhang for more than eight nucleotides, the POT1-ssDNA complex can 
be extended by telomerase [9]. It seems that if POT1 is forced to stay away from the 3’ 
terminus, it will no longer repress telomerase activity. Thus, we speculated that when 
TPP1 bound to POT1, POT1’s position on the ssDNA would be changed. Unfortunately, 
our hypothesis was proved to be wrong by the SVPI enzyme digestion results: even when 
TPP1 was presented, majority of the POT1 molecules still located at the 3’ end of ssDNA 
primer. This result also matched the kinetic study result that POT1-TPP1 complex would 
prefer to bind to the 3’ end of ssDNA primer with higher affinity (Kd = 0.7 nM, see 
Chapter 2). However, it is still possible that there are a few POT1-TPP1 complex bind to 
the internal site on the primer (Kd = 7.4 nM, see Chapter 2) and leave the 3’ G-overhang 
unoccupied for the processive telomerase extension.   
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 Another possible solution is the telomerase recruitment model. I and other group 
have already detected the direct in vitro interaction between TPP1 and hTERT [10, 11], 
the protein component of telomerase. By collaborating with Dr. Neal Lue’s lab in Weill 
Medical College of Cornell University, we also provided evidence showing that the 
Candida albicans telomerase protein Est3, the potential homologue of TPP1, may 
mediate a conserved function as TPP1 in telomerase recruitment and regulation [12]. 
Therefore, I propose that through direct interaction with TPP1, telomerase is recruited to 
its ssDNA substrate for telomere elongation. The direct TPP1-hTERT interaction also 
prevents telomerase from falling off from the extended ssDNA in the translocation step 
(see Chapter 1), therefore results in the increased telomerase processivity. In order to test 
my hypothesis, the interaction domains as well as the essential residues of TPP1 and 
hTERT need to be characterized first. And then the TPP1 truncations or mutants that fail 
to interact with telomerase will be used in the in vitro telomerase activity assay to check 
whether ssDNA primer can still be extended by telomerase with increased processivity 
and activity.  
 It is also necessary to check how POT1-TPP1 complex is organized on single-
stranded telomeric DNA. As telomeric DNA being extended by telomerase, more POT1 
binding sites will be generated so more POT1-TPP1 complexes will be loaded on the 
ssDNA. Whether the increased telomerase activity and processivity is brought by the 
accumulation effect of more telomerase recruitments by more POT1-TPP1 complexes? 
There are data suggesting that only one upstream binding POT1-TPP1 complex is enough 
to increase telomerase processivity (Latrick and Cech, unpublished). Furthermore, a 
single amino-acid mutation on the surface of TEN (telomerase essential N-terminal) 
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domain of hTERT would eliminate the enhanced processivity, which further suggested 
the specific interaction between TPP1 and telomerase (Latrick and Cech, unpublished). 
Besides, the structural view of how POT1-TPP1 complex localizes on longer single-
stranded telomeric DNA will definitely help address the question. Currently, colleagues 
in our lab are working on determining the crystal structure of POT1-TPP1-ssDNA 
(10mer) by using the fusion protein strategy. Moreover, our preliminary electronic 
microscopy (EM) data and 3D reconstruction model suggested that when POT1 bound to 
132mer ssDNA that contains 11 tandem POT1 binding sites, the POT1-ssDNA complex 
presented a cylinder-like higher-ordered structure, which further supported the notion that 
POT1 blocks telomerase’s access to ssDNA substrate. Similarly, EM studies can be 
applied to exam whether the structure of the POT1-TPP1-ssDNA ternary complex is in a 
favorable state for telomerase extension.  
 
5.2 Taz1, the functional homologue of human TRF1 and TRF2 in fission yeast 
The double-stranded telomeric DNA binding proteins are found in budding yeast, fission 
yeast and mammals [13-21]. Structurally, they all share the C-terminal Myb-domain to 
mediate duplex telomeric DNA interaction in a sequence specific manner. Besides, the 
TRFH (TRF homology) domain is found in human double-stranded telomeric proteins, 
TRF1 and TRF2 [18]. Structural evidence reveals that the helical-TRFH domain is 
responsible for the homodimerization for both TRF1 and TRF2 [18]. Taz1, the only 
double-stranded telomeric DNA binding protein in fission yeast, is proposed to be the 
structural homologue of human TRF1 and TRF2, and therefore to bear the similar TRFH-
like domain for its dimerization. By solving the crystal structure of Taz1TRFH, I found out 
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that although Taz1TRFH is -helix-rich as TRFH domains in TRF1 and TRF2, it is not 
responsible for Taz1 homodimerization due to the different structural architecture. 
Instead, Taz1 dimerizes via the formation of a four-helix-bundle through the dimerization 
domain that is outside Taz1TRFH. Despite the structural differences, Taz1 still functions 
similarly as TRF1 and TRF2. First, Taz1 dimerizes in order to bind duplex telomeric 
DNA tightly. Like TRF1 and TRF2, disruption of dimerization will sweep Taz1 from the 
duplex telomeric DNA, as confirmed by in vitro binding data and in vivo evidence. 
Second, our solution structure of Taz1-Rap1, as well as the in vivo biochemical data, 
clearly show that Taz1 and Rap1 mimic their homologues TRF2 and Rap1 in human. 
Collectively, I concluded that Taz1 is not structurally conserved with TRF1 and TRF2 as 
we expected before, but it is indeed a functional homologue of TRF1 and TRF2. 
 We are surprised to discover the different structural architecture of Taz1 and are 
curious about the reason that why the homology proteins would bear such different 
domain structures. According to my current results, it is not accurate to take the TRFH 
domain as the signature motif of all double-stranded telomeric DNA binding proteins 
since the structure of Taz1TRFH is so different from those in human TRF1 and TRF2. At 
this stage, I cannot propose a proper explanation for the structural difference between 
Taz1 and human TRF1 and TRF2. It is possible that different structural architecture is 
developed for diverse functions. In higher organisms, during the evolution, more 
complicated functions are needed and might be designated to the TRF proteins. For 
example, higher species such as human have developed two TRF proteins: TRF1 and 
TRF2. Different structural architectures with distinctive functions have been rearranged 
in order to tolerate the evolutionary stress. Therefore, more structural studies on the 
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dsDNA telomeric proteins in other species (such as the ancient organism Trypanosoma) 
are required in order to address the question that how double-stranded telomeric proteins 
evolved during the evolution.    
 
5.3 Long-term goals 
In human, shelterin complex is made up of six telomeric proteins: TRF1, TRF2, TIN2, 
Rap1, POT1 and TPP1 [2]. Almost every component has its corresponding homologue in 
other species. For example, POT1-TPP1 is structurally conserved with TEBP /  
complex in ciliates (see Chapter 2). Rap1 is found in budding yeast, fission yeast and 
mammals (see Chapter 3). Taz1 is the functional homologue of TRF1 and TRF2 (see 
Chapter 3). Both TRF-like protein and POT1-like protein have been found in 
trypanosome T. brucei (personal communications with Dr. Li Bibo). Recently, the 
components of a shelterin-like complex in S. pombe have been identified successively. 
They are Tpz1, Poz1 and Ccq1 [22] (see Fig. 1.9 in Chapter 1). They form a telomere-
associated complex with previous identified Taz1, Rap1 and Pot1, further suggesting that 
the telomere-end-protection mechanism by a telomeric-protein complex is conserved. 
Although the detailed biological functions of the telomeric-protein complexes in different 
species are still under investigation, the overall function remains the same: to protect 
telomere and regulate telomerase activity. To better understand telomere and telomerase, 
more structural and functional information of every component of shelterin-like complex 
and related pathways need to be characterized. So far, our lab has solved the crystal 
structures of most components of human shelterin complex. Meanwhile, I am exploring 
how telomere is maintained and processed in telomerase-negative ALT (alternative 
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lengthening of telomeres) cells on the structural basis. The structural study on the double 
Holliday junction (dHJ) dissovalsome BLM-TOPOIII -RMI1-RMI2 (BTR) complex, 
which potentially associated with telomere in ALT cells, is performed in order to help us 
understand how telomere is processed and metabolized under abnormal conditions (such 
as lose telomere end protection) via homologous recombination. The long-term goal is 
that by modeling all the available structures, we would be able to draw the overall 
structural picture showing how shelterin complex and other telomere-associated proteins 
protect telomeres and regulate telomerase, which will provide insights for better 
understand the mysterious chromosome ends. 
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